{"idB": "1316175_12_item1a_p100_s0", "idA": "1316175_11_item1a_p104_s0", "sentA": "If our or our licensors patent positions do not adequately protect our product candidates or any future products, others could compete with us more directly, which would harm our business.", "sentB": "If our or our licensors' patent positions do not adequately protect our product candidates or any future products, others could compete with us more directly or prevent us from commercializing our products, which would harm our business.", "type": 2, "words": ["<tag1>", "If", "our", "or", "our", "licensors", "patent", "positions", "do", "not", "adequately", "protect", "our", "product", "candidates", "or", "any", "future", "products,", "others", "could", "compete", "with", "us", "more", "directly,", "which", "would", "harm", "our", "business.", "<tag2>", "If", "our", "or", "our", "licensors'", "patent", "positions", "do", "not", "adequately", "protect", "our", "product", "candidates", "or", "any", "future", "products,", "others", "could", "compete", "with", "us", "more", "directly", "or", "prevent", "us", "from", "commercializing", "our", "products,", "which", "would", "harm", "our", "business.", "<tag3>"], "wordsA": ["If", "our", "or", "our", "licensors", "patent", "positions", "do", "not", "adequately", "protect", "our", "product", "candidates", "or", "any", "future", "products,", "others", "could", "compete", "with", "us", "more", "directly,", "which", "would", "harm", "our", "business."], "wordsB": ["If", "our", "or", "our", "licensors'", "patent", "positions", "do", "not", "adequately", "protect", "our", "product", "candidates", "or", "any", "future", "products,", "others", "could", "compete", "with", "us", "more", "directly", "or", "prevent", "us", "from", "commercializing", "our", "products,", "which", "would", "harm", "our", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.013291636481881142, 0.0075603062286973, 0.008545982651412487, 0.005776507314294577, 0.020192397758364677, 0.02129787765443325, 0.016894252970814705, 0.09597020596265793, 0.12606267631053925, 0.07641364634037018, 0.02415870688855648, 0.011517531238496304, 0.030097205191850662, 0.022514518350362778, 0.004852621350437403, 0.005777099169790745, 0.008512035943567753, 0.011738347820937634, 0.006104322616010904, 0.007123458199203014, 0.007919332012534142, 0.006935635581612587, 0.007287276443094015, 0.005953664891421795, 0.009374147281050682, 0.006557418033480644, 0.5388737916946411, 0.1372477412223816, 0.6611770987510681, 0.6700786352157593, 0.17983464896678925, 0.11786157637834549, 0.0010249374900013208, 0.008857915177941322, 0.011110386811196804, 0.009603273123502731, 0.017939459532499313, -1]}
{"idB": "1316175_12_item1a_p101_s2", "idA": "1316175_11_item1a_p105_s2", "sentA": "We have also entered into exclusive license agreements for certain composition of matter, method of use and method of making patents and patent applications for certain of our development compounds.", "sentB": "Our blisibimod portfolio includes exclusively and non-exclusively licensed patents and patent applications from Amgen Inc.", "type": 2, "words": ["<tag1>", "We", "have", "also", "entered", "into", "exclusive", "license", "agreements", "for", "certain", "composition", "of", "matter,", "method", "of", "use", "and", "method", "of", "making", "patents", "and", "patent", "applications", "for", "certain", "of", "our", "development", "compounds.", "<tag2>", "Our", "blisibimod", "portfolio", "includes", "exclusively", "and", "non-exclusively", "licensed", "patents", "and", "patent", "applications", "from", "Amgen", "Inc.", "<tag3>"], "wordsA": ["We", "have", "also", "entered", "into", "exclusive", "license", "agreements", "for", "certain", "composition", "of", "matter,", "method", "of", "use", "and", "method", "of", "making", "patents", "and", "patent", "applications", "for", "certain", "of", "our", "development", "compounds."], "wordsB": ["Our", "blisibimod", "portfolio", "includes", "exclusively", "and", "non-exclusively", "licensed", "patents", "and", "patent", "applications", "from", "Amgen", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.016632650047540665, 0.14859449863433838, 0.16051484644412994, 0.019617628306150436, 0.5050618052482605, 0.03570835664868355, 0.6061581969261169, 0.22300586104393005, 0.17992663383483887, 0.006683651357889175, 0.043076418340206146, 0.06129120662808418, 0.015759941190481186, 0.3238930106163025, 0.116721972823143, -1]}
{"idB": "1316175_12_item1a_p107_s0", "idA": "1316175_11_item1a_p111_s0", "sentA": "the patents of others will not have an adverse effect on our business.", "sentB": "we or our licensors were the first to make the inventions covered by each of our pending patent applications; we or our licensors were the first to file patent applications for these inventions; others will not independently develop similar or alternative technologies or duplicate any of our technologies; any of our or our licensors' pending patent applications will result in issued patents; any of our or our licensors' patents will be valid or enforceable; any patents issued to us or our licensors and collaborators will provide a basis for commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties; we will develop additional proprietary technologies or product candidates that are patentable; or the patents of others will not have an adverse effect on our business.", "type": 2, "words": ["<tag1>", "the", "patents", "of", "others", "will", "not", "have", "an", "adverse", "effect", "on", "our", "business.", "<tag2>", "we", "or", "our", "licensors", "were", "the", "first", "to", "make", "the", "inventions", "covered", "by", "each", "of", "our", "pending", "patent", "applications;", "we", "or", "our", "licensors", "were", "the", "first", "to", "file", "patent", "applications", "for", "these", "inventions;", "others", "will", "not", "independently", "develop", "similar", "or", "alternative", "technologies", "or", "duplicate", "any", "of", "our", "technologies;", "any", "of", "our", "or", "our", "licensors'", "pending", "patent", "applications", "will", "result", "in", "issued", "patents;", "any", "of", "our", "or", "our", "licensors'", "patents", "will", "be", "valid", "or", "enforceable;", "any", "patents", "issued", "to", "us", "or", "our", "licensors", "and", "collaborators", "will", "provide", "a", "basis", "for", "commercially", "viable", "products,", "will", "provide", "us", "with", "any", "competitive", "advantages", "or", "will", "not", "be", "challenged", "by", "third", "parties;", "we", "will", "develop", "additional", "proprietary", "technologies", "or", "product", "candidates", "that", "are", "patentable;", "or", "the", "patents", "of", "others", "will", "not", "have", "an", "adverse", "effect", "on", "our", "business.", "<tag3>"], "wordsA": ["the", "patents", "of", "others", "will", "not", "have", "an", "adverse", "effect", "on", "our", "business."], "wordsB": ["we", "or", "our", "licensors", "were", "the", "first", "to", "make", "the", "inventions", "covered", "by", "each", "of", "our", "pending", "patent", "applications;", "we", "or", "our", "licensors", "were", "the", "first", "to", "file", "patent", "applications", "for", "these", "inventions;", "others", "will", "not", "independently", "develop", "similar", "or", "alternative", "technologies", "or", "duplicate", "any", "of", "our", "technologies;", "any", "of", "our", "or", "our", "licensors'", "pending", "patent", "applications", "will", "result", "in", "issued", "patents;", "any", "of", "our", "or", "our", "licensors'", "patents", "will", "be", "valid", "or", "enforceable;", "any", "patents", "issued", "to", "us", "or", "our", "licensors", "and", "collaborators", "will", "provide", "a", "basis", "for", "commercially", "viable", "products,", "will", "provide", "us", "with", "any", "competitive", "advantages", "or", "will", "not", "be", "challenged", "by", "third", "parties;", "we", "will", "develop", "additional", "proprietary", "technologies", "or", "product", "candidates", "that", "are", "patentable;", "or", "the", "patents", "of", "others", "will", "not", "have", "an", "adverse", "effect", "on", "our", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.03703887760639191, 0.024027742445468903, 0.012259640730917454, 0.04024540260434151, 0.013429151847958565, 0.01503036916255951, 0.055830348283052444, 0.040522001683712006, 0.07806587964296341, 0.03955971449613571, 0.13001950085163116, 0.013035205192863941, 0.006821634713560343, 0.00943162851035595, 0.005259227938950062, 0.008385369554162025, 0.01800992526113987, 0.03225822374224663, 0.047450952231884, 0.01694233901798725, 0.010557021014392376, 0.008154266513884068, 0.033685628324747086, 0.008958014659583569, 0.008631854318082333, 0.03319103643298149, 0.027291765436530113, 0.08468641340732574, 0.07945650070905685, 0.08646973967552185, 0.008675813674926758, 0.009145112708210945, 0.034156426787376404, 0.008076769299805164, 0.01316638570278883, 0.07283076643943787, 0.05068241059780121, 0.06829069554805756, 0.04448312520980835, 0.0031288587488234043, 0.04039256274700165, 0.060907140374183655, 0.013324050232768059, 0.20149526000022888, 0.03468150645494461, 0.013999822549521923, 0.02347697876393795, 0.057813629508018494, 0.06788012385368347, 0.007827352732419968, 0.015330550260841846, 0.007131610997021198, 0.00838291086256504, 0.012383691035211086, 0.016512960195541382, 0.021642131730914116, 0.02651403285562992, 0.010763709433376789, 0.02527375891804695, 0.03182932361960411, 0.24811170995235443, 0.32402220368385315, 0.12831369042396545, 0.008445970714092255, 0.014716288074851036, 0.008040162734687328, 0.00995637010782957, 0.03464450687170029, 0.127103790640831, 0.03867573291063309, 0.11945609748363495, 0.5386234521865845, 0.28520411252975464, 0.7049413919448853, 0.05414541810750961, 0.2054968923330307, 0.04397422820329666, 0.019823947921395302, 0.023034442216157913, 0.018859662115573883, 0.011070984415709972, 0.03477946296334267, 0.018827995285391808, 0.035820189863443375, 0.01473964098840952, 0.06967861205339432, 0.056313470005989075, 0.16560101509094238, 0.033199187368154526, 0.08447224646806717, 0.10468751192092896, 0.10392087697982788, 0.011858589947223663, 0.029055196791887283, 0.03728737682104111, 0.03970654681324959, 0.023482566699385643, 0.06977282464504242, 0.0677308738231659, 0.007123182527720928, 0.010559224523603916, 0.04627983272075653, 0.015267299488186836, 0.07181766629219055, 0.015819303691387177, 0.04927924647927284, 0.05882636457681656, 0.007571627851575613, 0.005779750179499388, 0.06779199093580246, 0.04940945655107498, 0.08734538406133652, 0.1339629739522934, 0.008180663920938969, 0.05099854990839958, 0.060500603169202805, 0.00836773868650198, 0.008249873295426369, 0.021813537925481796, 0.006132111884653568, 0.004780614282935858, 0.053625140339136124, 0.0044241612777113914, 0.00999491661787033, 0.006278994493186474, 0.08544397354125977, 0.014269319362938404, 0.005292658694088459, 0.0151921221986413, 0.01080309972167015, 0.005611760076135397, 0.012317708693444729, 0.02121816575527191, -1]}
{"idB": "1316175_12_item1a_p108_s1", "idA": "1316175_11_item1a_p113_s0", "sentA": "We rely on trade secrets to protect our proprietary know-how and technological advances, especially where we do not believe patent protection is appropriate or obtainable.", "sentB": "Based on our analyses, if these patents were asserted against us, we do not believe that blisibimod would be found to infringe any valid claim of these patents.", "type": 2, "words": ["<tag1>", "We", "rely", "on", "trade", "secrets", "to", "protect", "our", "proprietary", "know-how", "and", "technological", "advances,", "especially", "where", "we", "do", "not", "believe", "patent", "protection", "is", "appropriate", "or", "obtainable.", "<tag2>", "Based", "on", "our", "analyses,", "if", "these", "patents", "were", "asserted", "against", "us,", "we", "do", "not", "believe", "that", "blisibimod", "would", "be", "found", "to", "infringe", "any", "valid", "claim", "of", "these", "patents.", "<tag3>"], "wordsA": ["We", "rely", "on", "trade", "secrets", "to", "protect", "our", "proprietary", "know-how", "and", "technological", "advances,", "especially", "where", "we", "do", "not", "believe", "patent", "protection", "is", "appropriate", "or", "obtainable."], "wordsB": ["Based", "on", "our", "analyses,", "if", "these", "patents", "were", "asserted", "against", "us,", "we", "do", "not", "believe", "that", "blisibimod", "would", "be", "found", "to", "infringe", "any", "valid", "claim", "of", "these", "patents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.021437127143144608, 0.012077116407454014, 0.01717185415327549, 0.06030723452568054, 0.04362749308347702, 0.01680859550833702, 0.26650455594062805, 0.08258314430713654, 0.1550264060497284, 0.17728537321090698, 0.07824858278036118, 0.027877524495124817, 0.2547807991504669, 0.3194871246814728, 0.2508700489997864, 0.10518134385347366, 0.28189617395401, 0.15015417337417603, 0.12829823791980743, 0.13563849031925201, 0.13746103644371033, 0.30370208621025085, 0.18050986528396606, 0.22997787594795227, 0.26291781663894653, 0.05626697838306427, 0.05334644764661789, 0.1826844960451126, -1]}
{"idB": "1316175_12_item1a_p110_s3", "idA": "1316175_11_item1a_p114_s0", "sentA": "not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information.", "sentB": "These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information.", "type": 2, "words": ["<tag1>", "not", "effectively", "prevent", "disclosure", "of", "confidential", "information", "and", "may", "not", "provide", "an", "adequate", "remedy", "in", "the", "event", "of", "unauthorized", "disclosure", "of", "confidential", "information.", "<tag2>", "These", "agreements", "may", "not", "effectively", "prevent", "disclosure", "of", "confidential", "information", "and", "may", "not", "provide", "an", "adequate", "remedy", "in", "the", "event", "of", "unauthorized", "disclosure", "of", "confidential", "information.", "<tag3>"], "wordsA": ["not", "effectively", "prevent", "disclosure", "of", "confidential", "information", "and", "may", "not", "provide", "an", "adequate", "remedy", "in", "the", "event", "of", "unauthorized", "disclosure", "of", "confidential", "information."], "wordsB": ["These", "agreements", "may", "not", "effectively", "prevent", "disclosure", "of", "confidential", "information", "and", "may", "not", "provide", "an", "adequate", "remedy", "in", "the", "event", "of", "unauthorized", "disclosure", "of", "confidential", "information."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.017768627032637596, 0.222463458776474, 0.02183670364320278, 0.04870576038956642, 0.014886771328747272, 0.018972478806972504, 0.008989599533379078, 0.0037734212819486856, 0.011134459637105465, 0.010396269150078297, 0.008628631941974163, 0.004392394796013832, 0.014623700641095638, 0.010388343594968319, 0.004308861680328846, 0.013366411440074444, 0.01551559567451477, 0.0025991250295192003, 0.0028031491674482822, 0.0035692418459802866, 0.0027103261090815067, 0.004397583659738302, 0.005620444193482399, 0.0024377356749027967, 0.009424146264791489, 0.008774776943027973, -1]}
{"idB": "1316175_12_item1a_p101_s1", "idA": "1316175_11_item1a_p116_s0", "sentA": "We have obtained exclusive, worldwide licenses, except for Japan, of the composition of matter, methods of making and methods of use for certain sPLA 2 compounds from Eli Lilly and Shionogi Co., Ltd.", "sentB": "Our varespladib sodium/varespladib portfolio includes patents and patent applications originally filed by Anthera and exclusively licensed or assigned cases from Eli Lilly and Shionogi Co., Ltd.", "type": 2, "words": ["<tag1>", "We", "have", "obtained", "exclusive,", "worldwide", "licenses,", "except", "for", "Japan,", "of", "the", "composition", "of", "matter,", "methods", "of", "making", "and", "methods", "of", "use", "for", "certain", "sPLA", "2", "compounds", "from", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "<tag2>", "Our", "varespladib", "sodium/varespladib", "portfolio", "includes", "patents", "and", "patent", "applications", "originally", "filed", "by", "Anthera", "and", "exclusively", "licensed", "or", "assigned", "cases", "from", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "<tag3>"], "wordsA": ["We", "have", "obtained", "exclusive,", "worldwide", "licenses,", "except", "for", "Japan,", "of", "the", "composition", "of", "matter,", "methods", "of", "making", "and", "methods", "of", "use", "for", "certain", "sPLA", "2", "compounds", "from", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd."], "wordsB": ["Our", "varespladib", "sodium/varespladib", "portfolio", "includes", "patents", "and", "patent", "applications", "originally", "filed", "by", "Anthera", "and", "exclusively", "licensed", "or", "assigned", "cases", "from", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.01285384502261877, 0.3681476414203644, 0.5655336976051331, 0.11166346073150635, 0.014493394643068314, 0.09393933415412903, 0.027277132496237755, 0.11913998425006866, 0.14986737072467804, 0.009177260100841522, 0.014762476086616516, 0.011626174673438072, 0.051269300282001495, 0.005499247927218676, 0.05543256551027298, 0.04207198694348335, 0.01494655292481184, 0.06782673299312592, 0.0939987301826477, 0.00645621819421649, 0.008314767852425575, 0.009321106597781181, 0.004515276290476322, 0.0068753426894545555, 0.006670001428574324, 0.008104720152914524, -1]}
{"idB": "1316175_12_item1a_p112_s0", "idA": "1316175_11_item1a_p116_s0", "sentA": "We have obtained exclusive, worldwide licenses, except for Japan, of the composition of matter, methods of making and methods of use for certain sPLA 2 compounds from Eli Lilly and Shionogi Co., Ltd.", "sentB": "We have obtained exclusive, worldwide licenses, except for Japan, of the composition of matter, methods of making and methods of use for certain sPLA2 compounds from Eli Lilly and Shionogi Co., Ltd.", "type": 2, "words": ["<tag1>", "We", "have", "obtained", "exclusive,", "worldwide", "licenses,", "except", "for", "Japan,", "of", "the", "composition", "of", "matter,", "methods", "of", "making", "and", "methods", "of", "use", "for", "certain", "sPLA", "2", "compounds", "from", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "<tag2>", "We", "have", "obtained", "exclusive,", "worldwide", "licenses,", "except", "for", "Japan,", "of", "the", "composition", "of", "matter,", "methods", "of", "making", "and", "methods", "of", "use", "for", "certain", "sPLA2", "compounds", "from", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "<tag3>"], "wordsA": ["We", "have", "obtained", "exclusive,", "worldwide", "licenses,", "except", "for", "Japan,", "of", "the", "composition", "of", "matter,", "methods", "of", "making", "and", "methods", "of", "use", "for", "certain", "sPLA", "2", "compounds", "from", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd."], "wordsB": ["We", "have", "obtained", "exclusive,", "worldwide", "licenses,", "except", "for", "Japan,", "of", "the", "composition", "of", "matter,", "methods", "of", "making", "and", "methods", "of", "use", "for", "certain", "sPLA2", "compounds", "from", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.001977192470803857, 0.0019446597434580326, 0.003025653539225459, 0.003964329604059458, 0.0037558902986347675, 0.00385745195671916, 0.0029636756516993046, 0.002562648616731167, 0.0028542312793433666, 0.0021166359074413776, 0.002068473957479, 0.002915680641308427, 0.0027255802415311337, 0.002841829787939787, 0.002262735739350319, 0.0024895546957850456, 0.0024853767827153206, 0.002062736777588725, 0.0022738371044397354, 0.0022614002227783203, 0.002715153619647026, 0.0016634324565529823, 0.002182340482249856, 0.9915648698806763, 0.09562715888023376, 0.0017736218869686127, 0.002479126211255789, 0.003151391400024295, 0.002214442938566208, 0.004159313626587391, 0.003261384554207325, 0.0038019740022718906, -1]}
{"idB": "1316175_12_item1a_p112_s1", "idA": "1316175_11_item1a_p116_s1", "sentA": "In addition, we are party to a license agreement with Amgen that provides exclusive and worldwide rights to develop and commercialize A-623, a novel BAFF inhibitor, as well as non-exclusive rights to certain technology relating to peptibody compositions and formulations.", "sentB": "In addition, we are party to a license agreement with Amgen that provides exclusive and worldwide rights to develop and commercialize blisibimod a novel BAFF inhibitor, as well as non-exclusive rights to certain technology relating to peptibody compositions and formulations.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "are", "party", "to", "a", "license", "agreement", "with", "Amgen", "that", "provides", "exclusive", "and", "worldwide", "rights", "to", "develop", "and", "commercialize", "A-623,", "a", "novel", "BAFF", "inhibitor,", "as", "well", "as", "non-exclusive", "rights", "to", "certain", "technology", "relating", "to", "peptibody", "compositions", "and", "formulations.", "<tag2>", "In", "addition,", "we", "are", "party", "to", "a", "license", "agreement", "with", "Amgen", "that", "provides", "exclusive", "and", "worldwide", "rights", "to", "develop", "and", "commercialize", "blisibimod", "a", "novel", "BAFF", "inhibitor,", "as", "well", "as", "non-exclusive", "rights", "to", "certain", "technology", "relating", "to", "peptibody", "compositions", "and", "formulations.", "<tag3>"], "wordsA": ["In", "addition,", "we", "are", "party", "to", "a", "license", "agreement", "with", "Amgen", "that", "provides", "exclusive", "and", "worldwide", "rights", "to", "develop", "and", "commercialize", "A-623,", "a", "novel", "BAFF", "inhibitor,", "as", "well", "as", "non-exclusive", "rights", "to", "certain", "technology", "relating", "to", "peptibody", "compositions", "and", "formulations."], "wordsB": ["In", "addition,", "we", "are", "party", "to", "a", "license", "agreement", "with", "Amgen", "that", "provides", "exclusive", "and", "worldwide", "rights", "to", "develop", "and", "commercialize", "blisibimod", "a", "novel", "BAFF", "inhibitor,", "as", "well", "as", "non-exclusive", "rights", "to", "certain", "technology", "relating", "to", "peptibody", "compositions", "and", "formulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0032587985042482615, 0.005337399430572987, 0.004640681203454733, 0.004051647149026394, 0.00854021031409502, 0.005518587771803141, 0.004721344448626041, 0.007057333365082741, 0.010061037726700306, 0.006599462125450373, 0.006470852065831423, 0.006631443742662668, 0.0036505903117358685, 0.005865505430847406, 0.007046569138765335, 0.004377350676804781, 0.005335989408195019, 0.003187247784808278, 0.004030360374599695, 0.003955726511776447, 0.014159035868942738, 0.9408336281776428, 0.004729275591671467, 0.005197187419980764, 0.005518368445336819, 0.005041731987148523, 0.0069703636690974236, 0.0044576129876077175, 0.005766848102211952, 0.009998464956879616, 0.005289335735142231, 0.0038996480870991945, 0.003752446500584483, 0.003459397004917264, 0.0033696587197482586, 0.0029234427493065596, 0.005528425797820091, 0.0034641919191926718, 0.0030361516401171684, 0.003082811366766691, -1]}
{"idB": "1316175_12_item1a_p113_s0", "idA": "1316175_11_item1a_p117_s0", "sentA": "We depend in part on our licensors to protect the proprietary rights covering our in-licensed sPLA 2 compounds and A-623, respectively.", "sentB": "We depend in part on our licensors to protect the proprietary rights covering our in-licensed sPLA2 compounds and blisibimod, respectively.", "type": 2, "words": ["<tag1>", "We", "depend", "in", "part", "on", "our", "licensors", "to", "protect", "the", "proprietary", "rights", "covering", "our", "in-licensed", "sPLA", "2", "compounds", "and", "A-623,", "respectively.", "<tag2>", "We", "depend", "in", "part", "on", "our", "licensors", "to", "protect", "the", "proprietary", "rights", "covering", "our", "in-licensed", "sPLA2", "compounds", "and", "blisibimod,", "respectively.", "<tag3>"], "wordsA": ["We", "depend", "in", "part", "on", "our", "licensors", "to", "protect", "the", "proprietary", "rights", "covering", "our", "in-licensed", "sPLA", "2", "compounds", "and", "A-623,", "respectively."], "wordsB": ["We", "depend", "in", "part", "on", "our", "licensors", "to", "protect", "the", "proprietary", "rights", "covering", "our", "in-licensed", "sPLA2", "compounds", "and", "blisibimod,", "respectively."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0036178864538669586, 0.006126897409558296, 0.003147863782942295, 0.003956940956413746, 0.0036761313676834106, 0.0030486276373267174, 0.005125027149915695, 0.0019747833721339703, 0.004363672342151403, 0.001950324629433453, 0.0047059440985322, 0.005487455055117607, 0.005332328844815493, 0.0033498918637633324, 0.00812735315412283, 0.5399907231330872, 0.1295730173587799, 0.02729429490864277, 0.8168085813522339, 0.006019129883497953, -1]}
{"idB": "1316175_12_item1a_p116_s0", "idA": "1316175_11_item1a_p120_s0", "sentA": "The United States Drug Price Competition and Patent Term Restoration Act of 1984, more commonly known as the Hatch-Waxman Act, provides for an extension of patent term for drug compounds for a period of up to five years to compensate for time spent in the regulatory approval process.", "sentB": "The United States Drug Price Competition and Patent Term Restoration Act of 1984, more commonly known as the \"Hatch-Waxman Act,\" provides for an extension of patent term for drug compounds for a period of up to five years to compensate for time spent in the regulatory approval process.", "type": 2, "words": ["<tag1>", "The", "United", "States", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "more", "commonly", "known", "as", "the", "Hatch-Waxman", "Act,", "provides", "for", "an", "extension", "of", "patent", "term", "for", "drug", "compounds", "for", "a", "period", "of", "up", "to", "five", "years", "to", "compensate", "for", "time", "spent", "in", "the", "regulatory", "approval", "process.", "<tag2>", "The", "United", "States", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "more", "commonly", "known", "as", "the", "\"Hatch-Waxman", "Act,\"", "provides", "for", "an", "extension", "of", "patent", "term", "for", "drug", "compounds", "for", "a", "period", "of", "up", "to", "five", "years", "to", "compensate", "for", "time", "spent", "in", "the", "regulatory", "approval", "process.", "<tag3>"], "wordsA": ["The", "United", "States", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "more", "commonly", "known", "as", "the", "Hatch-Waxman", "Act,", "provides", "for", "an", "extension", "of", "patent", "term", "for", "drug", "compounds", "for", "a", "period", "of", "up", "to", "five", "years", "to", "compensate", "for", "time", "spent", "in", "the", "regulatory", "approval", "process."], "wordsB": ["The", "United", "States", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "more", "commonly", "known", "as", "the", "\"Hatch-Waxman", "Act,\"", "provides", "for", "an", "extension", "of", "patent", "term", "for", "drug", "compounds", "for", "a", "period", "of", "up", "to", "five", "years", "to", "compensate", "for", "time", "spent", "in", "the", "regulatory", "approval", "process."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.021784787997603416, 0.12388650327920914, 0.09643044322729111, 0.10277506709098816, 0.09496849775314331, 0.09264275431632996, 0.02715487964451313, 0.07225972414016724, 0.05354995280504227, 0.06404683738946915, 0.07406267523765564, 0.043883804231882095, 0.06400210410356522, 0.07201634347438812, 0.07625780254602432, 0.06364434212446213, 0.07456924766302109, 0.043354582041502, 0.3725188970565796, 0.35705292224884033, 0.05475689098238945, 0.028187477961182594, 0.038078147917985916, 0.07349395751953125, 0.04936866834759712, 0.13935230672359467, 0.09976211190223694, 0.03514653071761131, 0.08468645811080933, 0.08191519230604172, 0.03330443799495697, 0.035436179488897324, 0.0441756509244442, 0.03274289146065712, 0.0749475434422493, 0.05557439848780632, 0.09381821006536484, 0.06557972729206085, 0.041540466248989105, 0.060357727110385895, 0.05130483955144882, 0.06903698295354843, 0.05775550752878189, 0.04384748637676239, 0.03571759909391403, 0.11804232746362686, 0.13572071492671967, 0.09450675547122955, -1]}
{"idB": "1316175_12_item1a_p116_s1", "idA": "1316175_11_item1a_p120_s1", "sentA": "Assuming we gain a five-year patent term extension for each of our current product candidates in clinical development, and that we continue to have rights under our license agreements with respect to these product candidates, we would have exclusive rights to varespladib s U.S. new chemical entity patent (the primary patent covering the compound as a new composition of matter) until 2019 and to A-623 s U.S. new chemical entity patent until 2027.", "sentB": "Assuming we gain a five-year patent term extension for each of our current product candidates in clinical development, and that we continue to have rights under our license agreements with respect to these product candidates, we would have exclusive rights to varespladib's U.S. \"new chemical entity\" patent (the primary patent covering the compound as a new composition of matter) until 2019 and to blisibimod's U.S. new chemical entity patent until 2027.", "type": 2, "words": ["<tag1>", "Assuming", "we", "gain", "a", "five-year", "patent", "term", "extension", "for", "each", "of", "our", "current", "product", "candidates", "in", "clinical", "development,", "and", "that", "we", "continue", "to", "have", "rights", "under", "our", "license", "agreements", "with", "respect", "to", "these", "product", "candidates,", "we", "would", "have", "exclusive", "rights", "to", "varespladib", "s", "U.S.", "new", "chemical", "entity", "patent", "(the", "primary", "patent", "covering", "the", "compound", "as", "a", "new", "composition", "of", "matter)", "until", "2019", "and", "to", "A-623", "s", "U.S.", "new", "chemical", "entity", "patent", "until", "2027.", "<tag2>", "Assuming", "we", "gain", "a", "five-year", "patent", "term", "extension", "for", "each", "of", "our", "current", "product", "candidates", "in", "clinical", "development,", "and", "that", "we", "continue", "to", "have", "rights", "under", "our", "license", "agreements", "with", "respect", "to", "these", "product", "candidates,", "we", "would", "have", "exclusive", "rights", "to", "varespladib's", "U.S.", "\"new", "chemical", "entity\"", "patent", "(the", "primary", "patent", "covering", "the", "compound", "as", "a", "new", "composition", "of", "matter)", "until", "2019", "and", "to", "blisibimod's", "U.S.", "new", "chemical", "entity", "patent", "until", "2027.", "<tag3>"], "wordsA": ["Assuming", "we", "gain", "a", "five-year", "patent", "term", "extension", "for", "each", "of", "our", "current", "product", "candidates", "in", "clinical", "development,", "and", "that", "we", "continue", "to", "have", "rights", "under", "our", "license", "agreements", "with", "respect", "to", "these", "product", "candidates,", "we", "would", "have", "exclusive", "rights", "to", "varespladib", "s", "U.S.", "new", "chemical", "entity", "patent", "(the", "primary", "patent", "covering", "the", "compound", "as", "a", "new", "composition", "of", "matter)", "until", "2019", "and", "to", "A-623", "s", "U.S.", "new", "chemical", "entity", "patent", "until", "2027."], "wordsB": ["Assuming", "we", "gain", "a", "five-year", "patent", "term", "extension", "for", "each", "of", "our", "current", "product", "candidates", "in", "clinical", "development,", "and", "that", "we", "continue", "to", "have", "rights", "under", "our", "license", "agreements", "with", "respect", "to", "these", "product", "candidates,", "we", "would", "have", "exclusive", "rights", "to", "varespladib's", "U.S.", "\"new", "chemical", "entity\"", "patent", "(the", "primary", "patent", "covering", "the", "compound", "as", "a", "new", "composition", "of", "matter)", "until", "2019", "and", "to", "blisibimod's", "U.S.", "new", "chemical", "entity", "patent", "until", "2027."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0146043561398983, 0.012753110378980637, 0.018894894048571587, 0.011683491058647633, 0.01657022349536419, 0.029207514598965645, 0.020903686061501503, 0.017177876085042953, 0.007420343346893787, 0.017317436635494232, 0.010559074580669403, 0.008638761006295681, 0.010229677893221378, 0.013072101399302483, 0.012523083947598934, 0.007573236711323261, 0.009675989858806133, 0.010559682734310627, 0.009060854092240334, 0.008242394775152206, 0.010981597006320953, 0.018019866198301315, 0.014813191257417202, 0.019055252894759178, 0.03142828121781349, 0.009937440976500511, 0.008942576125264168, 0.01799013838171959, 0.02182130701839924, 0.013743806630373001, 0.010327105410397053, 0.007349631283432245, 0.006964369211345911, 0.010056816041469574, 0.010949920862913132, 0.010874826461076736, 0.010665927082300186, 0.012133022770285606, 0.021976185962557793, 0.022473083809018135, 0.008269614540040493, 0.016823651269078255, 0.015746455639600754, 0.03140830993652344, 0.01687444932758808, 0.019248219206929207, 0.020196417346596718, 0.00822268333286047, 0.014185496605932713, 0.02497926726937294, 0.009427210316061974, 0.007070865947753191, 0.00940060243010521, 0.0060121784918010235, 0.007064387202262878, 0.007230757270008326, 0.009828824549913406, 0.008910153992474079, 0.009911567904055119, 0.007942568510770798, 0.009050549939274788, 0.005012804642319679, 0.005842788144946098, 0.7890070676803589, 0.022068602964282036, 0.008062213659286499, 0.01015839446336031, 0.009522520937025547, 0.017438890412449837, 0.007452794350683689, 0.009815293364226818, -1]}
{"idB": "1316175_12_item1a_p117_s1", "idA": "1316175_11_item1a_p121_s1", "sentA": "Assuming we gain such a five-year extension for each of our current product candidates in clinical development, and that we continue to have rights under our license agreements with respect to these product candidates, we would have exclusive rights to varespladib s European new chemical entity patents until 2020 and to A-623 s European new chemical entity patents until 2027.", "sentB": "Assuming we gain such a five-year extension for each of our current product candidates in clinical development, and that we continue to have rights under our license agreements with respect to these product candidates, we would have exclusive rights to varespladib's European new chemical entity patents until 2020 and to blisibimod's European new chemical entity patents until 2027.", "type": 2, "words": ["<tag1>", "Assuming", "we", "gain", "such", "a", "five-year", "extension", "for", "each", "of", "our", "current", "product", "candidates", "in", "clinical", "development,", "and", "that", "we", "continue", "to", "have", "rights", "under", "our", "license", "agreements", "with", "respect", "to", "these", "product", "candidates,", "we", "would", "have", "exclusive", "rights", "to", "varespladib", "s", "European", "new", "chemical", "entity", "patents", "until", "2020", "and", "to", "A-623", "s", "European", "new", "chemical", "entity", "patents", "until", "2027.", "<tag2>", "Assuming", "we", "gain", "such", "a", "five-year", "extension", "for", "each", "of", "our", "current", "product", "candidates", "in", "clinical", "development,", "and", "that", "we", "continue", "to", "have", "rights", "under", "our", "license", "agreements", "with", "respect", "to", "these", "product", "candidates,", "we", "would", "have", "exclusive", "rights", "to", "varespladib's", "European", "new", "chemical", "entity", "patents", "until", "2020", "and", "to", "blisibimod's", "European", "new", "chemical", "entity", "patents", "until", "2027.", "<tag3>"], "wordsA": ["Assuming", "we", "gain", "such", "a", "five-year", "extension", "for", "each", "of", "our", "current", "product", "candidates", "in", "clinical", "development,", "and", "that", "we", "continue", "to", "have", "rights", "under", "our", "license", "agreements", "with", "respect", "to", "these", "product", "candidates,", "we", "would", "have", "exclusive", "rights", "to", "varespladib", "s", "European", "new", "chemical", "entity", "patents", "until", "2020", "and", "to", "A-623", "s", "European", "new", "chemical", "entity", "patents", "until", "2027."], "wordsB": ["Assuming", "we", "gain", "such", "a", "five-year", "extension", "for", "each", "of", "our", "current", "product", "candidates", "in", "clinical", "development,", "and", "that", "we", "continue", "to", "have", "rights", "under", "our", "license", "agreements", "with", "respect", "to", "these", "product", "candidates,", "we", "would", "have", "exclusive", "rights", "to", "varespladib's", "European", "new", "chemical", "entity", "patents", "until", "2020", "and", "to", "blisibimod's", "European", "new", "chemical", "entity", "patents", "until", "2027."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.019485974684357643, 0.015145898796617985, 0.018691835924983025, 0.014089236967265606, 0.011969385668635368, 0.016680346801877022, 0.01781078800559044, 0.008985004387795925, 0.018117982894182205, 0.011314255185425282, 0.011329872533679008, 0.011679505929350853, 0.009622367098927498, 0.01157548651099205, 0.007249567192047834, 0.007822906598448753, 0.00964890606701374, 0.008625058457255363, 0.00819831807166338, 0.017404459416866302, 0.023211946710944176, 0.015002214349806309, 0.019963463768363, 0.02549290657043457, 0.009924408048391342, 0.01074240729212761, 0.0175015851855278, 0.017302460968494415, 0.01379951648414135, 0.011037098243832588, 0.007661544252187014, 0.007215479388833046, 0.010053317062556744, 0.016659118235111237, 0.012983920983970165, 0.015103977173566818, 0.01480838842689991, 0.024471832439303398, 0.019107569009065628, 0.007803127635270357, 0.326561838388443, 0.029717493802309036, 0.016135914251208305, 0.018302801996469498, 0.01572626456618309, 0.07164463400840759, 0.009563521482050419, 0.010587717406451702, 0.005699750501662493, 0.005068753845989704, 0.7267341613769531, 0.019938811659812927, 0.010803288780152798, 0.015538884326815605, 0.013521235436201096, 0.07217580080032349, 0.006989427376538515, 0.011900916695594788, -1]}
{"idB": "1316175_12_item1a_p117_s2", "idA": "1316175_11_item1a_p122_s2", "sentA": "Further, since A-623 has not been previously approved, A-623 could be eligible for 12 years of data exclusivity from the FDA.", "sentB": "In addition, since varespladib has not been previously approved in the United States, varespladib could be eligible for up to five years of New Chemical Entity, or NCE, exclusivity from the FDA.", "type": 2, "words": ["<tag1>", "Further,", "since", "A-623", "has", "not", "been", "previously", "approved,", "A-623", "could", "be", "eligible", "for", "12", "years", "of", "data", "exclusivity", "from", "the", "FDA.", "<tag2>", "In", "addition,", "since", "varespladib", "has", "not", "been", "previously", "approved", "in", "the", "United", "States,", "varespladib", "could", "be", "eligible", "for", "up", "to", "five", "years", "of", "New", "Chemical", "Entity,", "or", "NCE,", "exclusivity", "from", "the", "FDA.", "<tag3>"], "wordsA": ["Further,", "since", "A-623", "has", "not", "been", "previously", "approved,", "A-623", "could", "be", "eligible", "for", "12", "years", "of", "data", "exclusivity", "from", "the", "FDA."], "wordsB": ["In", "addition,", "since", "varespladib", "has", "not", "been", "previously", "approved", "in", "the", "United", "States,", "varespladib", "could", "be", "eligible", "for", "up", "to", "five", "years", "of", "New", "Chemical", "Entity,", "or", "NCE,", "exclusivity", "from", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.01334953773766756, 0.007779467850923538, 0.0078124795109033585, 0.4697699248790741, 0.016704421490430832, 0.08574041724205017, 0.015386493876576424, 0.03694051876664162, 0.03604637831449509, 0.00730894086882472, 0.006765016354620457, 0.013523482717573643, 0.017109157517552376, 0.03854982554912567, 0.004467130638659, 0.004256752785295248, 0.0187629796564579, 0.006688256282359362, 0.1625467985868454, 0.04351289942860603, 0.7710875272750854, 0.13531409204006195, 0.010472950525581837, 0.17430098354816437, 0.16877059638500214, 0.16066786646842957, 0.010737896896898746, 0.21600140631198883, 0.03816596791148186, 0.002999533200636506, 0.0023886633571237326, 0.011893860064446926, -1]}
{"idB": "1316175_12_item1a_p117_s4", "idA": "1316175_11_item1a_p122_s2", "sentA": "Further, since A-623 has not been previously approved, A-623 could be eligible for 12 years of data exclusivity from the FDA.", "sentB": "Further, since blisibimod has not been previously approved, blisibimod could be eligible for 12 years of data exclusivity from the FDA.", "type": 2, "words": ["<tag1>", "Further,", "since", "A-623", "has", "not", "been", "previously", "approved,", "A-623", "could", "be", "eligible", "for", "12", "years", "of", "data", "exclusivity", "from", "the", "FDA.", "<tag2>", "Further,", "since", "blisibimod", "has", "not", "been", "previously", "approved,", "blisibimod", "could", "be", "eligible", "for", "12", "years", "of", "data", "exclusivity", "from", "the", "FDA.", "<tag3>"], "wordsA": ["Further,", "since", "A-623", "has", "not", "been", "previously", "approved,", "A-623", "could", "be", "eligible", "for", "12", "years", "of", "data", "exclusivity", "from", "the", "FDA."], "wordsB": ["Further,", "since", "blisibimod", "has", "not", "been", "previously", "approved,", "blisibimod", "could", "be", "eligible", "for", "12", "years", "of", "data", "exclusivity", "from", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.005964822135865688, 0.007432701997458935, 0.9518080353736877, 0.0177933182567358, 0.19965429604053497, 0.020211245864629745, 0.026991216465830803, 0.038699921220541, 0.13820883631706238, 0.0029493721667677164, 0.003734172787517309, 0.005136081483215094, 0.002252055099233985, 0.0027619581669569016, 0.0026983502320945263, 0.0022868348751217127, 0.002964150393381715, 0.0032720789313316345, 0.002065956825390458, 0.0021565761417150497, 0.004966650158166885, -1]}
{"idB": "1316175_12_item1a_p118_s0", "idA": "1316175_11_item1a_p122_s3", "sentA": "During the data exclusivity period, competitors are barred from relying on the innovator biologic s safety and efficacy data to gain approval.", "sentB": "relying on the innovator biologic's safety and efficacy data to gain approval.", "type": 2, "words": ["<tag1>", "During", "the", "data", "exclusivity", "period,", "competitors", "are", "barred", "from", "relying", "on", "the", "innovator", "biologic", "s", "safety", "and", "efficacy", "data", "to", "gain", "approval.", "<tag2>", "relying", "on", "the", "innovator", "biologic's", "safety", "and", "efficacy", "data", "to", "gain", "approval.", "<tag3>"], "wordsA": ["During", "the", "data", "exclusivity", "period,", "competitors", "are", "barred", "from", "relying", "on", "the", "innovator", "biologic", "s", "safety", "and", "efficacy", "data", "to", "gain", "approval."], "wordsB": ["relying", "on", "the", "innovator", "biologic's", "safety", "and", "efficacy", "data", "to", "gain", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.8818867206573486, 0.20606528222560883, 0.07219159603118896, 0.34773990511894226, 0.1882328987121582, 0.11012473702430725, 0.02086685784161091, 0.022016098722815514, 0.07181631773710251, 0.02309981733560562, 0.024016154929995537, 0.0456063412129879, -1]}
{"idB": "1316175_12_item1a_p126_s1", "idA": "1316175_11_item1a_p131_s0", "sentA": "property infringement related to our product candidates, the pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual property rights.", "sentB": "Although we are not currently aware of any litigation or other proceedings or third-party claims of intellectual property infringement related to our product candidates, the pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual property rights.", "type": 2, "words": ["<tag1>", "property", "infringement", "related", "to", "our", "product", "candidates,", "the", "pharmaceutical", "industry", "is", "characterized", "by", "extensive", "litigation", "regarding", "patents", "and", "other", "intellectual", "property", "rights.", "<tag2>", "Although", "we", "are", "not", "currently", "aware", "of", "any", "litigation", "or", "other", "proceedings", "or", "third-party", "claims", "of", "intellectual", "property", "infringement", "related", "to", "our", "product", "candidates,", "the", "pharmaceutical", "industry", "is", "characterized", "by", "extensive", "litigation", "regarding", "patents", "and", "other", "intellectual", "property", "rights.", "<tag3>"], "wordsA": ["property", "infringement", "related", "to", "our", "product", "candidates,", "the", "pharmaceutical", "industry", "is", "characterized", "by", "extensive", "litigation", "regarding", "patents", "and", "other", "intellectual", "property", "rights."], "wordsB": ["Although", "we", "are", "not", "currently", "aware", "of", "any", "litigation", "or", "other", "proceedings", "or", "third-party", "claims", "of", "intellectual", "property", "infringement", "related", "to", "our", "product", "candidates,", "the", "pharmaceutical", "industry", "is", "characterized", "by", "extensive", "litigation", "regarding", "patents", "and", "other", "intellectual", "property", "rights."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.04768253117799759, 0.12505951523780823, 0.3808574676513672, 0.9001814126968384, 0.4649396240711212, 0.8652539849281311, 0.2595962584018707, 0.17606696486473083, 0.2722204625606537, 0.025131015107035637, 0.01776151917874813, 0.05163297429680824, 0.02687743492424488, 0.11063341051340103, 0.18233317136764526, 0.056354548782110214, 0.05410343036055565, 0.04601839929819107, 0.06521603465080261, 0.01624387688934803, 0.008040794171392918, 0.007430601865053177, 0.008322651498019695, 0.009846006520092487, 0.005441326182335615, 0.016264036297798157, 0.01678258553147316, 0.014324232004582882, 0.014095763675868511, 0.007786641828715801, 0.01808079145848751, 0.02828190289437771, 0.008722452446818352, 0.013428577221930027, 0.004538422450423241, 0.0035358374007046223, 0.0067716073244810104, 0.006098065059632063, 0.011947817169129848, -1]}
{"idB": "1316175_12_item1a_p108_s3", "idA": "1316175_11_item1a_p133_s0", "sentA": "Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings.", "sentB": "There is no assurance that a court would find in our favor on questions of infringement or validity, and we could incur substantial costs in litigation if we are required to defend against patent suits brought by third parties or if we initiate these suits.", "type": 2, "words": ["<tag1>", "Even", "if", "we", "are", "successful", "in", "these", "proceedings,", "we", "may", "incur", "substantial", "costs", "and", "divert", "management", "time", "and", "attention", "in", "pursuing", "these", "proceedings.", "<tag2>", "There", "is", "no", "assurance", "that", "a", "court", "would", "find", "in", "our", "favor", "on", "questions", "of", "infringement", "or", "validity,", "and", "we", "could", "incur", "substantial", "costs", "in", "litigation", "if", "we", "are", "required", "to", "defend", "against", "patent", "suits", "brought", "by", "third", "parties", "or", "if", "we", "initiate", "these", "suits.", "<tag3>"], "wordsA": ["Even", "if", "we", "are", "successful", "in", "these", "proceedings,", "we", "may", "incur", "substantial", "costs", "and", "divert", "management", "time", "and", "attention", "in", "pursuing", "these", "proceedings."], "wordsB": ["There", "is", "no", "assurance", "that", "a", "court", "would", "find", "in", "our", "favor", "on", "questions", "of", "infringement", "or", "validity,", "and", "we", "could", "incur", "substantial", "costs", "in", "litigation", "if", "we", "are", "required", "to", "defend", "against", "patent", "suits", "brought", "by", "third", "parties", "or", "if", "we", "initiate", "these", "suits."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.011530867777764797, 0.012667782604694366, 0.23136408627033234, 0.24835315346717834, 0.05634171888232231, 0.03970262408256531, 0.12407801300287247, 0.249339297413826, 0.2408137321472168, 0.18917950987815857, 0.15343937277793884, 0.18468011915683746, 0.016159603372216225, 0.040308937430381775, 0.02230711095035076, 0.04608093947172165, 0.043723348528146744, 0.04287086799740791, 0.0015873097581788898, 0.02100624330341816, 0.030556727200746536, 0.05107139050960541, 0.0505823940038681, 0.05787971243262291, 0.04832243174314499, 0.1529594212770462, 0.009169323369860649, 0.017411604523658752, 0.010793331079185009, 0.04145621135830879, 0.03338528424501419, 0.09854649007320404, 0.028154226019978523, 0.0765107199549675, 0.1525982767343521, 0.02809935249388218, 0.02626064233481884, 0.058429230004549026, 0.0828949511051178, 0.011027369648218155, 0.02258666418492794, 0.03587911278009415, 0.20192046463489532, 0.050414543598890305, 0.09718289226293564, -1]}
{"idB": "1316175_12_item1a_p108_s2", "idA": "1316175_11_item1a_p133_s1", "sentA": "If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court.", "sentB": "If we were to challenge the validity of any issued United States patent in court, we would need to overcome the presumption of validity that attaches to every United States patent by presenting clear and convincing evidence as to the invalidity of the patent's claims.", "type": 2, "words": ["<tag1>", "If", "we", "are", "unable", "to", "avoid", "infringing", "the", "patent", "rights", "of", "others,", "we", "may", "be", "required", "to", "seek", "a", "license,", "defend", "an", "infringement", "action", "or", "challenge", "the", "validity", "of", "the", "patents", "in", "court.", "<tag2>", "If", "we", "were", "to", "challenge", "the", "validity", "of", "any", "issued", "United", "States", "patent", "in", "court,", "we", "would", "need", "to", "overcome", "the", "presumption", "of", "validity", "that", "attaches", "to", "every", "United", "States", "patent", "by", "presenting", "clear", "and", "convincing", "evidence", "as", "to", "the", "invalidity", "of", "the", "patent's", "claims.", "<tag3>"], "wordsA": ["If", "we", "are", "unable", "to", "avoid", "infringing", "the", "patent", "rights", "of", "others,", "we", "may", "be", "required", "to", "seek", "a", "license,", "defend", "an", "infringement", "action", "or", "challenge", "the", "validity", "of", "the", "patents", "in", "court."], "wordsB": ["If", "we", "were", "to", "challenge", "the", "validity", "of", "any", "issued", "United", "States", "patent", "in", "court,", "we", "would", "need", "to", "overcome", "the", "presumption", "of", "validity", "that", "attaches", "to", "every", "United", "States", "patent", "by", "presenting", "clear", "and", "convincing", "evidence", "as", "to", "the", "invalidity", "of", "the", "patent's", "claims."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.013575296849012375, 0.028785306960344315, 0.033900219947099686, 0.035944338887929916, 0.25019192695617676, 0.03863907232880592, 0.10608160495758057, 0.014839322306215763, 0.044760458171367645, 0.12969352304935455, 0.12286277860403061, 0.13135138154029846, 0.2730451822280884, 0.006249604746699333, 0.0156557634472847, 0.008904126472771168, 0.01557224616408348, 0.032565198838710785, 0.027144810184836388, 0.27769193053245544, 0.04761413857340813, 0.1637611985206604, 0.09597406536340714, 0.19143256545066833, 0.007882887497544289, 0.0261391494423151, 0.016724968329072, 0.06584601104259491, 0.05409902334213257, 0.0621725358068943, 0.13281363248825073, 0.007748633623123169, 0.07041974365711212, 0.15975481271743774, 0.012100180611014366, 0.16480626165866852, 0.1519206315279007, 0.025448521599173546, 0.018800511956214905, 0.014231173321604729, 0.1940021514892578, 0.018819089978933334, 0.013588028028607368, 0.08938949555158615, 0.09661251306533813, -1]}
{"idB": "1316175_12_item1a_p50_s0", "idA": "1316175_11_item1a_p133_s1", "sentA": "If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court.", "sentB": "regulatory authorities may withdraw their approval of the product; regulatory authorities may require the addition of labeling statements, such as warnings or contraindications; we may be required to change the way the product is administered, conduct additional clinical studies or change the labeling of the product; we could be sued and held liable for harm caused to patients; and our reputation may suffer.", "type": 2, "words": ["<tag1>", "If", "we", "are", "unable", "to", "avoid", "infringing", "the", "patent", "rights", "of", "others,", "we", "may", "be", "required", "to", "seek", "a", "license,", "defend", "an", "infringement", "action", "or", "challenge", "the", "validity", "of", "the", "patents", "in", "court.", "<tag2>", "regulatory", "authorities", "may", "withdraw", "their", "approval", "of", "the", "product;", "regulatory", "authorities", "may", "require", "the", "addition", "of", "labeling", "statements,", "such", "as", "warnings", "or", "contraindications;", "we", "may", "be", "required", "to", "change", "the", "way", "the", "product", "is", "administered,", "conduct", "additional", "clinical", "studies", "or", "change", "the", "labeling", "of", "the", "product;", "we", "could", "be", "sued", "and", "held", "liable", "for", "harm", "caused", "to", "patients;", "and", "our", "reputation", "may", "suffer.", "<tag3>"], "wordsA": ["If", "we", "are", "unable", "to", "avoid", "infringing", "the", "patent", "rights", "of", "others,", "we", "may", "be", "required", "to", "seek", "a", "license,", "defend", "an", "infringement", "action", "or", "challenge", "the", "validity", "of", "the", "patents", "in", "court."], "wordsB": ["regulatory", "authorities", "may", "withdraw", "their", "approval", "of", "the", "product;", "regulatory", "authorities", "may", "require", "the", "addition", "of", "labeling", "statements,", "such", "as", "warnings", "or", "contraindications;", "we", "may", "be", "required", "to", "change", "the", "way", "the", "product", "is", "administered,", "conduct", "additional", "clinical", "studies", "or", "change", "the", "labeling", "of", "the", "product;", "we", "could", "be", "sued", "and", "held", "liable", "for", "harm", "caused", "to", "patients;", "and", "our", "reputation", "may", "suffer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.050084348767995834, 0.10709130018949509, 0.04991774633526802, 0.738054096698761, 0.2676018476486206, 0.4868551790714264, 0.08842242509126663, 0.07996455579996109, 0.22248238325119019, 0.016794510185718536, 0.024425901472568512, 0.009970692917704582, 0.12746021151542664, 0.019285889342427254, 0.1361074149608612, 0.0656970739364624, 0.2527856230735779, 0.20587950944900513, 0.001033605309203267, 0.007801705971360207, 0.054962798953056335, 0.02211732789874077, 0.14205986261367798, 0.012916868552565575, 0.005945275537669659, 0.00754935247823596, 0.05670855566859245, 0.053820714354515076, 0.34001293778419495, 0.10292886942625046, 0.07742860913276672, 0.05637088045477867, 0.1417529135942459, 0.048079442232847214, 0.06856591999530792, 0.08914031088352203, 0.06531333923339844, 0.13139982521533966, 0.1686406135559082, 0.008525651879608631, 0.1097681000828743, 0.024501310661435127, 0.11381875723600388, 0.01967126876115799, 0.02240261249244213, 0.06820037961006165, 0.020312350243330002, 0.02345605194568634, 0.04753130301833153, 0.25888291001319885, 0.0525653101503849, 0.3933728337287903, 0.4736001789569855, 0.15298855304718018, 0.23349633812904358, 0.07708358019590378, 0.04421908035874367, 0.11003062129020691, 0.003844380844384432, 0.037025757133960724, 0.23538623750209808, 0.05898330733180046, 0.18804249167442322, -1]}
{"idB": "1316175_12_item1a_p131_s0", "idA": "1316175_11_item1a_p136_s0", "sentA": "The market price for our common stock has been, and is likely to continue to be, volatile.", "sentB": "The market price for our common stock has been and is likely to continue to be volatile.", "type": 2, "words": ["<tag1>", "The", "market", "price", "for", "our", "common", "stock", "has", "been,", "and", "is", "likely", "to", "continue", "to", "be,", "volatile.", "<tag2>", "The", "market", "price", "for", "our", "common", "stock", "has", "been", "and", "is", "likely", "to", "continue", "to", "be", "volatile.", "<tag3>"], "wordsA": ["The", "market", "price", "for", "our", "common", "stock", "has", "been,", "and", "is", "likely", "to", "continue", "to", "be,", "volatile."], "wordsB": ["The", "market", "price", "for", "our", "common", "stock", "has", "been", "and", "is", "likely", "to", "continue", "to", "be", "volatile."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.01601254940032959, 0.40815600752830505, 0.5034387111663818, 0.0989106297492981, 0.11209912598133087, 0.38820821046829224, 0.40345102548599243, 0.10550007224082947, 0.1367558389902115, 0.05639706179499626, 0.040299274027347565, 0.09223491698503494, 0.05308486893773079, 0.09361304342746735, 0.0758994072675705, 0.11704239249229431, 0.6898755431175232, -1]}
{"idB": "1316175_12_item1a_p132_s0", "idA": "1316175_11_item1a_p137_s0", "sentA": "discussion of us or our stock price by the financial press and in online investor communities.", "sentB": "additions or departures of any of our key personnel; announcements related to litigation; changing legal or regulatory developments in the United States and other countries; and discussion of us or our stock price by the financial press and in online investor communities.", "type": 2, "words": ["<tag1>", "discussion", "of", "us", "or", "our", "stock", "price", "by", "the", "financial", "press", "and", "in", "online", "investor", "communities.", "<tag2>", "additions", "or", "departures", "of", "any", "of", "our", "key", "personnel;", "announcements", "related", "to", "litigation;", "changing", "legal", "or", "regulatory", "developments", "in", "the", "United", "States", "and", "other", "countries;", "and", "discussion", "of", "us", "or", "our", "stock", "price", "by", "the", "financial", "press", "and", "in", "online", "investor", "communities.", "<tag3>"], "wordsA": ["discussion", "of", "us", "or", "our", "stock", "price", "by", "the", "financial", "press", "and", "in", "online", "investor", "communities."], "wordsB": ["additions", "or", "departures", "of", "any", "of", "our", "key", "personnel;", "announcements", "related", "to", "litigation;", "changing", "legal", "or", "regulatory", "developments", "in", "the", "United", "States", "and", "other", "countries;", "and", "discussion", "of", "us", "or", "our", "stock", "price", "by", "the", "financial", "press", "and", "in", "online", "investor", "communities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.5781656503677368, 0.31972536444664, 0.710326611995697, 0.15156587958335876, 0.13207757472991943, 0.12014221400022507, 0.08211713284254074, 0.19707103073596954, 0.35234197974205017, 0.14743156731128693, 0.0452553816139698, 0.048229362815618515, 0.12825961410999298, 0.07301805168390274, 0.18131738901138306, 0.11689721792936325, 0.13821138441562653, 0.17410632967948914, 0.010713253170251846, 0.01351174432784319, 0.026300568133592606, 0.028036069124937057, 0.010430941358208656, 0.010609999299049377, 0.029165882617235184, 0.006885130424052477, 0.03009488433599472, 0.006660865154117346, 0.01790599524974823, 0.006121983751654625, 0.005317140836268663, 0.018814850598573685, 0.015324000269174576, 0.003163758432492614, 0.0035315323621034622, 0.007205543573945761, 0.007913975045084953, 0.0040268986485898495, 0.0033636107109487057, 0.0053067756816744804, 0.008050468750298023, 0.008550075814127922, -1]}
{"idB": "1316175_12_item1a_p133_s5", "idA": "1316175_11_item1a_p139_s0", "sentA": "trading price of our common stock to decline.", "sentB": "These broad market fluctuations may cause the trading price of our common stock to decline.", "type": 2, "words": ["<tag1>", "trading", "price", "of", "our", "common", "stock", "to", "decline.", "<tag2>", "These", "broad", "market", "fluctuations", "may", "cause", "the", "trading", "price", "of", "our", "common", "stock", "to", "decline.", "<tag3>"], "wordsA": ["trading", "price", "of", "our", "common", "stock", "to", "decline."], "wordsB": ["These", "broad", "market", "fluctuations", "may", "cause", "the", "trading", "price", "of", "our", "common", "stock", "to", "decline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.02271486259996891, 0.6487982869148254, 0.4934053122997284, 0.4374132752418518, 0.03470272943377495, 0.06403625011444092, 0.009121137671172619, 0.06804119795560837, 0.05206957831978798, 0.004531835671514273, 0.008414926938712597, 0.019676240161061287, 0.012514288537204266, 0.04759863391518593, 0.21851032972335815, -1]}
{"idB": "1316175_12_item1a_p140_s1", "idA": "1316175_11_item1a_p140_s1", "sentA": "We may become involved in this type of litigation in the future.", "sentB": "We may issue securities in the future pursuant to the shelf registration statement based on market conditions or other circumstances.", "type": 2, "words": ["<tag1>", "We", "may", "become", "involved", "in", "this", "type", "of", "litigation", "in", "the", "future.", "<tag2>", "We", "may", "issue", "securities", "in", "the", "future", "pursuant", "to", "the", "shelf", "registration", "statement", "based", "on", "market", "conditions", "or", "other", "circumstances.", "<tag3>"], "wordsA": ["We", "may", "become", "involved", "in", "this", "type", "of", "litigation", "in", "the", "future."], "wordsB": ["We", "may", "issue", "securities", "in", "the", "future", "pursuant", "to", "the", "shelf", "registration", "statement", "based", "on", "market", "conditions", "or", "other", "circumstances."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.031200820580124855, 0.024584023281931877, 0.7120146155357361, 0.8181082010269165, 0.009140304289758205, 0.00696928147226572, 0.02035023272037506, 0.02085106074810028, 0.00826792512089014, 0.007768544834107161, 0.037786129862070084, 0.05497710034251213, 0.04603452607989311, 0.007203650660812855, 0.0058419289998710155, 0.006567427888512611, 0.008748290129005909, 0.007188225165009499, 0.007205451373010874, 0.011943337507545948, -1]}
{"idB": "1316175_12_item1a_p136_s0", "idA": "1316175_11_item1a_p142_s0", "sentA": "Our executive officers, directors and greater than 5% stockholders, in the aggregate, own approximately 75% of our outstanding common stock.", "sentB": "Our executive officers, directors and greater than 5% stockholders, in the aggregate, own approximately 60% of our outstanding common stock.", "type": 2, "words": ["<tag1>", "Our", "executive", "officers,", "directors", "and", "greater", "than", "5%", "stockholders,", "in", "the", "aggregate,", "own", "approximately", "75%", "of", "our", "outstanding", "common", "stock.", "<tag2>", "Our", "executive", "officers,", "directors", "and", "greater", "than", "5%", "stockholders,", "in", "the", "aggregate,", "own", "approximately", "60%", "of", "our", "outstanding", "common", "stock.", "<tag3>"], "wordsA": ["Our", "executive", "officers,", "directors", "and", "greater", "than", "5%", "stockholders,", "in", "the", "aggregate,", "own", "approximately", "75%", "of", "our", "outstanding", "common", "stock."], "wordsB": ["Our", "executive", "officers,", "directors", "and", "greater", "than", "5%", "stockholders,", "in", "the", "aggregate,", "own", "approximately", "60%", "of", "our", "outstanding", "common", "stock."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0018371554324403405, 0.00427520927041769, 0.004180671647191048, 0.0034440786112099886, 0.0021887461189180613, 0.004433668218553066, 0.004663814324885607, 0.011569365859031677, 0.007975493557751179, 0.0025039527099579573, 0.0023234100081026554, 0.0037629029247909784, 0.019843945279717445, 0.03804037719964981, 0.9849802851676941, 0.015540109016001225, 0.007055769208818674, 0.009730116464197636, 0.015200614929199219, 0.018812425434589386, -1]}
{"idB": "1316175_12_item1a_p138_s0", "idA": "1316175_11_item1a_p144_s0", "sentA": "As of December 31, 2010, there were 32,880,353 shares of our common stock outstanding.", "sentB": "As of December 31, 2011, there were 40,938,041 shares of our common stock outstanding.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2010,", "there", "were", "32,880,353", "shares", "of", "our", "common", "stock", "outstanding.", "<tag2>", "As", "of", "December", "31,", "2011,", "there", "were", "40,938,041", "shares", "of", "our", "common", "stock", "outstanding.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2010,", "there", "were", "32,880,353", "shares", "of", "our", "common", "stock", "outstanding."], "wordsB": ["As", "of", "December", "31,", "2011,", "there", "were", "40,938,041", "shares", "of", "our", "common", "stock", "outstanding."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.006682720500975847, 0.00585581548511982, 0.020182738080620766, 0.02286367677152157, 0.8619639277458191, 0.004839839413762093, 0.008166578598320484, 0.7698730826377869, 0.2763720154762268, 0.003025259356945753, 0.0025690626353025436, 0.005581984296441078, 0.007474865298718214, 0.005879234988242388, -1]}
{"idB": "1316175_12_item1a_p138_s1", "idA": "1316175_11_item1a_p144_s1", "sentA": "In addition, as of December 31, 2010, we had outstanding options to purchase shares of our common stock and restricted stock units of 1,578,491 that, if exercised or released, will result in these additional shares becoming available for sale.", "sentB": "In addition, as of December 31, 2011, we had outstanding options to purchase shares of our common stock and restricted stock units of 2,490,146 that, if exercised or released, will result in these additional shares becoming available for sale.", "type": 2, "words": ["<tag1>", "In", "addition,", "as", "of", "December", "31,", "2010,", "we", "had", "outstanding", "options", "to", "purchase", "shares", "of", "our", "common", "stock", "and", "restricted", "stock", "units", "of", "1,578,491", "that,", "if", "exercised", "or", "released,", "will", "result", "in", "these", "additional", "shares", "becoming", "available", "for", "sale.", "<tag2>", "In", "addition,", "as", "of", "December", "31,", "2011,", "we", "had", "outstanding", "options", "to", "purchase", "shares", "of", "our", "common", "stock", "and", "restricted", "stock", "units", "of", "2,490,146", "that,", "if", "exercised", "or", "released,", "will", "result", "in", "these", "additional", "shares", "becoming", "available", "for", "sale.", "<tag3>"], "wordsA": ["In", "addition,", "as", "of", "December", "31,", "2010,", "we", "had", "outstanding", "options", "to", "purchase", "shares", "of", "our", "common", "stock", "and", "restricted", "stock", "units", "of", "1,578,491", "that,", "if", "exercised", "or", "released,", "will", "result", "in", "these", "additional", "shares", "becoming", "available", "for", "sale."], "wordsB": ["In", "addition,", "as", "of", "December", "31,", "2011,", "we", "had", "outstanding", "options", "to", "purchase", "shares", "of", "our", "common", "stock", "and", "restricted", "stock", "units", "of", "2,490,146", "that,", "if", "exercised", "or", "released,", "will", "result", "in", "these", "additional", "shares", "becoming", "available", "for", "sale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.002981754019856453, 0.004993979819118977, 0.003455002326518297, 0.00576292909681797, 0.006020864471793175, 0.008157900534570217, 0.6223661303520203, 0.0027543066535145044, 0.0028224275447428226, 0.003934450447559357, 0.005714511498808861, 0.0023062110412865877, 0.0042910329066216946, 0.007262990809977055, 0.002442935947328806, 0.0025292029604315758, 0.004187613260000944, 0.004828690085560083, 0.0034557399339973927, 0.0038925050757825375, 0.005615045316517353, 0.015875056385993958, 0.012640769593417645, 0.895285427570343, 0.005773007869720459, 0.0046784416772425175, 0.005907506216317415, 0.004795192275196314, 0.004413965158164501, 0.003300704061985016, 0.0031940522603690624, 0.002851754194125533, 0.0023296414874494076, 0.004008676391094923, 0.006088922265917063, 0.0035237413831055164, 0.004545468837022781, 0.0035841732751578093, 0.005105962045490742, -1]}
{"idB": "1316175_12_item1a_p139_s0", "idA": "1316175_11_item1a_p145_s0", "sentA": "We have registered all common stock that we may issue under our Amended and Restated 2010 Stock Option and Incentive Plan (the 2010 Plan ) and our Employee Stock Purchase Plan (the ESPP ).", "sentB": "We have registered all common stock that we may issue under our Amended and Restated 2010 Stock Option and Incentive Plan (the \"2010 Plan\") and our Employee Stock Purchase Plan (the \"ESPP\").", "type": 2, "words": ["<tag1>", "We", "have", "registered", "all", "common", "stock", "that", "we", "may", "issue", "under", "our", "Amended", "and", "Restated", "2010", "Stock", "Option", "and", "Incentive", "Plan", "(the", "2010", "Plan", ")", "and", "our", "Employee", "Stock", "Purchase", "Plan", "(the", "ESPP", ").", "<tag2>", "We", "have", "registered", "all", "common", "stock", "that", "we", "may", "issue", "under", "our", "Amended", "and", "Restated", "2010", "Stock", "Option", "and", "Incentive", "Plan", "(the", "\"2010", "Plan\")", "and", "our", "Employee", "Stock", "Purchase", "Plan", "(the", "\"ESPP\").", "<tag3>"], "wordsA": ["We", "have", "registered", "all", "common", "stock", "that", "we", "may", "issue", "under", "our", "Amended", "and", "Restated", "2010", "Stock", "Option", "and", "Incentive", "Plan", "(the", "2010", "Plan", ")", "and", "our", "Employee", "Stock", "Purchase", "Plan", "(the", "ESPP", ")."], "wordsB": ["We", "have", "registered", "all", "common", "stock", "that", "we", "may", "issue", "under", "our", "Amended", "and", "Restated", "2010", "Stock", "Option", "and", "Incentive", "Plan", "(the", "\"2010", "Plan\")", "and", "our", "Employee", "Stock", "Purchase", "Plan", "(the", "\"ESPP\")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.08373473584651947, 0.05376668646931648, 0.48525530099868774, 0.33104512095451355, 0.16533546149730682, 0.17322701215744019, 0.016901977360248566, 0.02725457213819027, 0.025807620957493782, 0.041522543877363205, 0.02745906263589859, 0.02252880670130253, 0.11078600585460663, 0.017089243978261948, 0.043173473328351974, 0.04294323921203613, 0.05036474019289017, 0.05406203120946884, 0.02169627510011196, 0.039704058319330215, 0.04339485615491867, 0.020175913348793983, 0.1550174057483673, 0.4848637282848358, 0.012272529304027557, 0.026215573772788048, 0.17500422894954681, 0.0982009544968605, 0.060063138604164124, 0.07040709257125854, 0.02110448107123375, 0.6940410733222961, -1]}
{"idB": "1316175_12_item1a_p139_s1", "idA": "1316175_11_item1a_p145_s1", "sentA": "As of February 28, 2011, an aggregate of 1,778,261 shares of our common stock has been reserved for future issuance under the 2010 Plan, plus any shares reserved and unissued under our 2005 Equity Incentive Plan, and an aggregate of 350,000 shares has been reserved for future issuance under our ESPP.", "sentB": "As of December 31, 2011, an aggregate of 1,748,858 shares of our common stock has been reserved for future issuance under the 2010 Plan, plus any shares reserved and unissued or cancelled under our 2005 Equity Incentive Plan, and an aggregate of 350,000 shares has been reserved for future issuance under our ESPP.", "type": 2, "words": ["<tag1>", "As", "of", "February", "28,", "2011,", "an", "aggregate", "of", "1,778,261", "shares", "of", "our", "common", "stock", "has", "been", "reserved", "for", "future", "issuance", "under", "the", "2010", "Plan,", "plus", "any", "shares", "reserved", "and", "unissued", "under", "our", "2005", "Equity", "Incentive", "Plan,", "and", "an", "aggregate", "of", "350,000", "shares", "has", "been", "reserved", "for", "future", "issuance", "under", "our", "ESPP.", "<tag2>", "As", "of", "December", "31,", "2011,", "an", "aggregate", "of", "1,748,858", "shares", "of", "our", "common", "stock", "has", "been", "reserved", "for", "future", "issuance", "under", "the", "2010", "Plan,", "plus", "any", "shares", "reserved", "and", "unissued", "or", "cancelled", "under", "our", "2005", "Equity", "Incentive", "Plan,", "and", "an", "aggregate", "of", "350,000", "shares", "has", "been", "reserved", "for", "future", "issuance", "under", "our", "ESPP.", "<tag3>"], "wordsA": ["As", "of", "February", "28,", "2011,", "an", "aggregate", "of", "1,778,261", "shares", "of", "our", "common", "stock", "has", "been", "reserved", "for", "future", "issuance", "under", "the", "2010", "Plan,", "plus", "any", "shares", "reserved", "and", "unissued", "under", "our", "2005", "Equity", "Incentive", "Plan,", "and", "an", "aggregate", "of", "350,000", "shares", "has", "been", "reserved", "for", "future", "issuance", "under", "our", "ESPP."], "wordsB": ["As", "of", "December", "31,", "2011,", "an", "aggregate", "of", "1,748,858", "shares", "of", "our", "common", "stock", "has", "been", "reserved", "for", "future", "issuance", "under", "the", "2010", "Plan,", "plus", "any", "shares", "reserved", "and", "unissued", "or", "cancelled", "under", "our", "2005", "Equity", "Incentive", "Plan,", "and", "an", "aggregate", "of", "350,000", "shares", "has", "been", "reserved", "for", "future", "issuance", "under", "our", "ESPP."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.006231300532817841, 0.012527808547019958, 0.8805840015411377, 0.8997270464897156, 0.02475995570421219, 0.0026352033019065857, 0.008940760046243668, 0.00511202635243535, 0.25415346026420593, 0.10670211166143417, 0.0035329991951584816, 0.003245689207687974, 0.005511803552508354, 0.005550762172788382, 0.00309436465613544, 0.002962051425129175, 0.005862041842192411, 0.003082163631916046, 0.0035044292453676462, 0.005432036705315113, 0.0027496584225445986, 0.0025393469259142876, 0.004139275755733252, 0.005265001207590103, 0.0036059306003153324, 0.003629543585702777, 0.016497423872351646, 0.007663150783628225, 0.0055562895722687244, 0.006963768973946571, 0.007877608761191368, 0.15695029497146606, 0.002859007101505995, 0.002831554738804698, 0.003613789100199938, 0.004860045854002237, 0.004546396434307098, 0.005089789628982544, 0.004102790262550116, 0.00245920242741704, 0.00809394009411335, 0.00330380373634398, 0.03347337618470192, 0.01851465366780758, 0.0031039209570735693, 0.0030855031218379736, 0.009263504296541214, 0.003924206364899874, 0.004078663419932127, 0.004833578132092953, 0.0032329470850527287, 0.0032565949950367212, 0.006297685671597719, -1]}
{"idB": "1316175_12_item1a_p139_s2", "idA": "1316175_11_item1a_p145_s2", "sentA": "These shares can be freely sold in the public market upon issuance, subject to the lock-up agreements referred to above.", "sentB": "These shares can be freely sold in the public market upon issuance.", "type": 2, "words": ["<tag1>", "These", "shares", "can", "be", "freely", "sold", "in", "the", "public", "market", "upon", "issuance,", "subject", "to", "the", "lock-up", "agreements", "referred", "to", "above.", "<tag2>", "These", "shares", "can", "be", "freely", "sold", "in", "the", "public", "market", "upon", "issuance.", "<tag3>"], "wordsA": ["These", "shares", "can", "be", "freely", "sold", "in", "the", "public", "market", "upon", "issuance,", "subject", "to", "the", "lock-up", "agreements", "referred", "to", "above."], "wordsB": ["These", "shares", "can", "be", "freely", "sold", "in", "the", "public", "market", "upon", "issuance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.057966448366642, 0.4434053301811218, 0.10353653132915497, 0.08314718306064606, 0.7839551568031311, 0.4886413812637329, 0.04845021292567253, 0.04166525974869728, 0.12736088037490845, 0.219730943441391, 0.07904063165187836, 0.4123537242412567, -1]}
{"idB": "1316175_12_item1a_p101_s0", "idA": "1316175_11_item1a_p14_s0", "sentA": "As of the date of this report, we anticipate that our existing cash, cash equivalents and short-term investments, will enable us to maintain our currently planned operations through at least the next 12 months.", "sentB": "As of the date of this report, we either own or hold license rights to numerous US, EP, and non-EP foreign patents relating to varespladib sodium/varespladib, other sPLA2 inhibiting compounds, and blisibimod.", "type": 2, "words": ["<tag1>", "As", "of", "the", "date", "of", "this", "report,", "we", "anticipate", "that", "our", "existing", "cash,", "cash", "equivalents", "and", "short-term", "investments,", "will", "enable", "us", "to", "maintain", "our", "currently", "planned", "operations", "through", "at", "least", "the", "next", "12", "months.", "<tag2>", "As", "of", "the", "date", "of", "this", "report,", "we", "either", "own", "or", "hold", "license", "rights", "to", "numerous", "US,", "EP,", "and", "non-EP", "foreign", "patents", "relating", "to", "varespladib", "sodium/varespladib,", "other", "sPLA2", "inhibiting", "compounds,", "and", "blisibimod.", "<tag3>"], "wordsA": ["As", "of", "the", "date", "of", "this", "report,", "we", "anticipate", "that", "our", "existing", "cash,", "cash", "equivalents", "and", "short-term", "investments,", "will", "enable", "us", "to", "maintain", "our", "currently", "planned", "operations", "through", "at", "least", "the", "next", "12", "months."], "wordsB": ["As", "of", "the", "date", "of", "this", "report,", "we", "either", "own", "or", "hold", "license", "rights", "to", "numerous", "US,", "EP,", "and", "non-EP", "foreign", "patents", "relating", "to", "varespladib", "sodium/varespladib,", "other", "sPLA2", "inhibiting", "compounds,", "and", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.006935708224773407, 0.0051228441298007965, 0.003924955148249865, 0.0047794547863304615, 0.0033298067282885313, 0.0029612064827233553, 0.009373235516250134, 0.05094141513109207, 0.045329730957746506, 0.41223928332328796, 0.14808665215969086, 0.3090655505657196, 0.44031497836112976, 0.2959277927875519, 0.046114481985569, 0.07335361838340759, 0.0719614326953888, 0.061358146369457245, 0.016017163172364235, 0.12998977303504944, 0.14558915793895721, 0.30260369181632996, 0.01507656555622816, 0.015343130566179752, 0.035005033016204834, 0.03659207001328468, 0.009920182637870312, 0.04592277854681015, 0.05421534553170204, 0.06157112866640091, 0.011428079567849636, 0.07468216866254807, -1]}
{"idB": "1316175_12_item1a_p13_s0", "idA": "1316175_11_item1a_p14_s0", "sentA": "As of the date of this report, we anticipate that our existing cash, cash equivalents and short-term investments, will enable us to maintain our currently planned operations through at least the next 12 months.", "sentB": "As of the date of this report, we anticipate that our existing cash, cash equivalents and short-term investments, will enable us to meet our obligations and sustain our operations through at least the next 12 months.", "type": 2, "words": ["<tag1>", "As", "of", "the", "date", "of", "this", "report,", "we", "anticipate", "that", "our", "existing", "cash,", "cash", "equivalents", "and", "short-term", "investments,", "will", "enable", "us", "to", "maintain", "our", "currently", "planned", "operations", "through", "at", "least", "the", "next", "12", "months.", "<tag2>", "As", "of", "the", "date", "of", "this", "report,", "we", "anticipate", "that", "our", "existing", "cash,", "cash", "equivalents", "and", "short-term", "investments,", "will", "enable", "us", "to", "meet", "our", "obligations", "and", "sustain", "our", "operations", "through", "at", "least", "the", "next", "12", "months.", "<tag3>"], "wordsA": ["As", "of", "the", "date", "of", "this", "report,", "we", "anticipate", "that", "our", "existing", "cash,", "cash", "equivalents", "and", "short-term", "investments,", "will", "enable", "us", "to", "maintain", "our", "currently", "planned", "operations", "through", "at", "least", "the", "next", "12", "months."], "wordsB": ["As", "of", "the", "date", "of", "this", "report,", "we", "anticipate", "that", "our", "existing", "cash,", "cash", "equivalents", "and", "short-term", "investments,", "will", "enable", "us", "to", "meet", "our", "obligations", "and", "sustain", "our", "operations", "through", "at", "least", "the", "next", "12", "months."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.005272833630442619, 0.00674882996827364, 0.004817324690520763, 0.006058831699192524, 0.004839214496314526, 0.004522522445768118, 0.012549752369523048, 0.006467514205724001, 0.009843855164945126, 0.005772668868303299, 0.005962430499494076, 0.010760537348687649, 0.013058696873486042, 0.008614831604063511, 0.008309189230203629, 0.004612800665199757, 0.007149551995098591, 0.010400625877082348, 0.00425473228096962, 0.00946426298469305, 0.01780708320438862, 0.020416149869561195, 0.3525913655757904, 0.21875929832458496, 0.3040353059768677, 0.031104231253266335, 0.7288198471069336, 0.22642722725868225, 0.18461216986179352, 0.006503988988697529, 0.0057873777113854885, 0.007052702829241753, 0.005213523283600807, 0.0092979297041893, 0.008287212811410427, 0.008444529958069324, -1]}
{"idB": "1316175_12_item1a_p108_s5", "idA": "1316175_11_item1a_p14_s2", "sentA": "Additional financing may not be available when we need it or may not be available on terms that are favorable to us.", "sentB": "Such a license may not be available on commercially acceptable terms, if at all.", "type": 2, "words": ["<tag1>", "Additional", "financing", "may", "not", "be", "available", "when", "we", "need", "it", "or", "may", "not", "be", "available", "on", "terms", "that", "are", "favorable", "to", "us.", "<tag2>", "Such", "a", "license", "may", "not", "be", "available", "on", "commercially", "acceptable", "terms,", "if", "at", "all.", "<tag3>"], "wordsA": ["Additional", "financing", "may", "not", "be", "available", "when", "we", "need", "it", "or", "may", "not", "be", "available", "on", "terms", "that", "are", "favorable", "to", "us."], "wordsB": ["Such", "a", "license", "may", "not", "be", "available", "on", "commercially", "acceptable", "terms,", "if", "at", "all."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.022582117468118668, 0.0473799891769886, 0.4246499538421631, 0.07778076082468033, 0.44657590985298157, 0.19696378707885742, 0.2947535812854767, 0.10413797944784164, 0.522284209728241, 0.6730503439903259, 0.42908012866973877, 0.06293480843305588, 0.0480956993997097, 0.06344310939311981, -1]}
{"idB": "1316175_12_item1a_p145_s2", "idA": "1316175_11_item1a_p150_s2", "sentA": "For example, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules subsequently implemented by the Securities and Exchange Commission, or SEC, and The NASDAQ Global Market, impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices.", "sentB": "For example, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and The NASDAQ Global Market, impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices.", "type": 2, "words": ["<tag1>", "For", "example,", "the", "Sarbanes-Oxley", "Act", "of", "2002,", "or", "the", "Sarbanes-Oxley", "Act,", "as", "well", "as", "rules", "subsequently", "implemented", "by", "the", "Securities", "and", "Exchange", "Commission,", "or", "SEC,", "and", "The", "NASDAQ", "Global", "Market,", "impose", "various", "requirements", "on", "public", "companies,", "including", "establishment", "and", "maintenance", "of", "effective", "disclosure", "and", "financial", "controls", "and", "changes", "in", "corporate", "governance", "practices.", "<tag2>", "For", "example,", "the", "Sarbanes-Oxley", "Act", "of", "2002,", "or", "the", "Sarbanes-Oxley", "Act,", "as", "well", "as", "rules", "subsequently", "implemented", "by", "the", "SEC", "and", "The", "NASDAQ", "Global", "Market,", "impose", "various", "requirements", "on", "public", "companies,", "including", "establishment", "and", "maintenance", "of", "effective", "disclosure", "and", "financial", "controls", "and", "changes", "in", "corporate", "governance", "practices.", "<tag3>"], "wordsA": ["For", "example,", "the", "Sarbanes-Oxley", "Act", "of", "2002,", "or", "the", "Sarbanes-Oxley", "Act,", "as", "well", "as", "rules", "subsequently", "implemented", "by", "the", "Securities", "and", "Exchange", "Commission,", "or", "SEC,", "and", "The", "NASDAQ", "Global", "Market,", "impose", "various", "requirements", "on", "public", "companies,", "including", "establishment", "and", "maintenance", "of", "effective", "disclosure", "and", "financial", "controls", "and", "changes", "in", "corporate", "governance", "practices."], "wordsB": ["For", "example,", "the", "Sarbanes-Oxley", "Act", "of", "2002,", "or", "the", "Sarbanes-Oxley", "Act,", "as", "well", "as", "rules", "subsequently", "implemented", "by", "the", "SEC", "and", "The", "NASDAQ", "Global", "Market,", "impose", "various", "requirements", "on", "public", "companies,", "including", "establishment", "and", "maintenance", "of", "effective", "disclosure", "and", "financial", "controls", "and", "changes", "in", "corporate", "governance", "practices."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.048527855426073074, 0.06503357738256454, 0.02598896250128746, 0.37628570199012756, 0.43167731165885925, 0.09323188662528992, 0.13977153599262238, 0.038812652230262756, 0.023929843679070473, 0.34823960065841675, 0.6310500502586365, 0.026796694844961166, 0.028205161914229393, 0.021537138149142265, 0.0635116770863533, 0.048703383654356, 0.04187712073326111, 0.03486275300383568, 0.032362185418605804, 0.42450782656669617, 0.03897123411297798, 0.028681736439466476, 0.13374190032482147, 0.07153777778148651, 0.1299438774585724, 0.07384859025478363, 0.05577147752046585, 0.10812226682901382, 0.07738164067268372, 0.3125590980052948, 0.48246827721595764, 0.0304110087454319, 0.05949961021542549, 0.040804896503686905, 0.05862458422780037, 0.03143170475959778, 0.10501768440008163, 0.07598711550235748, 0.02800336666405201, 0.05644991621375084, 0.07079332321882248, 0.019821342080831528, 0.03115544654428959, 0.023508116602897644, 0.089200958609581, 0.11300155520439148, 0.0731227919459343, -1]}
{"idB": "1316175_12_item1a_p151_s0", "idA": "1316175_11_item1a_p156_s0", "sentA": "the requirement of at least 75% of the outstanding common stock to amend any of the foregoing provisions.", "sentB": "a classified and staggered board of directors whose members can only be dismissed for cause; the prohibition on actions by written consent of our stockholders; the limitation on who may call a special meeting of stockholders; the establishment of advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon at stockholder meetings; the ability of our board of directors to issue preferred stock without stockholder approval, which would increase the number of outstanding shares and could thwart a takeover attempt; and the requirement of at least 75% of the outstanding common stock to amend any of the foregoing provisions.", "type": 2, "words": ["<tag1>", "the", "requirement", "of", "at", "least", "75%", "of", "the", "outstanding", "common", "stock", "to", "amend", "any", "of", "the", "foregoing", "provisions.", "<tag2>", "a", "classified", "and", "staggered", "board", "of", "directors", "whose", "members", "can", "only", "be", "dismissed", "for", "cause;", "the", "prohibition", "on", "actions", "by", "written", "consent", "of", "our", "stockholders;", "the", "limitation", "on", "who", "may", "call", "a", "special", "meeting", "of", "stockholders;", "the", "establishment", "of", "advance", "notice", "requirements", "for", "nominations", "for", "election", "to", "our", "board", "of", "directors", "or", "for", "proposing", "matters", "that", "can", "be", "acted", "upon", "at", "stockholder", "meetings;", "the", "ability", "of", "our", "board", "of", "directors", "to", "issue", "preferred", "stock", "without", "stockholder", "approval,", "which", "would", "increase", "the", "number", "of", "outstanding", "shares", "and", "could", "thwart", "a", "takeover", "attempt;", "and", "the", "requirement", "of", "at", "least", "75%", "of", "the", "outstanding", "common", "stock", "to", "amend", "any", "of", "the", "foregoing", "provisions.", "<tag3>"], "wordsA": ["the", "requirement", "of", "at", "least", "75%", "of", "the", "outstanding", "common", "stock", "to", "amend", "any", "of", "the", "foregoing", "provisions."], "wordsB": ["a", "classified", "and", "staggered", "board", "of", "directors", "whose", "members", "can", "only", "be", "dismissed", "for", "cause;", "the", "prohibition", "on", "actions", "by", "written", "consent", "of", "our", "stockholders;", "the", "limitation", "on", "who", "may", "call", "a", "special", "meeting", "of", "stockholders;", "the", "establishment", "of", "advance", "notice", "requirements", "for", "nominations", "for", "election", "to", "our", "board", "of", "directors", "or", "for", "proposing", "matters", "that", "can", "be", "acted", "upon", "at", "stockholder", "meetings;", "the", "ability", "of", "our", "board", "of", "directors", "to", "issue", "preferred", "stock", "without", "stockholder", "approval,", "which", "would", "increase", "the", "number", "of", "outstanding", "shares", "and", "could", "thwart", "a", "takeover", "attempt;", "and", "the", "requirement", "of", "at", "least", "75%", "of", "the", "outstanding", "common", "stock", "to", "amend", "any", "of", "the", "foregoing", "provisions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.007438283413648605, 0.11231078207492828, 0.011608922854065895, 0.16629533469676971, 0.21586599946022034, 0.04193684458732605, 0.12548427283763885, 0.007597147021442652, 0.0863867998123169, 0.07429860532283783, 0.07874717563390732, 0.15014661848545074, 0.36408889293670654, 0.09718118607997894, 0.062054675072431564, 0.010317527689039707, 0.287199467420578, 0.2557509243488312, 0.2970367670059204, 0.17292989790439606, 0.2147866040468216, 0.21536153554916382, 0.020480085164308548, 0.010811143554747105, 0.059852905571460724, 0.008935143239796162, 0.09965946525335312, 0.10834872722625732, 0.04159262403845787, 0.09663798660039902, 0.07316283881664276, 0.030858123674988747, 0.037191640585660934, 0.04421216994524002, 0.03236515447497368, 0.05449395254254341, 0.006517677567899227, 0.04858143627643585, 0.046635281294584274, 0.12733156979084015, 0.1111849769949913, 0.12097302824258804, 0.03931008651852608, 0.07250076532363892, 0.06862201541662216, 0.04479455575346947, 0.016536565497517586, 0.011993047781288624, 0.01944716088473797, 0.014033351093530655, 0.027005434036254883, 0.0006587391253560781, 0.01089533232152462, 0.023441122844815254, 0.01855059340596199, 0.00034598633646965027, 0.006302868016064167, 0.00198071775957942, 0.008988367393612862, 0.01137904915958643, 0.006657919380813837, 0.03740110248327255, 0.033502623438835144, 0.0065237171947956085, 0.04973696917295456, 0.01685154065489769, 0.01669384352862835, 0.06610255688428879, 0.03463100269436836, 0.06762180477380753, 0.12223943322896957, 0.21242459118366241, 0.2986793518066406, 0.31979745626449585, 0.4394422471523285, 0.23804524540901184, 0.2031514048576355, 0.00028747174656018615, 0.0022560853976756334, 0.018325647339224815, 0.0018054662505164742, 0.02409675531089306, 0.013280385173857212, 0.03806161507964134, 0.030958788469433784, 0.00043871605885215104, 0.014909290708601475, 0.06331299245357513, 0.021536745131015778, 0.03998421132564545, 0.04702438414096832, 0.005079152062535286, 0.005298792850226164, 0.01827695406973362, 0.0028926560189574957, 0.007175746839493513, 0.009091328829526901, 0.03235599026083946, 0.0047697690315544605, 0.005893542896956205, 0.013776952400803566, 0.01476959977298975, 0.021339239552617073, 0.0033538483548909426, 0.007061290554702282, 0.003981008194386959, 0.002847102005034685, 0.0036143180914223194, 0.006938185077160597, 0.009099110960960388, -1]}
{"idB": "1316175_12_item1a_p154_s0", "idA": "1316175_11_item1a_p159_s0", "sentA": "Generally, a change of more than 50% in the ownership of a corporation s stock, by value, over a three-year period constitutes an ownership change for U.S. federal income tax purposes.", "sentB": "Generally, a change of more than 50% in the ownership of a corporation's stock, by value, over a three-year period constitutes an ownership change for U.S. federal income tax purposes.", "type": 2, "words": ["<tag1>", "Generally,", "a", "change", "of", "more", "than", "50%", "in", "the", "ownership", "of", "a", "corporation", "s", "stock,", "by", "value,", "over", "a", "three-year", "period", "constitutes", "an", "ownership", "change", "for", "U.S.", "federal", "income", "tax", "purposes.", "<tag2>", "Generally,", "a", "change", "of", "more", "than", "50%", "in", "the", "ownership", "of", "a", "corporation's", "stock,", "by", "value,", "over", "a", "three-year", "period", "constitutes", "an", "ownership", "change", "for", "U.S.", "federal", "income", "tax", "purposes.", "<tag3>"], "wordsA": ["Generally,", "a", "change", "of", "more", "than", "50%", "in", "the", "ownership", "of", "a", "corporation", "s", "stock,", "by", "value,", "over", "a", "three-year", "period", "constitutes", "an", "ownership", "change", "for", "U.S.", "federal", "income", "tax", "purposes."], "wordsB": ["Generally,", "a", "change", "of", "more", "than", "50%", "in", "the", "ownership", "of", "a", "corporation's", "stock,", "by", "value,", "over", "a", "three-year", "period", "constitutes", "an", "ownership", "change", "for", "U.S.", "federal", "income", "tax", "purposes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.08437176048755646, 0.02419734187424183, 0.11255434155464172, 0.0655740350484848, 0.30310285091400146, 0.24346762895584106, 0.6744846701622009, 0.06350523233413696, 0.0513884499669075, 0.13044719398021698, 0.06412609666585922, 0.052162423729896545, 0.5076570510864258, 0.22143186628818512, 0.08042000234127045, 0.2124805450439453, 0.03268158435821533, 0.032114189118146896, 0.06110170856118202, 0.059705812484025955, 0.03181668370962143, 0.027409641072154045, 0.09637441486120224, 0.06879694759845734, 0.024658840149641037, 0.11008381843566895, 0.0793556496500969, 0.10825543105602264, 0.09397827088832855, 0.07260510325431824, -1]}
{"idB": "1316175_12_item1a_p14_s0", "idA": "1316175_11_item1a_p15_s0", "sentA": "terminate, reduce or delay our (i) establishment of sales and marketing capabilities, (ii) pursuit of strategic collaborations with others relating to the sales, marketing and commercialization of our product candidates or (iii) other activities that may be necessary to commercialize our product candidates, if approved for sale.", "sentB": "terminate, reduce or delay preclinical studies, clinical studies or other development activities for one or more of our product candidates; or terminate, reduce or delay our (i) establishment of sales and marketing capabilities, (ii) pursuit of strategic collaborations with others relating to the sales, marketing and commercialization of our product candidates or (iii) other activities that may be necessary to commercialize our product candidates, if approved for sale.", "type": 2, "words": ["<tag1>", "terminate,", "reduce", "or", "delay", "our", "(i)", "establishment", "of", "sales", "and", "marketing", "capabilities,", "(ii)", "pursuit", "of", "strategic", "collaborations", "with", "others", "relating", "to", "the", "sales,", "marketing", "and", "commercialization", "of", "our", "product", "candidates", "or", "(iii)", "other", "activities", "that", "may", "be", "necessary", "to", "commercialize", "our", "product", "candidates,", "if", "approved", "for", "sale.", "<tag2>", "terminate,", "reduce", "or", "delay", "preclinical", "studies,", "clinical", "studies", "or", "other", "development", "activities", "for", "one", "or", "more", "of", "our", "product", "candidates;", "or", "terminate,", "reduce", "or", "delay", "our", "(i)", "establishment", "of", "sales", "and", "marketing", "capabilities,", "(ii)", "pursuit", "of", "strategic", "collaborations", "with", "others", "relating", "to", "the", "sales,", "marketing", "and", "commercialization", "of", "our", "product", "candidates", "or", "(iii)", "other", "activities", "that", "may", "be", "necessary", "to", "commercialize", "our", "product", "candidates,", "if", "approved", "for", "sale.", "<tag3>"], "wordsA": ["terminate,", "reduce", "or", "delay", "our", "(i)", "establishment", "of", "sales", "and", "marketing", "capabilities,", "(ii)", "pursuit", "of", "strategic", "collaborations", "with", "others", "relating", "to", "the", "sales,", "marketing", "and", "commercialization", "of", "our", "product", "candidates", "or", "(iii)", "other", "activities", "that", "may", "be", "necessary", "to", "commercialize", "our", "product", "candidates,", "if", "approved", "for", "sale."], "wordsB": ["terminate,", "reduce", "or", "delay", "preclinical", "studies,", "clinical", "studies", "or", "other", "development", "activities", "for", "one", "or", "more", "of", "our", "product", "candidates;", "or", "terminate,", "reduce", "or", "delay", "our", "(i)", "establishment", "of", "sales", "and", "marketing", "capabilities,", "(ii)", "pursuit", "of", "strategic", "collaborations", "with", "others", "relating", "to", "the", "sales,", "marketing", "and", "commercialization", "of", "our", "product", "candidates", "or", "(iii)", "other", "activities", "that", "may", "be", "necessary", "to", "commercialize", "our", "product", "candidates,", "if", "approved", "for", "sale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.011839412152767181, 0.008687968365848064, 0.009423336945474148, 0.02170051820576191, 0.8784617781639099, 0.8220838904380798, 0.13611558079719543, 0.20130960643291473, 0.005440554581582546, 0.00490211509168148, 0.008057359606027603, 0.011022699996829033, 0.0030400657560676336, 0.003776916768401861, 0.0057597984559834, 0.0036711241118609905, 0.002917480655014515, 0.0038409288972616196, 0.006698531564325094, 0.010591085068881512, 0.011692150495946407, 0.009652332402765751, 0.008700717240571976, 0.009464715607464314, 0.00717198709025979, 0.006193477660417557, 0.02550375461578369, 0.006193718872964382, 0.005798445548862219, 0.005666379351168871, 0.006448707077652216, 0.005703683942556381, 0.006614534184336662, 0.008800296112895012, 0.004566133487969637, 0.005432587582617998, 0.006481068674474955, 0.007123526185750961, 0.005265543702989817, 0.004390249960124493, 0.0054758875630795956, 0.0048860362730920315, 0.004884812049567699, 0.005591414403170347, 0.005512443836778402, 0.00660906545817852, 0.006731244269758463, 0.0034665814600884914, 0.004166826140135527, 0.005934550426900387, 0.006113928742706776, 0.004733612295240164, 0.007876252755522728, 0.00359716615639627, 0.005848684813827276, 0.006577521562576294, 0.0050936066545546055, 0.005688488017767668, 0.007022772915661335, 0.0037906726356595755, 0.005732953082770109, 0.003608360653743148, 0.006012916564941406, 0.007494411896914244, 0.006093448493629694, 0.005282663740217686, 0.005278563592582941, 0.004691894631832838, -1]}
{"idB": "1316175_12_item1a_p16_s0", "idA": "1316175_11_item1a_p17_s0", "sentA": "In July 2006, we entered into a license agreement with Eli Lilly and Company, or Eli Lilly, and Shionogi Co., Ltd. to develop and commercialize certain secretory phospholipase A 2 , or sPLA 2 , inhibitors for the treatment of cardiovascular disease and other diseases.", "sentB": "In July 2006, we entered into a license agreement with Eli Lilly and Company, or Eli Lilly, and Shionogi Co., Ltd. to develop and commercialize certain secretory phospholipase A2, or sPLA2, inhibitors for the treatment of cardiovascular disease and other diseases.", "type": 2, "words": ["<tag1>", "In", "July", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Eli", "Lilly", "and", "Company,", "or", "Eli", "Lilly,", "and", "Shionogi", "Co.,", "Ltd.", "to", "develop", "and", "commercialize", "certain", "secretory", "phospholipase", "A", "2", ",", "or", "sPLA", "2", ",", "inhibitors", "for", "the", "treatment", "of", "cardiovascular", "disease", "and", "other", "diseases.", "<tag2>", "In", "July", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Eli", "Lilly", "and", "Company,", "or", "Eli", "Lilly,", "and", "Shionogi", "Co.,", "Ltd.", "to", "develop", "and", "commercialize", "certain", "secretory", "phospholipase", "A2,", "or", "sPLA2,", "inhibitors", "for", "the", "treatment", "of", "cardiovascular", "disease", "and", "other", "diseases.", "<tag3>"], "wordsA": ["In", "July", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Eli", "Lilly", "and", "Company,", "or", "Eli", "Lilly,", "and", "Shionogi", "Co.,", "Ltd.", "to", "develop", "and", "commercialize", "certain", "secretory", "phospholipase", "A", "2", ",", "or", "sPLA", "2", ",", "inhibitors", "for", "the", "treatment", "of", "cardiovascular", "disease", "and", "other", "diseases."], "wordsB": ["In", "July", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Eli", "Lilly", "and", "Company,", "or", "Eli", "Lilly,", "and", "Shionogi", "Co.,", "Ltd.", "to", "develop", "and", "commercialize", "certain", "secretory", "phospholipase", "A2,", "or", "sPLA2,", "inhibitors", "for", "the", "treatment", "of", "cardiovascular", "disease", "and", "other", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.002154533052816987, 0.0031735908705741167, 0.0037158008199185133, 0.002991413464769721, 0.003492181422188878, 0.002887573093175888, 0.002425611251965165, 0.004269339144229889, 0.006230030674487352, 0.0029476687777787447, 0.005304042715579271, 0.0072427960112690926, 0.00417183106765151, 0.005044602323323488, 0.003055226057767868, 0.004437677562236786, 0.0063208602368831635, 0.002966828877106309, 0.005791511386632919, 0.0034104783553630114, 0.0033480580896139145, 0.002239405643194914, 0.003763429122045636, 0.0026993462815880775, 0.004162429831922054, 0.0034571848809719086, 0.006573547143489122, 0.0572277195751667, 0.9737703800201416, 0.005535540170967579, 0.5151228308677673, 0.005790375173091888, 0.002130957320332527, 0.0021745087578892708, 0.0024351580068469048, 0.00224697170779109, 0.0027670878916978836, 0.0026830569840967655, 0.0020218926947563887, 0.002230475191026926, 0.0029542262200266123, -1]}
{"idB": "1316175_12_item1a_p16_s1", "idA": "1316175_11_item1a_p17_s1", "sentA": "Pursuant to our license agreement with them, we have an obligation to pay to each of Eli Lilly and Shionogi Co., Ltd. significant milestone and royalty payments based upon how we develop and commercialize certain sPLA 2 inhibitors, including varespladib and A-001, and our achievement of certain significant corporate, clinical and financial events.", "sentB": "Pursuant to our license agreement with them, we have an obligation to pay to each of Eli Lilly and Shionogi Co., Ltd. significant milestone and royalty payments based upon how we develop and commercialize certain sPLA2 inhibitors, including varespladib and varespladib sodium, and our achievement of certain significant corporate, clinical and financial events.", "type": 2, "words": ["<tag1>", "Pursuant", "to", "our", "license", "agreement", "with", "them,", "we", "have", "an", "obligation", "to", "pay", "to", "each", "of", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "significant", "milestone", "and", "royalty", "payments", "based", "upon", "how", "we", "develop", "and", "commercialize", "certain", "sPLA", "2", "inhibitors,", "including", "varespladib", "and", "A-001,", "and", "our", "achievement", "of", "certain", "significant", "corporate,", "clinical", "and", "financial", "events.", "<tag2>", "Pursuant", "to", "our", "license", "agreement", "with", "them,", "we", "have", "an", "obligation", "to", "pay", "to", "each", "of", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "significant", "milestone", "and", "royalty", "payments", "based", "upon", "how", "we", "develop", "and", "commercialize", "certain", "sPLA2", "inhibitors,", "including", "varespladib", "and", "varespladib", "sodium,", "and", "our", "achievement", "of", "certain", "significant", "corporate,", "clinical", "and", "financial", "events.", "<tag3>"], "wordsA": ["Pursuant", "to", "our", "license", "agreement", "with", "them,", "we", "have", "an", "obligation", "to", "pay", "to", "each", "of", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "significant", "milestone", "and", "royalty", "payments", "based", "upon", "how", "we", "develop", "and", "commercialize", "certain", "sPLA", "2", "inhibitors,", "including", "varespladib", "and", "A-001,", "and", "our", "achievement", "of", "certain", "significant", "corporate,", "clinical", "and", "financial", "events."], "wordsB": ["Pursuant", "to", "our", "license", "agreement", "with", "them,", "we", "have", "an", "obligation", "to", "pay", "to", "each", "of", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "significant", "milestone", "and", "royalty", "payments", "based", "upon", "how", "we", "develop", "and", "commercialize", "certain", "sPLA2", "inhibitors,", "including", "varespladib", "and", "varespladib", "sodium,", "and", "our", "achievement", "of", "certain", "significant", "corporate,", "clinical", "and", "financial", "events."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.004756649024784565, 0.00482746260240674, 0.004156304989010096, 0.005438981112092733, 0.007085785735398531, 0.005341097246855497, 0.0035033535677939653, 0.004272108897566795, 0.004903473891317844, 0.00503016309812665, 0.007190811913460493, 0.006280831061303616, 0.006743466015905142, 0.003974717576056719, 0.004972931928932667, 0.004691808018833399, 0.005658005829900503, 0.006285981275141239, 0.0042741745710372925, 0.006982876919209957, 0.004172358196228743, 0.004852632526308298, 0.004313935991376638, 0.005334802903234959, 0.004889837931841612, 0.005659087095409632, 0.007036752998828888, 0.0038850356359034777, 0.0035460367798805237, 0.0033502483274787664, 0.0035566671285778284, 0.004375731572508812, 0.004337959922850132, 0.004889761097729206, 0.004214398562908173, 0.9065052270889282, 0.07327229529619217, 0.0030987970530986786, 0.009043535217642784, 0.009831173345446587, 0.10970049351453781, 0.8768122792243958, 0.004440939985215664, 0.0036896264646202326, 0.00381070701405406, 0.004086045548319817, 0.0042024096474051476, 0.004033377859741449, 0.004523011855781078, 0.0038469997234642506, 0.004199775867164135, 0.004877104423940182, 0.004056618548929691, -1]}
{"idB": "1316175_12_item1a_p16_s3", "idA": "1316175_11_item1a_p17_s3", "sentA": "For A-001, we are required to pay up to $3.0 million upon achievement of certain clinical development milestones and up to $25.0 million upon achievement of certain approval and post-approval sales milestones.", "sentB": "For varespladib sodium, we are required to pay up to $3.0 million upon achievement of certain clinical development milestones and up to $25.0 million upon achievement of certain approval and post-approval sales milestones.", "type": 2, "words": ["<tag1>", "For", "A-001,", "we", "are", "required", "to", "pay", "up", "to", "$3.0", "million", "upon", "achievement", "of", "certain", "clinical", "development", "milestones", "and", "up", "to", "$25.0", "million", "upon", "achievement", "of", "certain", "approval", "and", "post-approval", "sales", "milestones.", "<tag2>", "For", "varespladib", "sodium,", "we", "are", "required", "to", "pay", "up", "to", "$3.0", "million", "upon", "achievement", "of", "certain", "clinical", "development", "milestones", "and", "up", "to", "$25.0", "million", "upon", "achievement", "of", "certain", "approval", "and", "post-approval", "sales", "milestones.", "<tag3>"], "wordsA": ["For", "A-001,", "we", "are", "required", "to", "pay", "up", "to", "$3.0", "million", "upon", "achievement", "of", "certain", "clinical", "development", "milestones", "and", "up", "to", "$25.0", "million", "upon", "achievement", "of", "certain", "approval", "and", "post-approval", "sales", "milestones."], "wordsB": ["For", "varespladib", "sodium,", "we", "are", "required", "to", "pay", "up", "to", "$3.0", "million", "upon", "achievement", "of", "certain", "clinical", "development", "milestones", "and", "up", "to", "$25.0", "million", "upon", "achievement", "of", "certain", "approval", "and", "post-approval", "sales", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.048608653247356415, 0.9837390184402466, 0.912971556186676, 0.0020412548910826445, 0.0016761650331318378, 0.002168439794331789, 0.0019031815463677049, 0.0028218235820531845, 0.002318090759217739, 0.002280113287270069, 0.00325856008566916, 0.002699513453990221, 0.0017469206359237432, 0.0019157988717779517, 0.0015595447039231658, 0.0017484131967648864, 0.0024408972822129726, 0.0025898779276758432, 0.0025063632056117058, 0.0018268618732690811, 0.0018773502670228481, 0.0019476847955957055, 0.0027900005225092173, 0.0022625450510531664, 0.0016577738570049405, 0.0017505584983155131, 0.0015820873668417335, 0.0017938320524990559, 0.0018172450363636017, 0.0016469658585265279, 0.002518897643312812, 0.0022492369171231985, 0.0025498908944427967, -1]}
{"idB": "1316175_12_item1a_p17_s0", "idA": "1316175_11_item1a_p17_s5", "sentA": "In addition, in December 2007, we entered into a license agreement with Amgen Inc., or Amgen, pursuant to which we obtained an exclusive worldwide license to certain technology and compounds relating to A-623.", "sentB": "In addition, in December 2007, we entered into a license agreement with Amgen Inc., or Amgen, pursuant to which we obtained an exclusive worldwide license to certain technology and compounds relating to blisibimod.", "type": 2, "words": ["<tag1>", "In", "addition,", "in", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen", "Inc.,", "or", "Amgen,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "A-623.", "<tag2>", "In", "addition,", "in", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen", "Inc.,", "or", "Amgen,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod.", "<tag3>"], "wordsA": ["In", "addition,", "in", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen", "Inc.,", "or", "Amgen,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "A-623."], "wordsB": ["In", "addition,", "in", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen", "Inc.,", "or", "Amgen,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0028269831091165543, 0.00381767307408154, 0.003558742580935359, 0.004006468690931797, 0.0038175322115421295, 0.003968783188611269, 0.005057250149548054, 0.004684783052653074, 0.003540619043633342, 0.005137553904205561, 0.006199606228619814, 0.003738384461030364, 0.0062232972122728825, 0.003926936071366072, 0.0032942364923655987, 0.004792234394699335, 0.003962161019444466, 0.003036440582945943, 0.00253959558904171, 0.003035689936950803, 0.0041832951828837395, 0.0035790817346423864, 0.00562784168869257, 0.004384813364595175, 0.008223223499953747, 0.0024582459591329098, 0.0031037384178489447, 0.005044702906161547, 0.0034393963869661093, 0.01257500983774662, 0.053537435829639435, 0.06872771680355072, 0.97325599193573, -1]}
{"idB": "1316175_12_item1a_p17_s1", "idA": "1316175_11_item1a_p17_s6", "sentA": "Pursuant to our license agreement with Amgen, we are required to make various milestone payments upon our achievement of certain development, regulatory and commercial objectives for any A-623 formulation.", "sentB": "Pursuant to our license agreement with Amgen, we are required to make various milestone payments upon our achievement of certain development, regulatory and commercial objectives for any blisibimod formulation.", "type": 2, "words": ["<tag1>", "Pursuant", "to", "our", "license", "agreement", "with", "Amgen,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "our", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives", "for", "any", "A-623", "formulation.", "<tag2>", "Pursuant", "to", "our", "license", "agreement", "with", "Amgen,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "our", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives", "for", "any", "blisibimod", "formulation.", "<tag3>"], "wordsA": ["Pursuant", "to", "our", "license", "agreement", "with", "Amgen,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "our", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives", "for", "any", "A-623", "formulation."], "wordsB": ["Pursuant", "to", "our", "license", "agreement", "with", "Amgen,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "our", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives", "for", "any", "blisibimod", "formulation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0026164052542299032, 0.00190817064139992, 0.0018630321137607098, 0.00404172670096159, 0.0051842182874679565, 0.002472098683938384, 0.0034526209346950054, 0.0019855620339512825, 0.0018428321927785873, 0.0030819557141512632, 0.0023210912477225065, 0.002346436260268092, 0.0021720726508647203, 0.002455062698572874, 0.002698696916922927, 0.0017308612586930394, 0.0017064135754480958, 0.001972104888409376, 0.0016492489958181977, 0.0017797404434531927, 0.002085368847474456, 0.002006330993026495, 0.0018294121837243438, 0.0022379178553819656, 0.0031626925338059664, 0.003923084121197462, 0.014018448069691658, 0.9746639728546143, 0.11634350568056107, -1]}
{"idB": "1316175_12_item1a_p17_s4", "idA": "1316175_11_item1a_p17_s9", "sentA": "The timing of our achievement of these events and corresponding milestone payments becoming due to Eli Lilly, Shionogi Co., Ltd. and Amgen is subject to factors relating to the clinical and regulatory development and commercialization of certain sPLA 2 inhibitors or A-623, as applicable, many of which are beyond our control.", "sentB": "The timing of our achievement of these events and corresponding milestone payments becoming due to Eli Lilly, Shionogi Co., Ltd. and Amgen is subject to factors relating to the clinical and regulatory development and commercialization of certain sPLA2 inhibitors or blisibimod, as applicable, many of which are beyond our control.", "type": 2, "words": ["<tag1>", "The", "timing", "of", "our", "achievement", "of", "these", "events", "and", "corresponding", "milestone", "payments", "becoming", "due", "to", "Eli", "Lilly,", "Shionogi", "Co.,", "Ltd.", "and", "Amgen", "is", "subject", "to", "factors", "relating", "to", "the", "clinical", "and", "regulatory", "development", "and", "commercialization", "of", "certain", "sPLA", "2", "inhibitors", "or", "A-623,", "as", "applicable,", "many", "of", "which", "are", "beyond", "our", "control.", "<tag2>", "The", "timing", "of", "our", "achievement", "of", "these", "events", "and", "corresponding", "milestone", "payments", "becoming", "due", "to", "Eli", "Lilly,", "Shionogi", "Co.,", "Ltd.", "and", "Amgen", "is", "subject", "to", "factors", "relating", "to", "the", "clinical", "and", "regulatory", "development", "and", "commercialization", "of", "certain", "sPLA2", "inhibitors", "or", "blisibimod,", "as", "applicable,", "many", "of", "which", "are", "beyond", "our", "control.", "<tag3>"], "wordsA": ["The", "timing", "of", "our", "achievement", "of", "these", "events", "and", "corresponding", "milestone", "payments", "becoming", "due", "to", "Eli", "Lilly,", "Shionogi", "Co.,", "Ltd.", "and", "Amgen", "is", "subject", "to", "factors", "relating", "to", "the", "clinical", "and", "regulatory", "development", "and", "commercialization", "of", "certain", "sPLA", "2", "inhibitors", "or", "A-623,", "as", "applicable,", "many", "of", "which", "are", "beyond", "our", "control."], "wordsB": ["The", "timing", "of", "our", "achievement", "of", "these", "events", "and", "corresponding", "milestone", "payments", "becoming", "due", "to", "Eli", "Lilly,", "Shionogi", "Co.,", "Ltd.", "and", "Amgen", "is", "subject", "to", "factors", "relating", "to", "the", "clinical", "and", "regulatory", "development", "and", "commercialization", "of", "certain", "sPLA2", "inhibitors", "or", "blisibimod,", "as", "applicable,", "many", "of", "which", "are", "beyond", "our", "control."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0026886004488915205, 0.005496474448591471, 0.0043323528952896595, 0.003430829616263509, 0.004824174102395773, 0.0045130690559744835, 0.0042524682357907295, 0.0048480769619345665, 0.004952314775437117, 0.005489584058523178, 0.005570561625063419, 0.005544151179492474, 0.00568088423460722, 0.004970495123416185, 0.004414970986545086, 0.005754154175519943, 0.007483700755983591, 0.00968295056372881, 0.005570726003497839, 0.006077637430280447, 0.004303766414523125, 0.006453523878008127, 0.004345858935266733, 0.0069747744128108025, 0.0045776646584272385, 0.005041032563894987, 0.005062747281044722, 0.0040572406724095345, 0.0036636213771998882, 0.004250187426805496, 0.005005822516977787, 0.004935314878821373, 0.004378161393105984, 0.00433350121602416, 0.00433044508099556, 0.0030575913842767477, 0.004093569237738848, 0.010141070932149887, 0.022658346220850945, 0.02332228608429432, 0.9790292978286743, 0.007140172179788351, 0.0044241612777113914, 0.005062449723482132, 0.003994089551270008, 0.004783738870173693, 0.007183026988059282, 0.10465085506439209, 0.07513570785522461, 0.09995271265506744, -1]}
{"idB": "1316175_12_item1a_p19_s1", "idA": "1316175_11_item1a_p19_s1", "sentA": "Our operations to date have been limited to organizing and staffing our company, acquiring product and technology rights, conducting product development activities for our primary product candidates, varespladib, A-623 and A-001, and performing research and development.", "sentB": "Our operations to date have been limited to organizing and staffing our company, acquiring product and technology rights, conducting product development activities for our primary product candidates, varespladib, blisibimod and varespladib sodium, and performing research and development.", "type": 2, "words": ["<tag1>", "Our", "operations", "to", "date", "have", "been", "limited", "to", "organizing", "and", "staffing", "our", "company,", "acquiring", "product", "and", "technology", "rights,", "conducting", "product", "development", "activities", "for", "our", "primary", "product", "candidates,", "varespladib,", "A-623", "and", "A-001,", "and", "performing", "research", "and", "development.", "<tag2>", "Our", "operations", "to", "date", "have", "been", "limited", "to", "organizing", "and", "staffing", "our", "company,", "acquiring", "product", "and", "technology", "rights,", "conducting", "product", "development", "activities", "for", "our", "primary", "product", "candidates,", "varespladib,", "blisibimod", "and", "varespladib", "sodium,", "and", "performing", "research", "and", "development.", "<tag3>"], "wordsA": ["Our", "operations", "to", "date", "have", "been", "limited", "to", "organizing", "and", "staffing", "our", "company,", "acquiring", "product", "and", "technology", "rights,", "conducting", "product", "development", "activities", "for", "our", "primary", "product", "candidates,", "varespladib,", "A-623", "and", "A-001,", "and", "performing", "research", "and", "development."], "wordsB": ["Our", "operations", "to", "date", "have", "been", "limited", "to", "organizing", "and", "staffing", "our", "company,", "acquiring", "product", "and", "technology", "rights,", "conducting", "product", "development", "activities", "for", "our", "primary", "product", "candidates,", "varespladib,", "blisibimod", "and", "varespladib", "sodium,", "and", "performing", "research", "and", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.004226370714604855, 0.00874590128660202, 0.0070384591817855835, 0.006273697596043348, 0.006021498236805201, 0.0058491844683885574, 0.008244195953011513, 0.006053254473954439, 0.006214315537363291, 0.0070494553074240685, 0.005777963902801275, 0.004017514176666737, 0.004789258819073439, 0.008787178434431553, 0.005570585839450359, 0.007196962833404541, 0.005347399041056633, 0.006194869056344032, 0.005171863362193108, 0.004913897253572941, 0.004947323352098465, 0.004503672476857901, 0.0025372523814439774, 0.0025064204819500446, 0.0050135329365730286, 0.006641631480306387, 0.013793625868856907, 0.011707655154168606, 0.7104348540306091, 0.042669449001550674, 0.0993000715970993, 0.764183759689331, 0.006272846832871437, 0.005112448241561651, 0.004222601652145386, 0.004942258354276419, 0.004214396700263023, -1]}
{"idB": "1316175_12_item1a_p20_s0", "idA": "1316175_11_item1a_p20_s0", "sentA": "We depend substantially on the success of our three primary product candidates, varespladib, A-623 and A-001, which are still under clinical development.", "sentB": "We depend substantially on the success of our product candidates which are still under clinical development.", "type": 2, "words": ["<tag1>", "We", "depend", "substantially", "on", "the", "success", "of", "our", "three", "primary", "product", "candidates,", "varespladib,", "A-623", "and", "A-001,", "which", "are", "still", "under", "clinical", "development.", "<tag2>", "We", "depend", "substantially", "on", "the", "success", "of", "our", "product", "candidates", "which", "are", "still", "under", "clinical", "development.", "<tag3>"], "wordsA": ["We", "depend", "substantially", "on", "the", "success", "of", "our", "three", "primary", "product", "candidates,", "varespladib,", "A-623", "and", "A-001,", "which", "are", "still", "under", "clinical", "development."], "wordsB": ["We", "depend", "substantially", "on", "the", "success", "of", "our", "product", "candidates", "which", "are", "still", "under", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.07506873458623886, 0.15739643573760986, 0.13452251255512238, 0.05654345080256462, 0.02069062739610672, 0.18727274239063263, 0.04703519493341446, 0.09469131380319595, 0.40447166562080383, 0.38948920369148254, 0.010901447385549545, 0.022763483226299286, 0.036617621779441833, 0.06780579686164856, 0.051322512328624725, 0.08263501524925232, -1]}
{"idB": "1316175_12_item1a_p93_s4", "idA": "1316175_11_item1a_p21_s0", "sentA": "To date, we have not obtained marketing approval for, or marketed, distributed or sold any product candidates.", "sentB": "To date, we have had no comments on any of these submissions.", "type": 2, "words": ["<tag1>", "To", "date,", "we", "have", "not", "obtained", "marketing", "approval", "for,", "or", "marketed,", "distributed", "or", "sold", "any", "product", "candidates.", "<tag2>", "To", "date,", "we", "have", "had", "no", "comments", "on", "any", "of", "these", "submissions.", "<tag3>"], "wordsA": ["To", "date,", "we", "have", "not", "obtained", "marketing", "approval", "for,", "or", "marketed,", "distributed", "or", "sold", "any", "product", "candidates."], "wordsB": ["To", "date,", "we", "have", "had", "no", "comments", "on", "any", "of", "these", "submissions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0058562844060361385, 0.01714996248483658, 0.035085294395685196, 0.08202436566352844, 0.2704639434814453, 0.9199720621109009, 0.9626909494400024, 0.14363056421279907, 0.09719783067703247, 0.054452743381261826, 0.07355092465877533, 0.17608103156089783, -1]}
{"idB": "1316175_12_item1a_p22_s0", "idA": "1316175_11_item1a_p22_s0", "sentA": "The success of our business depends primarily upon our ability to develop and commercialize our three primary product candidates successfully.", "sentB": "The success of our business depends primarily upon our ability to develop and commercialize our product candidates successfully.", "type": 2, "words": ["<tag1>", "The", "success", "of", "our", "business", "depends", "primarily", "upon", "our", "ability", "to", "develop", "and", "commercialize", "our", "three", "primary", "product", "candidates", "successfully.", "<tag2>", "The", "success", "of", "our", "business", "depends", "primarily", "upon", "our", "ability", "to", "develop", "and", "commercialize", "our", "product", "candidates", "successfully.", "<tag3>"], "wordsA": ["The", "success", "of", "our", "business", "depends", "primarily", "upon", "our", "ability", "to", "develop", "and", "commercialize", "our", "three", "primary", "product", "candidates", "successfully."], "wordsB": ["The", "success", "of", "our", "business", "depends", "primarily", "upon", "our", "ability", "to", "develop", "and", "commercialize", "our", "product", "candidates", "successfully."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.015317426063120365, 0.23037488758563995, 0.02040823921561241, 0.07784347236156464, 0.1289404183626175, 0.0634278953075409, 0.0610027089715004, 0.026187362149357796, 0.039200663566589355, 0.06427762657403946, 0.018202079460024834, 0.04149734601378441, 0.024323953315615654, 0.0423312783241272, 0.1446029543876648, 0.5577216148376465, 0.4844511151313782, 0.12562920153141022, -1]}
{"idB": "1316175_12_item1a_p23_s0", "idA": "1316175_11_item1a_p23_s0", "sentA": "Our next product candidate is A-623, which has completed several Phase 1 clinical studies and recently began enrollment for our Phase 2b clinical study.", "sentB": "Our lead product candidate is blisibimod, which has completed several Phase 1 clinical studies and has completed enrollment in a Phase 2b clinical study.", "type": 2, "words": ["<tag1>", "Our", "next", "product", "candidate", "is", "A-623,", "which", "has", "completed", "several", "Phase", "1", "clinical", "studies", "and", "recently", "began", "enrollment", "for", "our", "Phase", "2b", "clinical", "study.", "<tag2>", "Our", "lead", "product", "candidate", "is", "blisibimod,", "which", "has", "completed", "several", "Phase", "1", "clinical", "studies", "and", "has", "completed", "enrollment", "in", "a", "Phase", "2b", "clinical", "study.", "<tag3>"], "wordsA": ["Our", "next", "product", "candidate", "is", "A-623,", "which", "has", "completed", "several", "Phase", "1", "clinical", "studies", "and", "recently", "began", "enrollment", "for", "our", "Phase", "2b", "clinical", "study."], "wordsB": ["Our", "lead", "product", "candidate", "is", "blisibimod,", "which", "has", "completed", "several", "Phase", "1", "clinical", "studies", "and", "has", "completed", "enrollment", "in", "a", "Phase", "2b", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0072432830929756165, 0.3854827880859375, 0.21702225506305695, 0.12743638455867767, 0.007395008113235235, 0.8653005957603455, 7.340133015532047e-05, 0.002163093537092209, 0.005944863893091679, 0.0019021218176931143, 0.003161326516419649, 0.0028305102605372667, 0.003125591203570366, 0.003761806059628725, 8.021533722057939e-05, 0.0007912088767625391, 0.00908973440527916, 0.008596419356763363, 0.0013358447467908263, 0.001279334188438952, 0.002689771819859743, 0.0027295774780213833, 0.0029284730553627014, 0.003445760114118457, -1]}
{"idB": "1316175_12_item1a_p27_s0", "idA": "1316175_11_item1a_p28_s0", "sentA": "We are not permitted to market our varespladib and A-001 product candidates in the United States until we receive approval of a new drug application, or NDA, or with respect to our A-623 product candidate, approval of a biologics license application, or BLA, from the FDA, or in any foreign countries until we receive the requisite approval from such countries.", "sentB": "foreign countries until we receive the requisite approval from such countries.", "type": 2, "words": ["<tag1>", "We", "are", "not", "permitted", "to", "market", "our", "varespladib", "and", "A-001", "product", "candidates", "in", "the", "United", "States", "until", "we", "receive", "approval", "of", "a", "new", "drug", "application,", "or", "NDA,", "or", "with", "respect", "to", "our", "A-623", "product", "candidate,", "approval", "of", "a", "biologics", "license", "application,", "or", "BLA,", "from", "the", "FDA,", "or", "in", "any", "foreign", "countries", "until", "we", "receive", "the", "requisite", "approval", "from", "such", "countries.", "<tag2>", "foreign", "countries", "until", "we", "receive", "the", "requisite", "approval", "from", "such", "countries.", "<tag3>"], "wordsA": ["We", "are", "not", "permitted", "to", "market", "our", "varespladib", "and", "A-001", "product", "candidates", "in", "the", "United", "States", "until", "we", "receive", "approval", "of", "a", "new", "drug", "application,", "or", "NDA,", "or", "with", "respect", "to", "our", "A-623", "product", "candidate,", "approval", "of", "a", "biologics", "license", "application,", "or", "BLA,", "from", "the", "FDA,", "or", "in", "any", "foreign", "countries", "until", "we", "receive", "the", "requisite", "approval", "from", "such", "countries."], "wordsB": ["foreign", "countries", "until", "we", "receive", "the", "requisite", "approval", "from", "such", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.26332688331604004, 0.3664320111274719, 0.13427969813346863, 0.06596878170967102, 0.24770520627498627, 0.07047708332538605, 0.22815372049808502, 0.5562227368354797, 0.07186516374349594, 0.12697334587574005, 0.19726841151714325, -1]}
{"idB": "1316175_12_item1a_p2_s0", "idA": "1316175_11_item1a_p2_s0", "sentA": "We are a development stage company with only six years of operating history.", "sentB": "We are a development stage company with only seven years of operating history.", "type": 2, "words": ["<tag1>", "We", "are", "a", "development", "stage", "company", "with", "only", "six", "years", "of", "operating", "history.", "<tag2>", "We", "are", "a", "development", "stage", "company", "with", "only", "seven", "years", "of", "operating", "history.", "<tag3>"], "wordsA": ["We", "are", "a", "development", "stage", "company", "with", "only", "six", "years", "of", "operating", "history."], "wordsB": ["We", "are", "a", "development", "stage", "company", "with", "only", "seven", "years", "of", "operating", "history."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0036005512811243534, 0.0015957716386765242, 0.0013429257087409496, 0.006558343302458525, 0.006590795703232288, 0.011202972382307053, 0.010437902994453907, 0.04441740736365318, 0.9946165680885315, 0.14222446084022522, 0.010345899499952793, 0.011106285266578197, 0.012495899572968483, -1]}
{"idB": "1316175_12_item1a_p2_s1", "idA": "1316175_11_item1a_p2_s1", "sentA": "We have focused primarily on developing our three product candidates, varespladib, A-623 and varespladib sodium (A-001).", "sentB": "We have focused primarily on developing our three product candidates, varespladib, blisibimod and varespladib sodium.", "type": 2, "words": ["<tag1>", "We", "have", "focused", "primarily", "on", "developing", "our", "three", "product", "candidates,", "varespladib,", "A-623", "and", "varespladib", "sodium", "(A-001).", "<tag2>", "We", "have", "focused", "primarily", "on", "developing", "our", "three", "product", "candidates,", "varespladib,", "blisibimod", "and", "varespladib", "sodium.", "<tag3>"], "wordsA": ["We", "have", "focused", "primarily", "on", "developing", "our", "three", "product", "candidates,", "varespladib,", "A-623", "and", "varespladib", "sodium", "(A-001)."], "wordsB": ["We", "have", "focused", "primarily", "on", "developing", "our", "three", "product", "candidates,", "varespladib,", "blisibimod", "and", "varespladib", "sodium."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.004396248143166304, 0.002583968685939908, 0.007378638722002506, 0.006241525057703257, 0.0028500629123300314, 0.007691802456974983, 0.003237492637708783, 0.005721554160118103, 0.00876375287771225, 0.022900965064764023, 0.025214023888111115, 0.9064564108848572, 0.013923685997724533, 0.021576084196567535, 0.0376925989985466, -1]}
{"idB": "1316175_12_item1a_p7_s1", "idA": "1316175_11_item1a_p2_s1", "sentA": "We have focused primarily on developing our three product candidates, varespladib, A-623 and varespladib sodium (A-001).", "sentB": "Currently, we have three product candidates in clinical development: varespladib, blisibimod and varespladib sodium.", "type": 2, "words": ["<tag1>", "We", "have", "focused", "primarily", "on", "developing", "our", "three", "product", "candidates,", "varespladib,", "A-623", "and", "varespladib", "sodium", "(A-001).", "<tag2>", "Currently,", "we", "have", "three", "product", "candidates", "in", "clinical", "development:", "varespladib,", "blisibimod", "and", "varespladib", "sodium.", "<tag3>"], "wordsA": ["We", "have", "focused", "primarily", "on", "developing", "our", "three", "product", "candidates,", "varespladib,", "A-623", "and", "varespladib", "sodium", "(A-001)."], "wordsB": ["Currently,", "we", "have", "three", "product", "candidates", "in", "clinical", "development:", "varespladib,", "blisibimod", "and", "varespladib", "sodium."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.043691907078027725, 0.024179108440876007, 0.014721577987074852, 0.07218121737241745, 0.04430093243718147, 0.08566054701805115, 0.04755657538771629, 0.13293029367923737, 0.07318666577339172, 0.049657728523015976, 0.8363097310066223, 0.019381960853934288, 0.034749433398246765, 0.07677911967039108, -1]}
{"idB": "1316175_12_item1a_p2_s2", "idA": "1316175_11_item1a_p2_s2", "sentA": "We have financed our operations exclusively through equity offerings and private placements of convertible debt and we have incurred losses in each year since our inception in September 2004.", "sentB": "We have financed our operations exclusively through equity offerings, private placements of convertible debt, and debt financings and we have incurred losses in each year since our inception in September 2004.", "type": 2, "words": ["<tag1>", "We", "have", "financed", "our", "operations", "exclusively", "through", "equity", "offerings", "and", "private", "placements", "of", "convertible", "debt", "and", "we", "have", "incurred", "losses", "in", "each", "year", "since", "our", "inception", "in", "September", "2004.", "<tag2>", "We", "have", "financed", "our", "operations", "exclusively", "through", "equity", "offerings,", "private", "placements", "of", "convertible", "debt,", "and", "debt", "financings", "and", "we", "have", "incurred", "losses", "in", "each", "year", "since", "our", "inception", "in", "September", "2004.", "<tag3>"], "wordsA": ["We", "have", "financed", "our", "operations", "exclusively", "through", "equity", "offerings", "and", "private", "placements", "of", "convertible", "debt", "and", "we", "have", "incurred", "losses", "in", "each", "year", "since", "our", "inception", "in", "September", "2004."], "wordsB": ["We", "have", "financed", "our", "operations", "exclusively", "through", "equity", "offerings,", "private", "placements", "of", "convertible", "debt,", "and", "debt", "financings", "and", "we", "have", "incurred", "losses", "in", "each", "year", "since", "our", "inception", "in", "September", "2004."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.06098951771855354, 0.05040803924202919, 0.4063374698162079, 0.10995521396398544, 0.11511769890785217, 0.1432461440563202, 0.01604338362812996, 0.155351921916008, 0.2643902003765106, 0.06437627226114273, 0.07654053717851639, 0.017894452437758446, 0.21100208163261414, 0.08234398066997528, 0.009725209325551987, 0.22163282334804535, 0.35064852237701416, 0.0006225354736670852, 0.015429680235683918, 0.017126793041825294, 0.07935268431901932, 0.11394917219877243, 0.015973662957549095, 0.026324840262532234, 0.038472577929496765, 0.022780371829867363, 0.018325116485357285, 0.05768604204058647, 0.02830173261463642, 0.05617959797382355, 0.05036236718297005, -1]}
{"idB": "1316175_12_item1a_p2_s3", "idA": "1316175_11_item1a_p2_s4", "sentA": "As of December 31, 2010, we had an accumulated deficit of approximately $105.6 million.", "sentB": "As of December 31, 2011, we had an accumulated deficit of approximately $201.0 million.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2010,", "we", "had", "an", "accumulated", "deficit", "of", "approximately", "$105.6", "million.", "<tag2>", "As", "of", "December", "31,", "2011,", "we", "had", "an", "accumulated", "deficit", "of", "approximately", "$201.0", "million.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2010,", "we", "had", "an", "accumulated", "deficit", "of", "approximately", "$105.6", "million."], "wordsB": ["As", "of", "December", "31,", "2011,", "we", "had", "an", "accumulated", "deficit", "of", "approximately", "$201.0", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.005824458319693804, 0.004722428508102894, 0.017990842461586, 0.02602287195622921, 0.9702680706977844, 0.0029748459346592426, 0.0027274289168417454, 0.002356909913942218, 0.005534774158149958, 0.009630104526877403, 0.004759177565574646, 0.012954500503838062, 0.8839669823646545, 0.3816274404525757, -1]}
{"idB": "1316175_12_item1a_p31_s0", "idA": "1316175_11_item1a_p32_s0", "sentA": "retaining patients who have initiated a clinical study, but may withdraw due to treatment protocol, adverse effects from the therapy, lack of efficacy from the treatment, personal issues or who are lost to further follow-up.", "sentB": "obtaining regulatory approval to commence a clinical study or complying with conditions imposed by a regulatory authority regarding the scope or design of a clinical study; reaching agreement on acceptable terms with prospective clinical research organizations, or CROs, and study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and study sites; manufacturing, including manufacturing sufficient quantities of a product candidate or other materials for use in clinical studies; obtaining institutional review board, or IRB, approval or the approval of other reviewing entities to conduct a clinical study at a prospective site; recruiting and enrolling patients to participate in clinical studies for a variety of reasons, including size of patient population, nature of clinical study protocol, the availability of approved effective treatments for the relevant disease and competition from other clinical study programs for similar indications; severe or unexpected drug-related adverse effects experienced by patients in a clinical study; and retaining patients who have initiated a clinical study, but may withdraw due to treatment protocol, adverse effects from the therapy, lack of efficacy from the treatment, personal issues or who are lost to further follow-up.", "type": 2, "words": ["<tag1>", "retaining", "patients", "who", "have", "initiated", "a", "clinical", "study,", "but", "may", "withdraw", "due", "to", "treatment", "protocol,", "adverse", "effects", "from", "the", "therapy,", "lack", "of", "efficacy", "from", "the", "treatment,", "personal", "issues", "or", "who", "are", "lost", "to", "further", "follow-up.", "<tag2>", "obtaining", "regulatory", "approval", "to", "commence", "a", "clinical", "study", "or", "complying", "with", "conditions", "imposed", "by", "a", "regulatory", "authority", "regarding", "the", "scope", "or", "design", "of", "a", "clinical", "study;", "reaching", "agreement", "on", "acceptable", "terms", "with", "prospective", "clinical", "research", "organizations,", "or", "CROs,", "and", "study", "sites,", "the", "terms", "of", "which", "can", "be", "subject", "to", "extensive", "negotiation", "and", "may", "vary", "significantly", "among", "different", "CROs", "and", "study", "sites;", "manufacturing,", "including", "manufacturing", "sufficient", "quantities", "of", "a", "product", "candidate", "or", "other", "materials", "for", "use", "in", "clinical", "studies;", "obtaining", "institutional", "review", "board,", "or", "IRB,", "approval", "or", "the", "approval", "of", "other", "reviewing", "entities", "to", "conduct", "a", "clinical", "study", "at", "a", "prospective", "site;", "recruiting", "and", "enrolling", "patients", "to", "participate", "in", "clinical", "studies", "for", "a", "variety", "of", "reasons,", "including", "size", "of", "patient", "population,", "nature", "of", "clinical", "study", "protocol,", "the", "availability", "of", "approved", "effective", "treatments", "for", "the", "relevant", "disease", "and", "competition", "from", "other", "clinical", "study", "programs", "for", "similar", "indications;", "severe", "or", "unexpected", "drug-related", "adverse", "effects", "experienced", "by", "patients", "in", "a", "clinical", "study;", "and", "retaining", "patients", "who", "have", "initiated", "a", "clinical", "study,", "but", "may", "withdraw", "due", "to", "treatment", "protocol,", "adverse", "effects", "from", "the", "therapy,", "lack", "of", "efficacy", "from", "the", "treatment,", "personal", "issues", "or", "who", "are", "lost", "to", "further", "follow-up.", "<tag3>"], "wordsA": ["retaining", "patients", "who", "have", "initiated", "a", "clinical", "study,", "but", "may", "withdraw", "due", "to", "treatment", "protocol,", "adverse", "effects", "from", "the", "therapy,", "lack", "of", "efficacy", "from", "the", "treatment,", "personal", "issues", "or", "who", "are", "lost", "to", "further", "follow-up."], "wordsB": ["obtaining", "regulatory", "approval", "to", "commence", "a", "clinical", "study", "or", "complying", "with", "conditions", "imposed", "by", "a", "regulatory", "authority", "regarding", "the", "scope", "or", "design", "of", "a", "clinical", "study;", "reaching", "agreement", "on", "acceptable", "terms", "with", "prospective", "clinical", "research", "organizations,", "or", "CROs,", "and", "study", "sites,", "the", "terms", "of", "which", "can", "be", "subject", "to", "extensive", "negotiation", "and", "may", "vary", "significantly", "among", "different", "CROs", "and", "study", "sites;", "manufacturing,", "including", "manufacturing", "sufficient", "quantities", "of", "a", "product", "candidate", "or", "other", "materials", "for", "use", "in", "clinical", "studies;", "obtaining", "institutional", "review", "board,", "or", "IRB,", "approval", "or", "the", "approval", "of", "other", "reviewing", "entities", "to", "conduct", "a", "clinical", "study", "at", "a", "prospective", "site;", "recruiting", "and", "enrolling", "patients", "to", "participate", "in", "clinical", "studies", "for", "a", "variety", "of", "reasons,", "including", "size", "of", "patient", "population,", "nature", "of", "clinical", "study", "protocol,", "the", "availability", "of", "approved", "effective", "treatments", "for", "the", "relevant", "disease", "and", "competition", "from", "other", "clinical", "study", "programs", "for", "similar", "indications;", "severe", "or", "unexpected", "drug-related", "adverse", "effects", "experienced", "by", "patients", "in", "a", "clinical", "study;", "and", "retaining", "patients", "who", "have", "initiated", "a", "clinical", "study,", "but", "may", "withdraw", "due", "to", "treatment", "protocol,", "adverse", "effects", "from", "the", "therapy,", "lack", "of", "efficacy", "from", "the", "treatment,", "personal", "issues", "or", "who", "are", "lost", "to", "further", "follow-up."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.08693194389343262, 0.15059757232666016, 0.08922813832759857, 0.0070723192766308784, 0.009209065698087215, 0.0054499986581504345, 0.008251301944255829, 0.007124842144548893, 0.01254411693662405, 0.009225805290043354, 0.00881814956665039, 0.0057705240324139595, 0.006322717759758234, 0.006247328128665686, 0.006592731457203627, 0.007130169775336981, 0.006557094864547253, 0.004699733108282089, 0.007730785291641951, 0.0066283284686505795, 0.010182232595980167, 0.011417418718338013, 0.008289583027362823, 0.006592063698917627, 0.013098555617034435, 0.013227594085037708, 0.153137668967247, 0.17627017199993134, 0.049596719443798065, 0.12750962376594543, 0.11077392101287842, 0.02140824683010578, 0.023749208077788353, 0.02452872321009636, 0.024989863857626915, 0.026029067113995552, 0.008652456104755402, 0.02621869370341301, 0.007122992537915707, 0.027876116335392, 0.038858916610479355, 0.004887960851192474, 0.04158606752753258, 0.01063564419746399, 0.01676071807742119, 0.01756572723388672, 0.0125165656208992, 0.015332219190895557, 0.01292914804071188, 0.04948125034570694, 0.04748862236738205, 0.0038970245514065027, 0.017029186710715294, 0.05536337569355965, 0.03493692725896835, 0.01925896294414997, 0.035244766622781754, 0.05243200436234474, 0.010216346010565758, 0.02699216455221176, 0.04687544330954552, 0.077738456428051, 0.01055233646184206, 0.14841128885746002, 0.22033199667930603, 0.16406720876693726, 0.09638291597366333, 0.0534818209707737, 0.061463888734579086, 0.05277084931731224, 0.016084669157862663, 0.017407843843102455, 0.06868385523557663, 0.012265796773135662, 0.012297096662223339, 0.006073327269405127, 0.011445924639701843, 0.015396016649901867, 0.09587555378675461, 0.16252699494361877, 0.17940649390220642, 0.16429224610328674, 0.008245225064456463, 0.04983925074338913, 0.027066079899668694, 0.004780670627951622, 0.00202825665473938, 0.011612949892878532, 0.005561118479818106, 0.005454673431813717, 0.016269689425826073, 0.02247549407184124, 0.006241874303668737, 0.00909963995218277, 0.00778251001611352, 0.012114415876567364, 0.014464504085481167, 0.004781233612447977, 0.005466914735734463, 0.01195570733398199, 0.013523169793188572, 0.09780757129192352, 0.0745474100112915, 0.13938164710998535, 0.07030344009399414, 0.006836974527686834, 0.016402924433350563, 0.006983042694628239, 0.011135346256196499, 0.0119429100304842, 0.00859285518527031, 0.01121601089835167, 0.0062274690717458725, 0.0031481035985052586, 0.006588201969861984, 0.005002816207706928, 0.005094696767628193, 0.005578538868576288, 0.008327875286340714, 0.006849312223494053, 0.004259712994098663, 0.0052253976464271545, 0.005537125747650862, 0.0062019238248467445, 0.004651055205613375, 0.006130577065050602, 0.0062346020713448524, 0.005297676660120487, 0.0063399518840014935, 0.01175333745777607, 0.013833926990628242, 0.005739134736359119, 0.00877455435693264, 0.006617587059736252, 0.00732768140733242, 0.00791096594184637, 0.007329911459237337, 0.004784799180924892, 0.004748926032334566, 0.006509711034595966, 0.006347661837935448, 0.004908460658043623, 0.005116378888487816, 0.004484836477786303, 0.012408659793436527, 0.004053257871419191, 0.01366081926971674, 0.004924813751131296, 0.006328358314931393, 0.00515159172937274, 0.0051810843870043755, 0.003835430135950446, 0.0032192603684961796, 0.00606431532651186, 0.004057362210005522, 0.004289092030376196, 0.005740187596529722, 0.019048091024160385, 0.004066744819283485, 0.00664801150560379, 0.013471475802361965, 0.004729058127850294, 0.013849789276719093, 0.00583998579531908, 0.005049410741776228, 0.006080714054405689, 0.006202482618391514, 0.002603051485493779, 0.0066666798666119576, 0.006399951409548521, 0.005351676139980555, 0.0054751550778746605, 0.005655941087752581, 0.004711159970611334, 0.0048827361315488815, 0.004923347383737564, 0.004226234275847673, 0.005253959447145462, 0.006151286419481039, 0.006421518512070179, 0.006856322288513184, 0.004663375671952963, 0.004167209845036268, 0.005580009892582893, 0.0049344138242304325, 0.005490198731422424, 0.006109126377850771, 0.0050627910532057285, 0.0066254623234272, 0.005064784549176693, 0.005777205806225538, 0.0038614333607256413, 0.004551401827484369, 0.007230264134705067, -1]}
{"idB": "1316175_12_item1a_p32_s1", "idA": "1316175_11_item1a_p33_s1", "sentA": "For example, the independent statistician that is conducting the data review may recommend that we stop our VISTA-16 study for varespladib if certain biomarkers of inflammation and lipid profiles fail to meet pre-specified reductions from a subset of the first 1,000 or more patients.", "sentB": "For example, while an independent statistician has completed an analysis of various biomarkers of cardiovascular risk and determined that treatment with once-daily varespladib met the pre-specified criteria for the VISTA-16 study to proceed, an independent DSMB reviewing the clinical data from the VISTA-16 study may recommend the clinical study discontinue based on safety and tolerability.", "type": 2, "words": ["<tag1>", "For", "example,", "the", "independent", "statistician", "that", "is", "conducting", "the", "data", "review", "may", "recommend", "that", "we", "stop", "our", "VISTA-16", "study", "for", "varespladib", "if", "certain", "biomarkers", "of", "inflammation", "and", "lipid", "profiles", "fail", "to", "meet", "pre-specified", "reductions", "from", "a", "subset", "of", "the", "first", "1,000", "or", "more", "patients.", "<tag2>", "For", "example,", "while", "an", "independent", "statistician", "has", "completed", "an", "analysis", "of", "various", "biomarkers", "of", "cardiovascular", "risk", "and", "determined", "that", "treatment", "with", "once-daily", "varespladib", "met", "the", "pre-specified", "criteria", "for", "the", "VISTA-16", "study", "to", "proceed,", "an", "independent", "DSMB", "reviewing", "the", "clinical", "data", "from", "the", "VISTA-16", "study", "may", "recommend", "the", "clinical", "study", "discontinue", "based", "on", "safety", "and", "tolerability.", "<tag3>"], "wordsA": ["For", "example,", "the", "independent", "statistician", "that", "is", "conducting", "the", "data", "review", "may", "recommend", "that", "we", "stop", "our", "VISTA-16", "study", "for", "varespladib", "if", "certain", "biomarkers", "of", "inflammation", "and", "lipid", "profiles", "fail", "to", "meet", "pre-specified", "reductions", "from", "a", "subset", "of", "the", "first", "1,000", "or", "more", "patients."], "wordsB": ["For", "example,", "while", "an", "independent", "statistician", "has", "completed", "an", "analysis", "of", "various", "biomarkers", "of", "cardiovascular", "risk", "and", "determined", "that", "treatment", "with", "once-daily", "varespladib", "met", "the", "pre-specified", "criteria", "for", "the", "VISTA-16", "study", "to", "proceed,", "an", "independent", "DSMB", "reviewing", "the", "clinical", "data", "from", "the", "VISTA-16", "study", "may", "recommend", "the", "clinical", "study", "discontinue", "based", "on", "safety", "and", "tolerability."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.003170090029016137, 0.004671718925237656, 0.010637526400387287, 0.002316603669896722, 0.011448536068201065, 0.023045051842927933, 0.04957585409283638, 0.39426279067993164, 0.056357234716415405, 0.11014457046985626, 0.02290118858218193, 0.026558764278888702, 0.06788250803947449, 0.018110143020749092, 0.21047209203243256, 0.1765669584274292, 0.00019032764248549938, 0.09587635099887848, 0.039145007729530334, 0.12007173895835876, 0.02708560787141323, 0.2400742620229721, 0.07107669115066528, 0.12315879762172699, 0.02433590777218342, 0.0290903951972723, 0.08232488483190536, 0.006192226894199848, 0.004980802070349455, 0.01752524822950363, 0.043327197432518005, 0.03484547510743141, 0.04825041815638542, 0.0073961918242275715, 0.05155336111783981, 0.08340445905923843, 0.03185582533478737, 0.006716623902320862, 0.025001101195812225, 0.0257875993847847, 0.0028376413974910975, 0.002653051633387804, 0.007440691813826561, 0.012848933227360249, 0.014503423124551773, 0.16540312767028809, 0.02362685091793537, 0.06587951630353928, 0.10034457594156265, 0.7312978506088257, 0.04631431773304939, 0.050673265010118484, 0.14945034682750702, 0.06833483278751373, 0.13879790902137756, -1]}
{"idB": "1316175_12_item1a_p33_s0", "idA": "1316175_11_item1a_p33_s2", "sentA": "In addition, a clinical study may be suspended or terminated by us, the FDA, the IRB or other reviewing entity overseeing the clinical study at issue, any of our clinical study sites with respect to that site, or other regulatory authorities due to a number of factors, including:", "sentB": "our clinical study sites with respect to that site, or other regulatory authorities due to a number of factors, including:", "type": 2, "words": ["<tag1>", "In", "addition,", "a", "clinical", "study", "may", "be", "suspended", "or", "terminated", "by", "us,", "the", "FDA,", "the", "IRB", "or", "other", "reviewing", "entity", "overseeing", "the", "clinical", "study", "at", "issue,", "any", "of", "our", "clinical", "study", "sites", "with", "respect", "to", "that", "site,", "or", "other", "regulatory", "authorities", "due", "to", "a", "number", "of", "factors,", "including:", "<tag2>", "our", "clinical", "study", "sites", "with", "respect", "to", "that", "site,", "or", "other", "regulatory", "authorities", "due", "to", "a", "number", "of", "factors,", "including:", "<tag3>"], "wordsA": ["In", "addition,", "a", "clinical", "study", "may", "be", "suspended", "or", "terminated", "by", "us,", "the", "FDA,", "the", "IRB", "or", "other", "reviewing", "entity", "overseeing", "the", "clinical", "study", "at", "issue,", "any", "of", "our", "clinical", "study", "sites", "with", "respect", "to", "that", "site,", "or", "other", "regulatory", "authorities", "due", "to", "a", "number", "of", "factors,", "including:"], "wordsB": ["our", "clinical", "study", "sites", "with", "respect", "to", "that", "site,", "or", "other", "regulatory", "authorities", "due", "to", "a", "number", "of", "factors,", "including:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.08977664262056351, 0.4740820825099945, 0.6177663207054138, 0.6631333231925964, 0.11985931545495987, 0.1051407977938652, 0.05936224013566971, 0.047440700232982635, 0.17618265748023987, 0.013347270898520947, 0.015904240310192108, 0.03912070766091347, 0.05865243077278137, 0.024650301784276962, 0.016317028552293777, 0.015814760699868202, 0.017935099080204964, 0.013164464384317398, 0.02708134986460209, 0.11685913801193237, -1]}
{"idB": "1316175_12_item1a_p34_s0", "idA": "1316175_11_item1a_p34_s0", "sentA": "lack of adequate funding to continue the clinical study, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional clinical studies and increased expenses associated with the services of our CROs and other third parties.", "sentB": "failure to conduct the clinical study in accordance with regulatory requirements or our clinical protocols; inspection of the clinical study operations or study sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold; unforeseen safety issues or any determination that a clinical study presents unacceptable health risks; and lack of adequate funding to continue the clinical study, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional clinical studies and increased expenses associated with the services of our CROs and other third parties.", "type": 2, "words": ["<tag1>", "lack", "of", "adequate", "funding", "to", "continue", "the", "clinical", "study,", "including", "the", "incurrence", "of", "unforeseen", "costs", "due", "to", "enrollment", "delays,", "requirements", "to", "conduct", "additional", "clinical", "studies", "and", "increased", "expenses", "associated", "with", "the", "services", "of", "our", "CROs", "and", "other", "third", "parties.", "<tag2>", "failure", "to", "conduct", "the", "clinical", "study", "in", "accordance", "with", "regulatory", "requirements", "or", "our", "clinical", "protocols;", "inspection", "of", "the", "clinical", "study", "operations", "or", "study", "sites", "by", "the", "FDA", "or", "other", "regulatory", "authorities", "resulting", "in", "the", "imposition", "of", "a", "clinical", "hold;", "unforeseen", "safety", "issues", "or", "any", "determination", "that", "a", "clinical", "study", "presents", "unacceptable", "health", "risks;", "and", "lack", "of", "adequate", "funding", "to", "continue", "the", "clinical", "study,", "including", "the", "incurrence", "of", "unforeseen", "costs", "due", "to", "enrollment", "delays,", "requirements", "to", "conduct", "additional", "clinical", "studies", "and", "increased", "expenses", "associated", "with", "the", "services", "of", "our", "CROs", "and", "other", "third", "parties.", "<tag3>"], "wordsA": ["lack", "of", "adequate", "funding", "to", "continue", "the", "clinical", "study,", "including", "the", "incurrence", "of", "unforeseen", "costs", "due", "to", "enrollment", "delays,", "requirements", "to", "conduct", "additional", "clinical", "studies", "and", "increased", "expenses", "associated", "with", "the", "services", "of", "our", "CROs", "and", "other", "third", "parties."], "wordsB": ["failure", "to", "conduct", "the", "clinical", "study", "in", "accordance", "with", "regulatory", "requirements", "or", "our", "clinical", "protocols;", "inspection", "of", "the", "clinical", "study", "operations", "or", "study", "sites", "by", "the", "FDA", "or", "other", "regulatory", "authorities", "resulting", "in", "the", "imposition", "of", "a", "clinical", "hold;", "unforeseen", "safety", "issues", "or", "any", "determination", "that", "a", "clinical", "study", "presents", "unacceptable", "health", "risks;", "and", "lack", "of", "adequate", "funding", "to", "continue", "the", "clinical", "study,", "including", "the", "incurrence", "of", "unforeseen", "costs", "due", "to", "enrollment", "delays,", "requirements", "to", "conduct", "additional", "clinical", "studies", "and", "increased", "expenses", "associated", "with", "the", "services", "of", "our", "CROs", "and", "other", "third", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.6576916575431824, 0.6541401147842407, 0.5386281609535217, 0.024632269516587257, 0.05896126851439476, 0.061571743339300156, 0.009552784264087677, 0.007304305676370859, 0.006254030391573906, 0.00944491382688284, 0.013749509118497372, 0.005366967990994453, 0.00547034852206707, 0.01084878109395504, 0.017233027145266533, 0.10874877125024796, 0.11188504099845886, 0.04046924039721489, 0.16192291676998138, 0.17940567433834076, 0.0719672292470932, 0.05042845010757446, 0.0933784618973732, 0.10096803307533264, 0.01136329397559166, 0.011529278941452503, 0.01539379172027111, 0.008589552715420723, 0.006512288935482502, 0.016691630706191063, 0.02996821701526642, 0.007227208465337753, 0.007056600879877806, 0.008263391442596912, 0.02366122044622898, 0.011853075586259365, 0.012025488540530205, 0.04214221611618996, 0.02230694517493248, 0.021556420251727104, 0.0899609923362732, 0.17971129715442657, 0.012458669021725655, 0.023127373307943344, 0.10782186686992645, 0.029210807755589485, 0.007907336577773094, 0.05445580929517746, 0.05315811187028885, 0.10850000381469727, 0.3147473633289337, 0.20464059710502625, 0.16375301778316498, 0.004879164509475231, 0.030155031010508537, 0.0069882492534816265, 0.04312809184193611, 0.06745278090238571, 0.004297332838177681, 0.005668249912559986, 0.0050382548943161964, 0.0084039606153965, 0.009848293848335743, 0.008200461976230145, 0.008153348229825497, 0.005005987826734781, 0.004004492424428463, 0.00801862496882677, 0.0054907770827412605, 0.0045370422303676605, 0.005513675510883331, 0.0057772682048380375, 0.007386801764369011, 0.00739885913208127, 0.01242376770824194, 0.006875877268612385, 0.00700622983276844, 0.0074729910120368, 0.008202343247830868, 0.0049164509400725365, 0.004568483214825392, 0.007144967094063759, 0.004459340590983629, 0.005141503643244505, 0.0050145843997597694, 0.005399858113378286, 0.004814354237169027, 0.0053847311064600945, 0.006516563706099987, 0.0036374880000948906, 0.004167831037193537, 0.005264966282993555, 0.00631792563945055, -1]}
{"idB": "1316175_12_item1a_p3_s2", "idA": "1316175_11_item1a_p3_s2", "sentA": "We expect our development expenses, as well as our clinical product manufacturing expenses, to increase in connection with our pivotal Phase 3 clinical study named VISTA-16 for varespladib, our Phase 2b clinical study named PEARL-SC for A-623 and other clinical studies related to the development of A-623.", "sentB": "We expect our development expenses, as well as our clinical product manufacturing expenses, to increase in connection with our Phase 2b clinical study named PEARL-SC for blisibimod and other clinical studies related to the development of blisibimod.", "type": 2, "words": ["<tag1>", "We", "expect", "our", "development", "expenses,", "as", "well", "as", "our", "clinical", "product", "manufacturing", "expenses,", "to", "increase", "in", "connection", "with", "our", "pivotal", "Phase", "3", "clinical", "study", "named", "VISTA-16", "for", "varespladib,", "our", "Phase", "2b", "clinical", "study", "named", "PEARL-SC", "for", "A-623", "and", "other", "clinical", "studies", "related", "to", "the", "development", "of", "A-623.", "<tag2>", "We", "expect", "our", "development", "expenses,", "as", "well", "as", "our", "clinical", "product", "manufacturing", "expenses,", "to", "increase", "in", "connection", "with", "our", "Phase", "2b", "clinical", "study", "named", "PEARL-SC", "for", "blisibimod", "and", "other", "clinical", "studies", "related", "to", "the", "development", "of", "blisibimod.", "<tag3>"], "wordsA": ["We", "expect", "our", "development", "expenses,", "as", "well", "as", "our", "clinical", "product", "manufacturing", "expenses,", "to", "increase", "in", "connection", "with", "our", "pivotal", "Phase", "3", "clinical", "study", "named", "VISTA-16", "for", "varespladib,", "our", "Phase", "2b", "clinical", "study", "named", "PEARL-SC", "for", "A-623", "and", "other", "clinical", "studies", "related", "to", "the", "development", "of", "A-623."], "wordsB": ["We", "expect", "our", "development", "expenses,", "as", "well", "as", "our", "clinical", "product", "manufacturing", "expenses,", "to", "increase", "in", "connection", "with", "our", "Phase", "2b", "clinical", "study", "named", "PEARL-SC", "for", "blisibimod", "and", "other", "clinical", "studies", "related", "to", "the", "development", "of", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.006778538227081299, 0.014925476163625717, 0.006476161070168018, 0.01160245668143034, 0.018119394779205322, 0.005868498235940933, 0.0038561474066227674, 0.004581434186547995, 0.0032963913399726152, 0.0062135495245456696, 0.007275240961462259, 0.008287074975669384, 0.012674660421907902, 0.004029313568025827, 0.0052675167098641396, 0.0044223591685295105, 0.004580203909426928, 0.004033289849758148, 0.003194567281752825, 0.0060932086780667305, 0.01555190235376358, 0.007591194938868284, 0.0077484543435275555, 0.004689160734415054, 0.012351540848612785, 0.02589547634124756, 0.9787846207618713, 0.0034178476780653, 0.002856068080291152, 0.006134517956525087, 0.007015112321823835, 0.003450242569670081, 0.003299160860478878, 0.0037394589744508266, 0.008003312163054943, 0.009363340213894844, 0.2577711343765259, -1]}
{"idB": "1316175_12_item1a_p37_s0", "idA": "1316175_11_item1a_p40_s0", "sentA": "Because the results of preclinical testing or earlier clinical studies are not necessarily predictive of future results, varespladib, A-623, A-001 or any other product candidate we advance into clinical studies may not have favorable results in later clinical studies or receive regulatory approval.", "sentB": "Because the results of preclinical testing or earlier clinical studies are not necessarily predictive of future results, varespladib, blisibimod, varespladib sodium or any other product candidate we advance into clinical studies may not have favorable results in later clinical studies or receive regulatory approval.", "type": 2, "words": ["<tag1>", "Because", "the", "results", "of", "preclinical", "testing", "or", "earlier", "clinical", "studies", "are", "not", "necessarily", "predictive", "of", "future", "results,", "varespladib,", "A-623,", "A-001", "or", "any", "other", "product", "candidate", "we", "advance", "into", "clinical", "studies", "may", "not", "have", "favorable", "results", "in", "later", "clinical", "studies", "or", "receive", "regulatory", "approval.", "<tag2>", "Because", "the", "results", "of", "preclinical", "testing", "or", "earlier", "clinical", "studies", "are", "not", "necessarily", "predictive", "of", "future", "results,", "varespladib,", "blisibimod,", "varespladib", "sodium", "or", "any", "other", "product", "candidate", "we", "advance", "into", "clinical", "studies", "may", "not", "have", "favorable", "results", "in", "later", "clinical", "studies", "or", "receive", "regulatory", "approval.", "<tag3>"], "wordsA": ["Because", "the", "results", "of", "preclinical", "testing", "or", "earlier", "clinical", "studies", "are", "not", "necessarily", "predictive", "of", "future", "results,", "varespladib,", "A-623,", "A-001", "or", "any", "other", "product", "candidate", "we", "advance", "into", "clinical", "studies", "may", "not", "have", "favorable", "results", "in", "later", "clinical", "studies", "or", "receive", "regulatory", "approval."], "wordsB": ["Because", "the", "results", "of", "preclinical", "testing", "or", "earlier", "clinical", "studies", "are", "not", "necessarily", "predictive", "of", "future", "results,", "varespladib,", "blisibimod,", "varespladib", "sodium", "or", "any", "other", "product", "candidate", "we", "advance", "into", "clinical", "studies", "may", "not", "have", "favorable", "results", "in", "later", "clinical", "studies", "or", "receive", "regulatory", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.005372142419219017, 0.0026751321274787188, 0.010611646808683872, 0.0022204406559467316, 0.006696674507111311, 0.00516206119209528, 0.0022150310687720776, 0.0031560533680021763, 0.003742957254871726, 0.003292564768344164, 0.006247188430279493, 0.06268071383237839, 0.018368320539593697, 0.016212185844779015, 0.0033641383051872253, 0.008134882897138596, 0.006503379438072443, 0.014634360559284687, 0.5066351890563965, 0.07001174986362457, 0.5369675755500793, 0.002972750458866358, 0.0030898211989551783, 0.0036787569988518953, 0.005242946092039347, 0.005453237798064947, 0.0024210026022046804, 0.003318258561193943, 0.00257020047865808, 0.0040464322082698345, 0.0035765620414167643, 0.002576270839199424, 0.008796191774308681, 0.0032928683795034885, 0.006132675334811211, 0.004272640682756901, 0.0017908349400386214, 0.003993750084191561, 0.004052840173244476, 0.004262606613337994, 0.002123982645571232, 0.003153891069814563, 0.005384794902056456, 0.006201489362865686, -1]}
{"idB": "1316175_12_item1a_p39_s1", "idA": "1316175_11_item1a_p42_s1", "sentA": "Despite the results reported in earlier clinical studies for our product candidates, including varespladib, A-623 and A-001, we do not know whether any Phase 3 or other clinical studies we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any of our product candidates.", "sentB": "Despite the results reported in earlier clinical studies for our product candidates, including varespladib, blisibimod and varespladib sodium, we do not know whether any Phase 3 or other clinical studies we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any of our product candidates.", "type": 2, "words": ["<tag1>", "Despite", "the", "results", "reported", "in", "earlier", "clinical", "studies", "for", "our", "product", "candidates,", "including", "varespladib,", "A-623", "and", "A-001,", "we", "do", "not", "know", "whether", "any", "Phase", "3", "or", "other", "clinical", "studies", "we", "may", "conduct", "will", "demonstrate", "adequate", "efficacy", "and", "safety", "to", "result", "in", "regulatory", "approval", "to", "market", "any", "of", "our", "product", "candidates.", "<tag2>", "Despite", "the", "results", "reported", "in", "earlier", "clinical", "studies", "for", "our", "product", "candidates,", "including", "varespladib,", "blisibimod", "and", "varespladib", "sodium,", "we", "do", "not", "know", "whether", "any", "Phase", "3", "or", "other", "clinical", "studies", "we", "may", "conduct", "will", "demonstrate", "adequate", "efficacy", "and", "safety", "to", "result", "in", "regulatory", "approval", "to", "market", "any", "of", "our", "product", "candidates.", "<tag3>"], "wordsA": ["Despite", "the", "results", "reported", "in", "earlier", "clinical", "studies", "for", "our", "product", "candidates,", "including", "varespladib,", "A-623", "and", "A-001,", "we", "do", "not", "know", "whether", "any", "Phase", "3", "or", "other", "clinical", "studies", "we", "may", "conduct", "will", "demonstrate", "adequate", "efficacy", "and", "safety", "to", "result", "in", "regulatory", "approval", "to", "market", "any", "of", "our", "product", "candidates."], "wordsB": ["Despite", "the", "results", "reported", "in", "earlier", "clinical", "studies", "for", "our", "product", "candidates,", "including", "varespladib,", "blisibimod", "and", "varespladib", "sodium,", "we", "do", "not", "know", "whether", "any", "Phase", "3", "or", "other", "clinical", "studies", "we", "may", "conduct", "will", "demonstrate", "adequate", "efficacy", "and", "safety", "to", "result", "in", "regulatory", "approval", "to", "market", "any", "of", "our", "product", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.006706698797643185, 0.0037338323891162872, 0.0072633069939911366, 0.004668336361646652, 0.0033536539413034916, 0.0040330165065824986, 0.004056780133396387, 0.004590498749166727, 0.0030399144161492586, 0.0028463059570640326, 0.0052014244720339775, 0.005598848685622215, 0.00523972837254405, 0.011263401247560978, 0.7746383547782898, 0.018281737342476845, 0.13159823417663574, 0.7995980381965637, 0.007456894498318434, 0.07687392085790634, 0.0803208276629448, 0.03707941994071007, 0.010200818069279194, 0.004375509452074766, 0.005069843027740717, 0.0039851781912148, 0.003442830638960004, 0.003216926008462906, 0.003807441331446171, 0.004020648077130318, 0.0029255577828735113, 0.0035351673141121864, 0.003433922538533807, 0.004180897492915392, 0.004136925563216209, 0.005810785572975874, 0.004607995040714741, 0.0042474339716136456, 0.0041884444653987885, 0.003590537467971444, 0.00311084627173841, 0.0035905102267861366, 0.0045477221719920635, 0.004440547898411751, 0.0035079545341432095, 0.006196347996592522, 0.011750811710953712, 0.004195901565253735, 0.003995055332779884, 0.008038322441279888, 0.011440551839768887, -1]}
{"idB": "1316175_12_item1a_p108_s4", "idA": "1316175_11_item1a_p43_s0", "sentA": "If we breach the license agreements for our primary product candidates, we could lose the ability to continue the development and commercialization of our primary product candidates.", "sentB": "If third party patents are determined to be valid and construed to cover blisibimod, the development and commercialization of this program could be affected, subjecting us to potential liability for damages and in addition may require us to obtain a license to continue marketing the affected product.", "type": 2, "words": ["<tag1>", "If", "we", "breach", "the", "license", "agreements", "for", "our", "primary", "product", "candidates,", "we", "could", "lose", "the", "ability", "to", "continue", "the", "development", "and", "commercialization", "of", "our", "primary", "product", "candidates.", "<tag2>", "If", "third", "party", "patents", "are", "determined", "to", "be", "valid", "and", "construed", "to", "cover", "blisibimod,", "the", "development", "and", "commercialization", "of", "this", "program", "could", "be", "affected,", "subjecting", "us", "to", "potential", "liability", "for", "damages", "and", "in", "addition", "may", "require", "us", "to", "obtain", "a", "license", "to", "continue", "marketing", "the", "affected", "product.", "<tag3>"], "wordsA": ["If", "we", "breach", "the", "license", "agreements", "for", "our", "primary", "product", "candidates,", "we", "could", "lose", "the", "ability", "to", "continue", "the", "development", "and", "commercialization", "of", "our", "primary", "product", "candidates."], "wordsB": ["If", "third", "party", "patents", "are", "determined", "to", "be", "valid", "and", "construed", "to", "cover", "blisibimod,", "the", "development", "and", "commercialization", "of", "this", "program", "could", "be", "affected,", "subjecting", "us", "to", "potential", "liability", "for", "damages", "and", "in", "addition", "may", "require", "us", "to", "obtain", "a", "license", "to", "continue", "marketing", "the", "affected", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.019467761740088463, 0.33848297595977783, 0.45560193061828613, 0.5671653747558594, 0.05399927496910095, 0.07186003029346466, 0.08671620488166809, 0.06720826774835587, 0.20349228382110596, 0.008330348879098892, 0.05693734809756279, 0.010861273854970932, 0.0455377958714962, 0.033425599336624146, 0.0060152397491037846, 0.029685471206903458, 0.003439549822360277, 0.01945892907679081, 0.005745254922658205, 0.008862430229783058, 0.04002309963107109, 0.01931707188487053, 0.03774675726890564, 0.15171916782855988, 0.02163918875157833, 0.017694387584924698, 0.019335191696882248, 0.023453660309314728, 0.041370801627635956, 0.031362954527139664, 0.03505566716194153, 0.00010790253145387396, 0.008512478321790695, 0.0001423582580173388, 0.005978539120405912, 0.04573496803641319, 0.020032158121466637, 0.07099272310733795, 0.15989406406879425, 0.0985536128282547, 0.13731612265110016, 0.012582407332956791, 0.02381168305873871, 0.0872974693775177, 0.020600657910108566, 0.17702984809875488, 0.1626635044813156, -1]}
{"idB": "1316175_12_item1a_p41_s0", "idA": "1316175_11_item1a_p44_s0", "sentA": "We are party to an agreement with Eli Lilly and Shionogi Co., Ltd. containing exclusive, worldwide licenses, except for Japan, of the composition of matter, methods of making and methods of use for certain sPLA 2 inhibitors.", "sentB": "We are party to an agreement with Eli Lilly and Shionogi Co., Ltd. containing exclusive, worldwide licenses, except for Japan, of the composition of matter, methods of making and methods of use for certain sPLA2 inhibitors.", "type": 2, "words": ["<tag1>", "We", "are", "party", "to", "an", "agreement", "with", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "containing", "exclusive,", "worldwide", "licenses,", "except", "for", "Japan,", "of", "the", "composition", "of", "matter,", "methods", "of", "making", "and", "methods", "of", "use", "for", "certain", "sPLA", "2", "inhibitors.", "<tag2>", "We", "are", "party", "to", "an", "agreement", "with", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "containing", "exclusive,", "worldwide", "licenses,", "except", "for", "Japan,", "of", "the", "composition", "of", "matter,", "methods", "of", "making", "and", "methods", "of", "use", "for", "certain", "sPLA2", "inhibitors.", "<tag3>"], "wordsA": ["We", "are", "party", "to", "an", "agreement", "with", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "containing", "exclusive,", "worldwide", "licenses,", "except", "for", "Japan,", "of", "the", "composition", "of", "matter,", "methods", "of", "making", "and", "methods", "of", "use", "for", "certain", "sPLA", "2", "inhibitors."], "wordsB": ["We", "are", "party", "to", "an", "agreement", "with", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "containing", "exclusive,", "worldwide", "licenses,", "except", "for", "Japan,", "of", "the", "composition", "of", "matter,", "methods", "of", "making", "and", "methods", "of", "use", "for", "certain", "sPLA2", "inhibitors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.004701247438788414, 0.004195124376565218, 0.012661116197705269, 0.007115450222045183, 0.006652005482465029, 0.01086820662021637, 0.0068216281943023205, 0.008870374411344528, 0.00985575933009386, 0.006722861435264349, 0.011333944275975227, 0.006484889425337315, 0.0071114893071353436, 0.006877446081489325, 0.03486268222332001, 0.011099008843302727, 0.010476612485945225, 0.008682016283273697, 0.0062330132350325584, 0.005802873056381941, 0.005011696368455887, 0.004540303722023964, 0.006876909174025059, 0.00713583966717124, 0.006551748141646385, 0.005545907653868198, 0.006404691841453314, 0.006176509894430637, 0.005667550954967737, 0.005674587097018957, 0.006418805569410324, 0.005281690042465925, 0.0038465466350317, 0.004694562871009111, 0.9665187001228333, 0.2846390902996063, -1]}
{"idB": "1316175_12_item1a_p41_s1", "idA": "1316175_11_item1a_p44_s1", "sentA": "We are also party to an agreement with Amgen containing exclusive, worldwide licenses of the composition of matter and methods of use for A-623.", "sentB": "We are also party to an agreement with Amgen containing exclusive, worldwide licenses of the composition of matter and methods of use for blisibimod.", "type": 2, "words": ["<tag1>", "We", "are", "also", "party", "to", "an", "agreement", "with", "Amgen", "containing", "exclusive,", "worldwide", "licenses", "of", "the", "composition", "of", "matter", "and", "methods", "of", "use", "for", "A-623.", "<tag2>", "We", "are", "also", "party", "to", "an", "agreement", "with", "Amgen", "containing", "exclusive,", "worldwide", "licenses", "of", "the", "composition", "of", "matter", "and", "methods", "of", "use", "for", "blisibimod.", "<tag3>"], "wordsA": ["We", "are", "also", "party", "to", "an", "agreement", "with", "Amgen", "containing", "exclusive,", "worldwide", "licenses", "of", "the", "composition", "of", "matter", "and", "methods", "of", "use", "for", "A-623."], "wordsB": ["We", "are", "also", "party", "to", "an", "agreement", "with", "Amgen", "containing", "exclusive,", "worldwide", "licenses", "of", "the", "composition", "of", "matter", "and", "methods", "of", "use", "for", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.003933761268854141, 0.0022366491612046957, 0.0024992467369884253, 0.007124747149646282, 0.002142855664715171, 0.002061843406409025, 0.005567123647779226, 0.002499101683497429, 0.004385487642139196, 0.003982506226748228, 0.00512647582218051, 0.0029781798366457224, 0.003978927619755268, 0.0018910113722085953, 0.0018274723552167416, 0.0027205143123865128, 0.0022063767537474632, 0.003718990134075284, 0.0025164068210870028, 0.0034545050002634525, 0.0032741366885602474, 0.023511357605457306, 0.045925531536340714, 0.961042582988739, -1]}
{"idB": "1316175_12_item1a_p42_s1", "idA": "1316175_11_item1a_p45_s1", "sentA": "Our licensors could effectively take control of the development and commercialization of varespladib, A-623 and A-001 after an uncured, material breach of our license agreements by us or if we voluntarily terminate the agreements.", "sentB": "Our licensors could effectively take control of the development and commercialization of varespladib, blisibimod and varespladib sodium after an uncured, material breach of our license agreements by us or if we voluntarily terminate the agreements.", "type": 2, "words": ["<tag1>", "Our", "licensors", "could", "effectively", "take", "control", "of", "the", "development", "and", "commercialization", "of", "varespladib,", "A-623", "and", "A-001", "after", "an", "uncured,", "material", "breach", "of", "our", "license", "agreements", "by", "us", "or", "if", "we", "voluntarily", "terminate", "the", "agreements.", "<tag2>", "Our", "licensors", "could", "effectively", "take", "control", "of", "the", "development", "and", "commercialization", "of", "varespladib,", "blisibimod", "and", "varespladib", "sodium", "after", "an", "uncured,", "material", "breach", "of", "our", "license", "agreements", "by", "us", "or", "if", "we", "voluntarily", "terminate", "the", "agreements.", "<tag3>"], "wordsA": ["Our", "licensors", "could", "effectively", "take", "control", "of", "the", "development", "and", "commercialization", "of", "varespladib,", "A-623", "and", "A-001", "after", "an", "uncured,", "material", "breach", "of", "our", "license", "agreements", "by", "us", "or", "if", "we", "voluntarily", "terminate", "the", "agreements."], "wordsB": ["Our", "licensors", "could", "effectively", "take", "control", "of", "the", "development", "and", "commercialization", "of", "varespladib,", "blisibimod", "and", "varespladib", "sodium", "after", "an", "uncured,", "material", "breach", "of", "our", "license", "agreements", "by", "us", "or", "if", "we", "voluntarily", "terminate", "the", "agreements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.002825975650921464, 0.008224895223975182, 0.003523339983075857, 0.004671718925237656, 0.0040089222602546215, 0.004024310503154993, 0.0030802376568317413, 0.0031617560889571905, 0.0031714073847979307, 0.0035400167107582092, 0.004080356098711491, 0.0053723822347819805, 0.012660358101129532, 0.785318911075592, 0.01679033786058426, 0.09105423837900162, 0.6659183502197266, 0.003203757805749774, 0.003204858861863613, 0.004703001584857702, 0.0035410630516707897, 0.004069575108587742, 0.002421622397378087, 0.002613948890939355, 0.005471799056977034, 0.006450046319514513, 0.003242703853175044, 0.0066548800095915794, 0.0033482585567981005, 0.005095146130770445, 0.005621497053653002, 0.015302819199860096, 0.060470324009656906, 0.006841026712208986, 0.03439875319600105, -1]}
{"idB": "1316175_12_item1a_p42_s3", "idA": "1316175_11_item1a_p45_s3", "sentA": "Any uncured, material breach under the licenses could result in our loss of exclusive rights and may lead to a complete termination of our product development and any commercialization efforts for varespladib, A-623 or A-001.", "sentB": "Any uncured, material breach under the licenses could result in our loss of exclusive rights and may lead to a complete termination of our product development and any commercialization efforts for varespladib, blisibimod or varespladib sodium.", "type": 2, "words": ["<tag1>", "Any", "uncured,", "material", "breach", "under", "the", "licenses", "could", "result", "in", "our", "loss", "of", "exclusive", "rights", "and", "may", "lead", "to", "a", "complete", "termination", "of", "our", "product", "development", "and", "any", "commercialization", "efforts", "for", "varespladib,", "A-623", "or", "A-001.", "<tag2>", "Any", "uncured,", "material", "breach", "under", "the", "licenses", "could", "result", "in", "our", "loss", "of", "exclusive", "rights", "and", "may", "lead", "to", "a", "complete", "termination", "of", "our", "product", "development", "and", "any", "commercialization", "efforts", "for", "varespladib,", "blisibimod", "or", "varespladib", "sodium.", "<tag3>"], "wordsA": ["Any", "uncured,", "material", "breach", "under", "the", "licenses", "could", "result", "in", "our", "loss", "of", "exclusive", "rights", "and", "may", "lead", "to", "a", "complete", "termination", "of", "our", "product", "development", "and", "any", "commercialization", "efforts", "for", "varespladib,", "A-623", "or", "A-001."], "wordsB": ["Any", "uncured,", "material", "breach", "under", "the", "licenses", "could", "result", "in", "our", "loss", "of", "exclusive", "rights", "and", "may", "lead", "to", "a", "complete", "termination", "of", "our", "product", "development", "and", "any", "commercialization", "efforts", "for", "varespladib,", "blisibimod", "or", "varespladib", "sodium."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0028581779915839434, 0.007916637696325779, 0.0035494451876729727, 0.004654854070395231, 0.002840789733454585, 0.0023757177405059338, 0.0034194360487163067, 0.002903733402490616, 0.0025884988717734814, 0.0025390537921339273, 0.0027876358944922686, 0.004610149655491114, 0.003033693414181471, 0.007049791980534792, 0.006190208252519369, 0.0002944011357612908, 0.0027133203111588955, 0.002652211580425501, 0.002754001645371318, 0.00267529534175992, 0.005794137250632048, 0.004750828258693218, 0.002178023336455226, 0.0024887174367904663, 0.003991842269897461, 0.004454159177839756, 0.0019267364405095577, 0.0020110674668103456, 0.004504615440964699, 0.006506433244794607, 0.013821150176227093, 0.01679256558418274, 0.8793378472328186, 0.052109334617853165, 0.11660277843475342, 0.9421907663345337, -1]}
{"idB": "1316175_12_item1a_p45_s2", "idA": "1316175_11_item1a_p50_s0", "sentA": "Although there are no sPLA 2 inhibitor compounds currently approved by the FDA for the treatment of acute chest syndrome associated with sickle cell disease, Droxia, or hydroxyurea, is approved for the prevention of vaso-occlusive crisis, or VOC, in sickle cell disease and thus could reduce the pool of patients with VOC at risk for acute chest syndrome.", "sentB": "For lupus, Human Genome Sciences, Inc.'s and GlaxoSmithKline plc's BAFF antagonist monoclonal antibody, Benlysta, was recently approved by the FDA for treatment of lupus.", "type": 2, "words": ["<tag1>", "Although", "there", "are", "no", "sPLA", "2", "inhibitor", "compounds", "currently", "approved", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease,", "Droxia,", "or", "hydroxyurea,", "is", "approved", "for", "the", "prevention", "of", "vaso-occlusive", "crisis,", "or", "VOC,", "in", "sickle", "cell", "disease", "and", "thus", "could", "reduce", "the", "pool", "of", "patients", "with", "VOC", "at", "risk", "for", "acute", "chest", "syndrome.", "<tag2>", "For", "lupus,", "Human", "Genome", "Sciences,", "Inc.'s", "and", "GlaxoSmithKline", "plc's", "BAFF", "antagonist", "monoclonal", "antibody,", "Benlysta,", "was", "recently", "approved", "by", "the", "FDA", "for", "treatment", "of", "lupus.", "<tag3>"], "wordsA": ["Although", "there", "are", "no", "sPLA", "2", "inhibitor", "compounds", "currently", "approved", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease,", "Droxia,", "or", "hydroxyurea,", "is", "approved", "for", "the", "prevention", "of", "vaso-occlusive", "crisis,", "or", "VOC,", "in", "sickle", "cell", "disease", "and", "thus", "could", "reduce", "the", "pool", "of", "patients", "with", "VOC", "at", "risk", "for", "acute", "chest", "syndrome."], "wordsB": ["For", "lupus,", "Human", "Genome", "Sciences,", "Inc.'s", "and", "GlaxoSmithKline", "plc's", "BAFF", "antagonist", "monoclonal", "antibody,", "Benlysta,", "was", "recently", "approved", "by", "the", "FDA", "for", "treatment", "of", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.07117298990488052, 0.11225568503141403, 0.22478418052196503, 0.23250271379947662, 0.12767358124256134, 0.14301905035972595, 0.042056161910295486, 0.2883140742778778, 0.14493700861930847, 0.33437615633010864, 0.31397268176078796, 0.19363278150558472, 0.35201963782310486, 0.13850902020931244, 0.0050728218629956245, 0.016183219850063324, 0.03694064915180206, 0.0033555643167346716, 0.003392503596842289, 0.015605218708515167, 0.005877311807125807, 0.04777513071894646, 0.026037579402327538, 0.12165674567222595, -1]}
{"idB": "1316175_12_item1a_p45_s3", "idA": "1316175_11_item1a_p50_s1", "sentA": "Further, we are aware of companies with other products in development that are being tested for potential treatment of lupus, including Human Genome Sciences, Inc. and GlaxoSmithKline plc, who have a BAFF antagonist monoclonal antibody product candidate, Benlysta, which recently reported favorable results from two Phase 3 clinical studies in lupus; ZymoGenetics, Inc. and Merck Serono S.A., whose dual BAFF/APRIL antagonist fusion protein, Atacicept, is in a Phase 3 clinical study for lupus; and Immunomedics, Inc. and UCB S.A., who recently reported favorable results for their CD-22 antagonist humanized antibody, epratuzumab, which completed a Phase 2b clinical study in lupus and has begun a Phase 3 study.", "sentB": "Further, we are aware of companies with other products in development that are being tested for potential treatment of lupus, Bristol-Myers Squibb Company and Merck Serono S.A., whose dual BAFF/APRIL antagonist fusion protein, Atacicept, is in a Phase 3 clinical study for lupus; and Immunomedics, Inc. and UCB S.A., who recently reported favorable results for their CD-22 antagonist humanized antibody, epratuzumab, which completed a Phase 2b clinical study in lupus and has begun a Phase 3 study, and Eli Lilly's anti-BLYS monoclonal antibody, LY2127399, which has begun two Phase 3 studies.", "type": 2, "words": ["<tag1>", "Further,", "we", "are", "aware", "of", "companies", "with", "other", "products", "in", "development", "that", "are", "being", "tested", "for", "potential", "treatment", "of", "lupus,", "including", "Human", "Genome", "Sciences,", "Inc.", "and", "GlaxoSmithKline", "plc,", "who", "have", "a", "BAFF", "antagonist", "monoclonal", "antibody", "product", "candidate,", "Benlysta,", "which", "recently", "reported", "favorable", "results", "from", "two", "Phase", "3", "clinical", "studies", "in", "lupus;", "ZymoGenetics,", "Inc.", "and", "Merck", "Serono", "S.A.,", "whose", "dual", "BAFF/APRIL", "antagonist", "fusion", "protein,", "Atacicept,", "is", "in", "a", "Phase", "3", "clinical", "study", "for", "lupus;", "and", "Immunomedics,", "Inc.", "and", "UCB", "S.A.,", "who", "recently", "reported", "favorable", "results", "for", "their", "CD-22", "antagonist", "humanized", "antibody,", "epratuzumab,", "which", "completed", "a", "Phase", "2b", "clinical", "study", "in", "lupus", "and", "has", "begun", "a", "Phase", "3", "study.", "<tag2>", "Further,", "we", "are", "aware", "of", "companies", "with", "other", "products", "in", "development", "that", "are", "being", "tested", "for", "potential", "treatment", "of", "lupus,", "Bristol-Myers", "Squibb", "Company", "and", "Merck", "Serono", "S.A.,", "whose", "dual", "BAFF/APRIL", "antagonist", "fusion", "protein,", "Atacicept,", "is", "in", "a", "Phase", "3", "clinical", "study", "for", "lupus;", "and", "Immunomedics,", "Inc.", "and", "UCB", "S.A.,", "who", "recently", "reported", "favorable", "results", "for", "their", "CD-22", "antagonist", "humanized", "antibody,", "epratuzumab,", "which", "completed", "a", "Phase", "2b", "clinical", "study", "in", "lupus", "and", "has", "begun", "a", "Phase", "3", "study,", "and", "Eli", "Lilly's", "anti-BLYS", "monoclonal", "antibody,", "LY2127399,", "which", "has", "begun", "two", "Phase", "3", "studies.", "<tag3>"], "wordsA": ["Further,", "we", "are", "aware", "of", "companies", "with", "other", "products", "in", "development", "that", "are", "being", "tested", "for", "potential", "treatment", "of", "lupus,", "including", "Human", "Genome", "Sciences,", "Inc.", "and", "GlaxoSmithKline", "plc,", "who", "have", "a", "BAFF", "antagonist", "monoclonal", "antibody", "product", "candidate,", "Benlysta,", "which", "recently", "reported", "favorable", "results", "from", "two", "Phase", "3", "clinical", "studies", "in", "lupus;", "ZymoGenetics,", "Inc.", "and", "Merck", "Serono", "S.A.,", "whose", "dual", "BAFF/APRIL", "antagonist", "fusion", "protein,", "Atacicept,", "is", "in", "a", "Phase", "3", "clinical", "study", "for", "lupus;", "and", "Immunomedics,", "Inc.", "and", "UCB", "S.A.,", "who", "recently", "reported", "favorable", "results", "for", "their", "CD-22", "antagonist", "humanized", "antibody,", "epratuzumab,", "which", "completed", "a", "Phase", "2b", "clinical", "study", "in", "lupus", "and", "has", "begun", "a", "Phase", "3", "study."], "wordsB": ["Further,", "we", "are", "aware", "of", "companies", "with", "other", "products", "in", "development", "that", "are", "being", "tested", "for", "potential", "treatment", "of", "lupus,", "Bristol-Myers", "Squibb", "Company", "and", "Merck", "Serono", "S.A.,", "whose", "dual", "BAFF/APRIL", "antagonist", "fusion", "protein,", "Atacicept,", "is", "in", "a", "Phase", "3", "clinical", "study", "for", "lupus;", "and", "Immunomedics,", "Inc.", "and", "UCB", "S.A.,", "who", "recently", "reported", "favorable", "results", "for", "their", "CD-22", "antagonist", "humanized", "antibody,", "epratuzumab,", "which", "completed", "a", "Phase", "2b", "clinical", "study", "in", "lupus", "and", "has", "begun", "a", "Phase", "3", "study,", "and", "Eli", "Lilly's", "anti-BLYS", "monoclonal", "antibody,", "LY2127399,", "which", "has", "begun", "two", "Phase", "3", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0069499691016972065, 0.007314059417694807, 0.006719703786075115, 0.008243181742727757, 0.005835284013301134, 0.007490680553019047, 0.008688462898135185, 0.006885488983243704, 0.008357509039342403, 0.007190798409283161, 0.007578730117529631, 0.007136546075344086, 0.004989506211131811, 0.005515129305422306, 0.005953134037554264, 0.004654307849705219, 0.005269663408398628, 0.00587015924975276, 0.004834424704313278, 0.01112802978605032, 0.8303825259208679, 0.9175556898117065, 0.34285348653793335, 0.007086590863764286, 0.007610816042870283, 0.011338776908814907, 0.008624414913356304, 0.007811020594090223, 0.007919948548078537, 0.009967813268303871, 0.008995162323117256, 0.008731023408472538, 0.007057747337967157, 0.008770432323217392, 0.004995363764464855, 0.005885879509150982, 0.005917645990848541, 0.006759092677384615, 0.006146700121462345, 0.005633541848510504, 0.005592973902821541, 0.0038500709924846888, 0.009437769651412964, 0.004462393932044506, 0.00887791533023119, 0.006545872427523136, 0.005387947428971529, 0.0074889762327075005, 0.007148269098252058, 0.007212710566818714, 0.00665530189871788, 0.005495439283549786, 0.00670201238244772, 0.00556127168238163, 0.004980308003723621, 0.005151483695954084, 0.009570530615746975, 0.009165225550532341, 0.0069166817702353, 0.008622433990240097, 0.011554913595318794, 0.007141327951103449, 0.004658891819417477, 0.0053183771669864655, 0.005903670564293861, 0.0073375278152525425, 0.005101507063955069, 0.005455257836729288, 0.003959218971431255, 0.00675269914790988, 0.007570137735456228, 0.005125741939991713, 0.004836606793105602, 0.004350921139121056, 0.006194228772073984, 0.006418644916266203, 0.008312860503792763, 0.003944705706089735, 0.12893423438072205, 0.4318554997444153, 0.23153004050254822, 0.01955808326601982, 0.05667729675769806, 0.6409848928451538, 0.011282583698630333, 0.005025449674576521, 0.005181845743209124, 0.004258305765688419, 0.006536693777889013, 0.006886597257107496, 0.012686421163380146, -1]}
{"idB": "1316175_12_item1a_p45_s1", "idA": "1316175_11_item1a_p51_s3", "sentA": "We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available.", "sentB": "All of the sPLA2 inhibitor compounds we are currently developing, if approved, will face intense competition, either as monotherapies or in combination therapies.", "type": 2, "words": ["<tag1>", "We", "anticipate", "that", "we", "will", "face", "intense", "and", "increasing", "competition", "as", "new", "drugs", "enter", "the", "market", "and", "advanced", "technologies", "become", "available.", "<tag2>", "All", "of", "the", "sPLA2", "inhibitor", "compounds", "we", "are", "currently", "developing,", "if", "approved,", "will", "face", "intense", "competition,", "either", "as", "monotherapies", "or", "in", "combination", "therapies.", "<tag3>"], "wordsA": ["We", "anticipate", "that", "we", "will", "face", "intense", "and", "increasing", "competition", "as", "new", "drugs", "enter", "the", "market", "and", "advanced", "technologies", "become", "available."], "wordsB": ["All", "of", "the", "sPLA2", "inhibitor", "compounds", "we", "are", "currently", "developing,", "if", "approved,", "will", "face", "intense", "competition,", "either", "as", "monotherapies", "or", "in", "combination", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.09897393733263016, 0.030141867697238922, 0.01794503815472126, 0.35481253266334534, 0.362695574760437, 0.22850601375102997, 0.005051509942859411, 0.005257315002381802, 0.006029131822288036, 0.022261153906583786, 0.05018719658255577, 0.02317505143582821, 0.005899021867662668, 0.018700003623962402, 0.03469252213835716, 0.034137576818466187, 0.014265282079577446, 0.05682412162423134, 0.5777369737625122, 0.06809822469949722, 0.04357938840985298, 0.2722291350364685, 0.3351694941520691, -1]}
{"idB": "1316175_12_item1a_p57_s0", "idA": "1316175_11_item1a_p62_s0", "sentA": "seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.", "sentB": "issue warning letters or untitled letters; seek an injunction or impose civil or criminal penalties or monetary fines; suspend or withdraw regulatory approval; suspend any ongoing clinical studies; refuse to approve pending applications or supplements to applications filed by us; suspend or impose restrictions on operations, including costly new manufacturing requirements; or seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.", "type": 2, "words": ["<tag1>", "seize", "or", "detain", "products,", "refuse", "to", "permit", "the", "import", "or", "export", "of", "products,", "or", "require", "us", "to", "initiate", "a", "product", "recall.", "<tag2>", "issue", "warning", "letters", "or", "untitled", "letters;", "seek", "an", "injunction", "or", "impose", "civil", "or", "criminal", "penalties", "or", "monetary", "fines;", "suspend", "or", "withdraw", "regulatory", "approval;", "suspend", "any", "ongoing", "clinical", "studies;", "refuse", "to", "approve", "pending", "applications", "or", "supplements", "to", "applications", "filed", "by", "us;", "suspend", "or", "impose", "restrictions", "on", "operations,", "including", "costly", "new", "manufacturing", "requirements;", "or", "seize", "or", "detain", "products,", "refuse", "to", "permit", "the", "import", "or", "export", "of", "products,", "or", "require", "us", "to", "initiate", "a", "product", "recall.", "<tag3>"], "wordsA": ["seize", "or", "detain", "products,", "refuse", "to", "permit", "the", "import", "or", "export", "of", "products,", "or", "require", "us", "to", "initiate", "a", "product", "recall."], "wordsB": ["issue", "warning", "letters", "or", "untitled", "letters;", "seek", "an", "injunction", "or", "impose", "civil", "or", "criminal", "penalties", "or", "monetary", "fines;", "suspend", "or", "withdraw", "regulatory", "approval;", "suspend", "any", "ongoing", "clinical", "studies;", "refuse", "to", "approve", "pending", "applications", "or", "supplements", "to", "applications", "filed", "by", "us;", "suspend", "or", "impose", "restrictions", "on", "operations,", "including", "costly", "new", "manufacturing", "requirements;", "or", "seize", "or", "detain", "products,", "refuse", "to", "permit", "the", "import", "or", "export", "of", "products,", "or", "require", "us", "to", "initiate", "a", "product", "recall."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.1608375459909439, 0.17617854475975037, 0.1756284236907959, 0.018944647163152695, 0.08083716034889221, 0.17670004069805145, 0.11668287217617035, 0.10170189291238785, 0.1012897863984108, 0.010953923687338829, 0.06664116680622101, 0.0605083666741848, 0.03377696871757507, 0.07213335484266281, 0.07507350295782089, 0.0009883943712338805, 0.03533973544836044, 0.058415737003088, 0.2673346996307373, 0.1501048505306244, 0.239337757229805, 0.07018124312162399, 0.08850312232971191, 0.21623055636882782, 0.014847438782453537, 0.030271295458078384, 0.07171674817800522, 0.08730213344097137, 0.134381964802742, 0.00048766672261990607, 0.07671473175287247, 0.03235892951488495, 0.06220487877726555, 0.013869202695786953, 0.029543567448854446, 0.011094915680587292, 0.03316107019782066, 0.007355812471359968, 0.00552790705114603, 0.01713343895971775, 0.12325822561979294, 0.015699412673711777, 0.03981660306453705, 0.046168360859155655, 0.01277153193950653, 0.0416608527302742, 0.0007272848743014038, 0.007340529467910528, 0.006072112359106541, 0.016223300248384476, 0.016180478036403656, 0.004495613742619753, 0.006613262463361025, 0.005831796210259199, 0.006128555629402399, 0.006912814453244209, 0.01624392159283161, 0.019983334466814995, 0.04133837670087814, 0.013579333201050758, 0.028266666457057, 0.007208965718746185, 0.014009355567395687, 0.006423831917345524, 0.01996491476893425, 0.0031173445750027895, 0.013444771058857441, 0.017404688522219658, 0.0068429154343903065, 0.012913481332361698, 0.005349696613848209, 0.03086073510348797, 0.024101581424474716, -1]}
{"idB": "1316175_12_item1a_p60_s0", "idA": "1316175_11_item1a_p65_s0", "sentA": "New federal legislation or regulatory requirements could affect the requirements for obtaining regulatory approvals of our product candidates or otherwise limit our ability to commercialize any approved products or subject our products to more rigorous post-approval requirements.", "sentB": "approved products or subject our products to more rigorous post-approval requirements.", "type": 2, "words": ["<tag1>", "New", "federal", "legislation", "or", "regulatory", "requirements", "could", "affect", "the", "requirements", "for", "obtaining", "regulatory", "approvals", "of", "our", "product", "candidates", "or", "otherwise", "limit", "our", "ability", "to", "commercialize", "any", "approved", "products", "or", "subject", "our", "products", "to", "more", "rigorous", "post-approval", "requirements.", "<tag2>", "approved", "products", "or", "subject", "our", "products", "to", "more", "rigorous", "post-approval", "requirements.", "<tag3>"], "wordsA": ["New", "federal", "legislation", "or", "regulatory", "requirements", "could", "affect", "the", "requirements", "for", "obtaining", "regulatory", "approvals", "of", "our", "product", "candidates", "or", "otherwise", "limit", "our", "ability", "to", "commercialize", "any", "approved", "products", "or", "subject", "our", "products", "to", "more", "rigorous", "post-approval", "requirements."], "wordsB": ["approved", "products", "or", "subject", "our", "products", "to", "more", "rigorous", "post-approval", "requirements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.8302189111709595, 0.6309574246406555, 0.020085766911506653, 0.29917141795158386, 0.08558925241231918, 0.19423915445804596, 0.02024390548467636, 0.03015439212322235, 0.04859870672225952, 0.16479268670082092, 0.09842051565647125, -1]}
{"idB": "1316175_12_item1a_p63_s0", "idA": "1316175_11_item1a_p68_s0", "sentA": "the willingness of patients to pay out-of-pocket in the absence of third-party coverage.", "sentB": "demonstration of clinical safety and efficacy compared to other products; the relative convenience, ease of administration and acceptance by physicians and payors of blisibimod in the treatment of lupus; the prevalence and severity of any adverse effects; limitations or warnings contained in a product's FDA-approved labeling; availability of alternative treatments; pricing and cost-effectiveness; the effectiveness of our or any future collaborators' sales and marketing strategies; our ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care programs, including Medicare and Medicaid; and the willingness of patients to pay out-of-pocket in the absence of third-party coverage.", "type": 2, "words": ["<tag1>", "the", "willingness", "of", "patients", "to", "pay", "out-of-pocket", "in", "the", "absence", "of", "third-party", "coverage.", "<tag2>", "demonstration", "of", "clinical", "safety", "and", "efficacy", "compared", "to", "other", "products;", "the", "relative", "convenience,", "ease", "of", "administration", "and", "acceptance", "by", "physicians", "and", "payors", "of", "blisibimod", "in", "the", "treatment", "of", "lupus;", "the", "prevalence", "and", "severity", "of", "any", "adverse", "effects;", "limitations", "or", "warnings", "contained", "in", "a", "product's", "FDA-approved", "labeling;", "availability", "of", "alternative", "treatments;", "pricing", "and", "cost-effectiveness;", "the", "effectiveness", "of", "our", "or", "any", "future", "collaborators'", "sales", "and", "marketing", "strategies;", "our", "ability", "to", "obtain", "and", "maintain", "sufficient", "third-party", "coverage", "or", "reimbursement", "from", "government", "health", "care", "programs,", "including", "Medicare", "and", "Medicaid;", "and", "the", "willingness", "of", "patients", "to", "pay", "out-of-pocket", "in", "the", "absence", "of", "third-party", "coverage.", "<tag3>"], "wordsA": ["the", "willingness", "of", "patients", "to", "pay", "out-of-pocket", "in", "the", "absence", "of", "third-party", "coverage."], "wordsB": ["demonstration", "of", "clinical", "safety", "and", "efficacy", "compared", "to", "other", "products;", "the", "relative", "convenience,", "ease", "of", "administration", "and", "acceptance", "by", "physicians", "and", "payors", "of", "blisibimod", "in", "the", "treatment", "of", "lupus;", "the", "prevalence", "and", "severity", "of", "any", "adverse", "effects;", "limitations", "or", "warnings", "contained", "in", "a", "product's", "FDA-approved", "labeling;", "availability", "of", "alternative", "treatments;", "pricing", "and", "cost-effectiveness;", "the", "effectiveness", "of", "our", "or", "any", "future", "collaborators'", "sales", "and", "marketing", "strategies;", "our", "ability", "to", "obtain", "and", "maintain", "sufficient", "third-party", "coverage", "or", "reimbursement", "from", "government", "health", "care", "programs,", "including", "Medicare", "and", "Medicaid;", "and", "the", "willingness", "of", "patients", "to", "pay", "out-of-pocket", "in", "the", "absence", "of", "third-party", "coverage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.09598921239376068, 0.07719621807336807, 0.1189471110701561, 0.17572444677352905, 0.1243729442358017, 0.1218668520450592, 0.027587981894612312, 0.019168581813573837, 0.033762771636247635, 0.04748370125889778, 0.006459339056164026, 0.03765447437763214, 0.06524571776390076, 0.06908952444791794, 0.04444289207458496, 0.06623125821352005, 0.02580321952700615, 0.05224527791142464, 0.011418495327234268, 0.047833703458309174, 0.009895484894514084, 0.04575753211975098, 0.048923809081315994, 0.09460936486721039, 0.026385463774204254, 0.013119306415319443, 0.05028316006064415, 0.036061253398656845, 0.032350506633520126, 0.006524567026644945, 0.037722088396549225, 0.02106163650751114, 0.02978650853037834, 0.011140021495521069, 0.02438519336283207, 0.02809116058051586, 0.03566765785217285, 0.12577171623706818, 0.027260489761829376, 0.06075209751725197, 0.007163965608924627, 0.006350038573145866, 0.006029386073350906, 0.03437843918800354, 0.03324631229043007, 0.035181280225515366, 0.04855797812342644, 0.024247989058494568, 0.06786217540502548, 0.10802500694990158, 0.045837026089429855, 0.049919113516807556, 0.11159517616033554, 0.011778386309742928, 0.06738115847110748, 0.012507302686572075, 0.037958160042762756, 0.02780837006866932, 0.018183860927820206, 0.037414003163576126, 0.06071710214018822, 0.10878665745258331, 0.07151073962450027, 0.10967955738306046, 0.07540208101272583, 0.025910254567861557, 0.12794137001037598, 0.09753064066171646, 0.1527208536863327, 0.10210158675909042, 0.2699744403362274, 0.19748230278491974, 0.11911708116531372, 0.32548367977142334, 0.010281044989824295, 0.1285136640071869, 0.009555239230394363, 0.08450739085674286, 0.10642864555120468, 0.09756512194871902, 0.09118903428316116, 0.008114052005112171, 0.1823093295097351, 0.1040167361497879, 0.3736944794654846, 0.004583487752825022, 0.0045334342867136, 0.022822672501206398, 0.005558508448302746, 0.03697381168603897, 0.004679476376622915, 0.022503651678562164, 0.013314977288246155, 0.004674020688980818, 0.006531586870551109, 0.06077837944030762, 0.004103571642190218, 0.01185098197311163, 0.018862802535295486, -1]}
{"idB": "1316175_12_item1a_p6_s0", "idA": "1316175_11_item1a_p6_s0", "sentA": "achieve broad market acceptance of our product candidates in the medical community and with third-party payors.", "sentB": "if regulatory approvals are obtained, begin the commercial manufacturing of our product candidates with our third-party manufacturers; launch commercial sales and effectively market our product candidates, either independently or in strategic collaborations with third parties; and achieve broad market acceptance of our product candidates in the medical community and with third-party payors.", "type": 2, "words": ["<tag1>", "achieve", "broad", "market", "acceptance", "of", "our", "product", "candidates", "in", "the", "medical", "community", "and", "with", "third-party", "payors.", "<tag2>", "if", "regulatory", "approvals", "are", "obtained,", "begin", "the", "commercial", "manufacturing", "of", "our", "product", "candidates", "with", "our", "third-party", "manufacturers;", "launch", "commercial", "sales", "and", "effectively", "market", "our", "product", "candidates,", "either", "independently", "or", "in", "strategic", "collaborations", "with", "third", "parties;", "and", "achieve", "broad", "market", "acceptance", "of", "our", "product", "candidates", "in", "the", "medical", "community", "and", "with", "third-party", "payors.", "<tag3>"], "wordsA": ["achieve", "broad", "market", "acceptance", "of", "our", "product", "candidates", "in", "the", "medical", "community", "and", "with", "third-party", "payors."], "wordsB": ["if", "regulatory", "approvals", "are", "obtained,", "begin", "the", "commercial", "manufacturing", "of", "our", "product", "candidates", "with", "our", "third-party", "manufacturers;", "launch", "commercial", "sales", "and", "effectively", "market", "our", "product", "candidates,", "either", "independently", "or", "in", "strategic", "collaborations", "with", "third", "parties;", "and", "achieve", "broad", "market", "acceptance", "of", "our", "product", "candidates", "in", "the", "medical", "community", "and", "with", "third-party", "payors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.036724623292684555, 0.11143384128808975, 0.1294780969619751, 0.08807326853275299, 0.04971138387918472, 0.043739281594753265, 0.029366033151745796, 0.2773321270942688, 0.268864244222641, 0.029592610895633698, 0.023795099928975105, 0.0802633985877037, 0.08278631418943405, 0.007478099782019854, 0.008593525737524033, 0.02266339585185051, 0.028559857979416847, 0.07164180278778076, 0.1455496996641159, 0.09078264236450195, 0.011732807382941246, 0.09419553726911545, 0.09065915644168854, 0.01991940662264824, 0.07356180250644684, 0.08016712218523026, 0.005663844291120768, 0.2593521773815155, 0.015004237182438374, 0.020787697285413742, 0.0588684007525444, 0.04843790456652641, 0.014117070473730564, 0.02458440512418747, 0.026629891246557236, 0.013045581988990307, 0.010000452399253845, 0.0158007200807333, 0.01646149531006813, 0.02341156080365181, 0.005212875083088875, 0.009399961680173874, 0.03128242492675781, 0.027030689641833305, 0.005234497599303722, 0.007952312938869, 0.01205895934253931, 0.013037622906267643, 0.0009770729811862111, 0.006788896396756172, 0.07288769632577896, 0.014763773418962955, -1]}
{"idB": "1316175_12_item1a_p66_s0", "idA": "1316175_11_item1a_p71_s0", "sentA": "We are highly dependent on Mr. Paul F. Truex, our President and Chief Executive Officer, Dr. Colin Hislop, our Senior Vice President and Chief Medical Officer and the other principal members of our executive team listed under Executive Officers in Part III of this report.", "sentB": "We are highly dependent on Mr. Paul F. Truex, our President and Chief Executive Officer, Dr. Colin Hislop, our Senior Vice President and Chief Medical Officer and the other principal members of our executive team.", "type": 2, "words": ["<tag1>", "We", "are", "highly", "dependent", "on", "Mr.", "Paul", "F.", "Truex,", "our", "President", "and", "Chief", "Executive", "Officer,", "Dr.", "Colin", "Hislop,", "our", "Senior", "Vice", "President", "and", "Chief", "Medical", "Officer", "and", "the", "other", "principal", "members", "of", "our", "executive", "team", "listed", "under", "Executive", "Officers", "in", "Part", "III", "of", "this", "report.", "<tag2>", "We", "are", "highly", "dependent", "on", "Mr.", "Paul", "F.", "Truex,", "our", "President", "and", "Chief", "Executive", "Officer,", "Dr.", "Colin", "Hislop,", "our", "Senior", "Vice", "President", "and", "Chief", "Medical", "Officer", "and", "the", "other", "principal", "members", "of", "our", "executive", "team.", "<tag3>"], "wordsA": ["We", "are", "highly", "dependent", "on", "Mr.", "Paul", "F.", "Truex,", "our", "President", "and", "Chief", "Executive", "Officer,", "Dr.", "Colin", "Hislop,", "our", "Senior", "Vice", "President", "and", "Chief", "Medical", "Officer", "and", "the", "other", "principal", "members", "of", "our", "executive", "team", "listed", "under", "Executive", "Officers", "in", "Part", "III", "of", "this", "report."], "wordsB": ["We", "are", "highly", "dependent", "on", "Mr.", "Paul", "F.", "Truex,", "our", "President", "and", "Chief", "Executive", "Officer,", "Dr.", "Colin", "Hislop,", "our", "Senior", "Vice", "President", "and", "Chief", "Medical", "Officer", "and", "the", "other", "principal", "members", "of", "our", "executive", "team."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.05960695818066597, 0.056969914585351944, 0.20480090379714966, 0.5649541616439819, 0.2289239466190338, 0.5531960725784302, 0.18906095623970032, 0.1907886564731598, 0.28417566418647766, 0.07060854882001877, 0.18421269953250885, 0.048400357365608215, 0.11571428179740906, 0.1562042385339737, 0.14639298617839813, 0.12614047527313232, 0.07858673483133316, 0.11728386580944061, 0.03127438575029373, 0.12648747861385345, 0.07809264957904816, 0.07476094365119934, 0.02011292055249214, 0.05306446924805641, 0.061698704957962036, 0.06236720457673073, 0.017248040065169334, 0.022381674498319626, 0.03320722281932831, 0.0655522495508194, 0.0613168366253376, 0.015609197318553925, 0.029113203287124634, 0.1464512199163437, 0.12522871792316437, -1]}
{"idB": "1316175_12_item1a_p73_s0", "idA": "1316175_11_item1a_p77_s4", "sentA": "These cost reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products and could seriously harm our business.", "sentB": "decrease the coverage and price that we receive for any approved products and could seriously harm our business.", "type": 2, "words": ["<tag1>", "These", "cost", "reduction", "initiatives", "and", "other", "provisions", "of", "this", "legislation", "could", "decrease", "the", "coverage", "and", "price", "that", "we", "receive", "for", "any", "approved", "products", "and", "could", "seriously", "harm", "our", "business.", "<tag2>", "decrease", "the", "coverage", "and", "price", "that", "we", "receive", "for", "any", "approved", "products", "and", "could", "seriously", "harm", "our", "business.", "<tag3>"], "wordsA": ["These", "cost", "reduction", "initiatives", "and", "other", "provisions", "of", "this", "legislation", "could", "decrease", "the", "coverage", "and", "price", "that", "we", "receive", "for", "any", "approved", "products", "and", "could", "seriously", "harm", "our", "business."], "wordsB": ["decrease", "the", "coverage", "and", "price", "that", "we", "receive", "for", "any", "approved", "products", "and", "could", "seriously", "harm", "our", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.6220371127128601, 0.07592590153217316, 0.15840929746627808, 0.02980152517557144, 0.0369117297232151, 0.011609891429543495, 0.051088668406009674, 0.0899774357676506, 0.0160293597728014, 0.018804097548127174, 0.12339028716087341, 0.06547164171934128, 0.0008655128185637295, 0.012841635383665562, 0.016533710062503815, 0.05747917294502258, 0.033590205013751984, 0.07671046257019043, -1]}
{"idB": "1316175_12_item1a_p74_s0", "idA": "1316175_11_item1a_p78_s0", "sentA": "their own reimbursement rates, and any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.", "sentB": "While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.", "type": 2, "words": ["<tag1>", "their", "own", "reimbursement", "rates,", "and", "any", "reduction", "in", "reimbursement", "that", "results", "from", "the", "MMA", "may", "result", "in", "a", "similar", "reduction", "in", "payments", "from", "private", "payors.", "<tag2>", "While", "the", "MMA", "applies", "only", "to", "drug", "benefits", "for", "Medicare", "beneficiaries,", "private", "payors", "often", "follow", "Medicare", "coverage", "policy", "and", "payment", "limitations", "in", "setting", "their", "own", "reimbursement", "rates,", "and", "any", "reduction", "in", "reimbursement", "that", "results", "from", "the", "MMA", "may", "result", "in", "a", "similar", "reduction", "in", "payments", "from", "private", "payors.", "<tag3>"], "wordsA": ["their", "own", "reimbursement", "rates,", "and", "any", "reduction", "in", "reimbursement", "that", "results", "from", "the", "MMA", "may", "result", "in", "a", "similar", "reduction", "in", "payments", "from", "private", "payors."], "wordsB": ["While", "the", "MMA", "applies", "only", "to", "drug", "benefits", "for", "Medicare", "beneficiaries,", "private", "payors", "often", "follow", "Medicare", "coverage", "policy", "and", "payment", "limitations", "in", "setting", "their", "own", "reimbursement", "rates,", "and", "any", "reduction", "in", "reimbursement", "that", "results", "from", "the", "MMA", "may", "result", "in", "a", "similar", "reduction", "in", "payments", "from", "private", "payors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.011717468500137329, 0.003897720715031028, 0.07674229890108109, 0.15056687593460083, 0.10936608165502548, 0.08805505931377411, 0.5426205992698669, 0.5928396582603455, 0.008721070364117622, 0.05162431299686432, 0.03182852640748024, 0.02408098801970482, 0.0287091676145792, 0.006947087123990059, 0.03181526064872742, 0.07360908389091492, 0.04117216169834137, 0.041012756526470184, 0.009967304766178131, 0.05686516687273979, 0.09389394521713257, 0.005457397550344467, 0.030813803896307945, 0.025972800329327583, 0.03269333392381668, 0.03622676432132721, 0.029992233961820602, 0.004959222860634327, 0.004286475945264101, 0.019880831241607666, 0.003790506860241294, 0.008389988914132118, 0.0030332114547491074, 0.00414308113977313, 0.0031592592131346464, 0.0035835702437907457, 0.01889057084918022, 0.003955894149839878, 0.0034341933205723763, 0.0034508430399000645, 0.0039987522177398205, 0.0041203671135008335, 0.02722805365920067, 0.004313954617828131, 0.02498394437134266, 0.0034304093569517136, 0.012599391862750053, 0.01203552633523941, -1]}
{"idB": "1316175_12_item1a_p80_s0", "idA": "1316175_11_item1a_p84_s0", "sentA": "decreased demand for our product candidates, if approved for commercial sale.", "sentB": "impairment of our business reputation; withdrawal of clinical study participants; costs of related litigation; distraction of management's attention from our primary business; substantial monetary awards to patients or other claimants; the inability to commercialize our product candidates; and decreased demand for our product candidates, if approved for commercial sale.", "type": 2, "words": ["<tag1>", "decreased", "demand", "for", "our", "product", "candidates,", "if", "approved", "for", "commercial", "sale.", "<tag2>", "impairment", "of", "our", "business", "reputation;", "withdrawal", "of", "clinical", "study", "participants;", "costs", "of", "related", "litigation;", "distraction", "of", "management's", "attention", "from", "our", "primary", "business;", "substantial", "monetary", "awards", "to", "patients", "or", "other", "claimants;", "the", "inability", "to", "commercialize", "our", "product", "candidates;", "and", "decreased", "demand", "for", "our", "product", "candidates,", "if", "approved", "for", "commercial", "sale.", "<tag3>"], "wordsA": ["decreased", "demand", "for", "our", "product", "candidates,", "if", "approved", "for", "commercial", "sale."], "wordsB": ["impairment", "of", "our", "business", "reputation;", "withdrawal", "of", "clinical", "study", "participants;", "costs", "of", "related", "litigation;", "distraction", "of", "management's", "attention", "from", "our", "primary", "business;", "substantial", "monetary", "awards", "to", "patients", "or", "other", "claimants;", "the", "inability", "to", "commercialize", "our", "product", "candidates;", "and", "decreased", "demand", "for", "our", "product", "candidates,", "if", "approved", "for", "commercial", "sale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.541317880153656, 0.27642887830734253, 0.20500750839710236, 0.38182851672172546, 0.41120007634162903, 0.3430851101875305, 0.10737495869398117, 0.10598327219486237, 0.12624360620975494, 0.12867078185081482, 0.02218957059085369, 0.008767813444137573, 0.01688949577510357, 0.04770410433411598, 0.08994432538747787, 0.031401511281728745, 0.06716865301132202, 0.06666247546672821, 0.018552055582404137, 0.01019230019301176, 0.02909153699874878, 0.024565650150179863, 0.05912422388792038, 0.1099015325307846, 0.13092269003391266, 0.010440542362630367, 0.032207220792770386, 0.014062640257179737, 0.0094143720343709, 0.029207894578576088, 0.01400341559201479, 0.6318047642707825, 0.5711969137191772, 0.6917455196380615, 0.014451634138822556, 0.10171160846948624, 0.11382558941841125, 0.006047140806913376, 0.0670454353094101, 0.029545031487941742, 0.00291464664041996, 0.004970577545464039, 0.01190183125436306, 0.011703604832291603, 0.0029842148069292307, 0.004289945121854544, 0.002960863057523966, 0.005113433580845594, 0.0051661329343914986, -1]}
{"idB": "1316175_12_item1a_p82_s0", "idA": "1316175_11_item1a_p85_s2", "sentA": "If and when we obtain marketing approval for any of our product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain this product liability insurance on commercially reasonable terms.", "sentB": "our product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain this product liability insurance on commercially reasonable terms.", "type": 2, "words": ["<tag1>", "If", "and", "when", "we", "obtain", "marketing", "approval", "for", "any", "of", "our", "product", "candidates,", "we", "intend", "to", "expand", "our", "insurance", "coverage", "to", "include", "the", "sale", "of", "commercial", "products;", "however,", "we", "may", "be", "unable", "to", "obtain", "this", "product", "liability", "insurance", "on", "commercially", "reasonable", "terms.", "<tag2>", "our", "product", "candidates,", "we", "intend", "to", "expand", "our", "insurance", "coverage", "to", "include", "the", "sale", "of", "commercial", "products;", "however,", "we", "may", "be", "unable", "to", "obtain", "this", "product", "liability", "insurance", "on", "commercially", "reasonable", "terms.", "<tag3>"], "wordsA": ["If", "and", "when", "we", "obtain", "marketing", "approval", "for", "any", "of", "our", "product", "candidates,", "we", "intend", "to", "expand", "our", "insurance", "coverage", "to", "include", "the", "sale", "of", "commercial", "products;", "however,", "we", "may", "be", "unable", "to", "obtain", "this", "product", "liability", "insurance", "on", "commercially", "reasonable", "terms."], "wordsB": ["our", "product", "candidates,", "we", "intend", "to", "expand", "our", "insurance", "coverage", "to", "include", "the", "sale", "of", "commercial", "products;", "however,", "we", "may", "be", "unable", "to", "obtain", "this", "product", "liability", "insurance", "on", "commercially", "reasonable", "terms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0541347973048687, 0.3737277686595917, 0.6470724940299988, 0.0229057464748621, 0.04257114604115486, 0.015726307407021523, 0.03804320842027664, 0.012755895964801311, 0.05235747620463371, 0.02897605486214161, 0.007560836151242256, 0.015124469064176083, 0.009554718621075153, 0.03169384226202965, 0.016275422647595406, 0.04896894097328186, 0.038092851638793945, 0.016308987513184547, 0.023119773715734482, 0.032791949808597565, 0.030320003628730774, 0.5597442984580994, 0.08742032200098038, 0.4762577414512634, 0.05253729969263077, 0.11272016912698746, 0.09410836547613144, 0.14380434155464172, 0.0107625937089324, 0.01096050813794136, 0.013545860536396503, 0.013411815278232098, -1]}
{"idB": "1316175_12_item1a_p91_s0", "idA": "1316175_11_item1a_p94_s2", "sentA": "If we are unable to arrange for third-party manufacturing sources, or to do so on commercially reasonable terms, we may not be able to complete development of our product candidates or market them.", "sentB": "commercially reasonable terms, we may not be able to complete development of our product candidates or market them.", "type": 2, "words": ["<tag1>", "If", "we", "are", "unable", "to", "arrange", "for", "third-party", "manufacturing", "sources,", "or", "to", "do", "so", "on", "commercially", "reasonable", "terms,", "we", "may", "not", "be", "able", "to", "complete", "development", "of", "our", "product", "candidates", "or", "market", "them.", "<tag2>", "commercially", "reasonable", "terms,", "we", "may", "not", "be", "able", "to", "complete", "development", "of", "our", "product", "candidates", "or", "market", "them.", "<tag3>"], "wordsA": ["If", "we", "are", "unable", "to", "arrange", "for", "third-party", "manufacturing", "sources,", "or", "to", "do", "so", "on", "commercially", "reasonable", "terms,", "we", "may", "not", "be", "able", "to", "complete", "development", "of", "our", "product", "candidates", "or", "market", "them."], "wordsB": ["commercially", "reasonable", "terms,", "we", "may", "not", "be", "able", "to", "complete", "development", "of", "our", "product", "candidates", "or", "market", "them."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 1, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.016146212816238403, 0.02738068625330925, 0.03694567829370499, 0.03844326734542847, 0.0967642068862915, 0.9121642112731934, 0.19830256700515747, 0.5327165126800537, 0.35416215658187866, 0.6286509037017822, 0.1500699371099472, 0.016497045755386353, 0.02225947193801403, 0.03161981329321861, 0.02134685404598713, 0.013751992024481297, 0.017027735710144043, 0.011082764714956284, -1]}
{"idB": "1316175_12_item1a_p93_s2", "idA": "1316175_11_item1a_p97_s1", "sentA": "We anticipate submitting this protocol to the FDA in Q2 2011.", "sentB": "We submitted plans to the FDA on March 4, 2011 and September 9, 2011 establishing criteria to demonstrate comparability of blisibimod manufactured by Fujifilm to that manufactured by Amgen.", "type": 2, "words": ["<tag1>", "We", "anticipate", "submitting", "this", "protocol", "to", "the", "FDA", "in", "Q2", "2011.", "<tag2>", "We", "submitted", "plans", "to", "the", "FDA", "on", "March", "4,", "2011", "and", "September", "9,", "2011", "establishing", "criteria", "to", "demonstrate", "comparability", "of", "blisibimod", "manufactured", "by", "Fujifilm", "to", "that", "manufactured", "by", "Amgen.", "<tag3>"], "wordsA": ["We", "anticipate", "submitting", "this", "protocol", "to", "the", "FDA", "in", "Q2", "2011."], "wordsB": ["We", "submitted", "plans", "to", "the", "FDA", "on", "March", "4,", "2011", "and", "September", "9,", "2011", "establishing", "criteria", "to", "demonstrate", "comparability", "of", "blisibimod", "manufactured", "by", "Fujifilm", "to", "that", "manufactured", "by", "Amgen."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.03469638526439667, 0.17090114951133728, 0.2758459448814392, 0.011636782437562943, 0.005377516150474548, 0.03944653272628784, 0.03607088699936867, 0.3309851586818695, 0.3061975836753845, 0.11337022483348846, 0.0684811994433403, 0.3913412392139435, 0.47575005888938904, 0.10572740435600281, 0.011907165870070457, 0.046720851212739944, 0.004662517458200455, 0.011033657938241959, 0.030041387304663658, 0.017037561163306236, 0.13008522987365723, 0.013691551983356476, 0.012063509784638882, 0.07518947869539261, 0.008123164065182209, 0.004366403445601463, 0.01383549440652132, 0.010610966011881828, 0.04132991284132004, -1]}
{"idB": "1316175_12_item1a_p93_s3", "idA": "1316175_11_item1a_p97_s1", "sentA": "We anticipate submitting this protocol to the FDA in Q2 2011.", "sentB": "Data confirming comparability to Phase 1 material (Amgen) was filed with the FDA on August 8, 2011 and September 8, 2011.", "type": 2, "words": ["<tag1>", "We", "anticipate", "submitting", "this", "protocol", "to", "the", "FDA", "in", "Q2", "2011.", "<tag2>", "Data", "confirming", "comparability", "to", "Phase", "1", "material", "(Amgen)", "was", "filed", "with", "the", "FDA", "on", "August", "8,", "2011", "and", "September", "8,", "2011.", "<tag3>"], "wordsA": ["We", "anticipate", "submitting", "this", "protocol", "to", "the", "FDA", "in", "Q2", "2011."], "wordsB": ["Data", "confirming", "comparability", "to", "Phase", "1", "material", "(Amgen)", "was", "filed", "with", "the", "FDA", "on", "August", "8,", "2011", "and", "September", "8,", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.35931167006492615, 0.20635062456130981, 0.4040711224079132, 0.03396789729595184, 0.05083410069346428, 0.05440253019332886, 0.07486015558242798, 0.062461648136377335, 0.012707569636404514, 0.05583367124199867, 0.024747518822550774, 0.013411462306976318, 0.039700236171483994, 0.026207566261291504, 0.29466450214385986, 0.2798655331134796, 0.052306562662124634, 0.07561700791120529, 0.441890686750412, 0.4107953906059265, 0.10224355757236481, -1]}
{"idB": "1316175_12_item1a_p93_s5", "idA": "1316175_11_item1a_p97_s2", "sentA": "Should the FDA not agree with our comparability protocol proposal or if we are unable to agree on the specifications for future A-623 manufacturing, further clinical development of A-623 beyond the PEARL-SC clinical study would be substantially delayed and we would incur substantial additional expense.", "sentB": "Should the FDA not agree with our comparability assessment or if we are unable to agree on the specifications for future blisibimod manufacturing, further clinical development of blisibimod beyond the PEARL-SC clinical study would be substantially delayed and we would incur substantial additional expense.", "type": 2, "words": ["<tag1>", "Should", "the", "FDA", "not", "agree", "with", "our", "comparability", "protocol", "proposal", "or", "if", "we", "are", "unable", "to", "agree", "on", "the", "specifications", "for", "future", "A-623", "manufacturing,", "further", "clinical", "development", "of", "A-623", "beyond", "the", "PEARL-SC", "clinical", "study", "would", "be", "substantially", "delayed", "and", "we", "would", "incur", "substantial", "additional", "expense.", "<tag2>", "Should", "the", "FDA", "not", "agree", "with", "our", "comparability", "assessment", "or", "if", "we", "are", "unable", "to", "agree", "on", "the", "specifications", "for", "future", "blisibimod", "manufacturing,", "further", "clinical", "development", "of", "blisibimod", "beyond", "the", "PEARL-SC", "clinical", "study", "would", "be", "substantially", "delayed", "and", "we", "would", "incur", "substantial", "additional", "expense.", "<tag3>"], "wordsA": ["Should", "the", "FDA", "not", "agree", "with", "our", "comparability", "protocol", "proposal", "or", "if", "we", "are", "unable", "to", "agree", "on", "the", "specifications", "for", "future", "A-623", "manufacturing,", "further", "clinical", "development", "of", "A-623", "beyond", "the", "PEARL-SC", "clinical", "study", "would", "be", "substantially", "delayed", "and", "we", "would", "incur", "substantial", "additional", "expense."], "wordsB": ["Should", "the", "FDA", "not", "agree", "with", "our", "comparability", "assessment", "or", "if", "we", "are", "unable", "to", "agree", "on", "the", "specifications", "for", "future", "blisibimod", "manufacturing,", "further", "clinical", "development", "of", "blisibimod", "beyond", "the", "PEARL-SC", "clinical", "study", "would", "be", "substantially", "delayed", "and", "we", "would", "incur", "substantial", "additional", "expense."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.010027240961790085, 0.004444411490112543, 0.02418980747461319, 0.4147581160068512, 0.23427462577819824, 0.019762394949793816, 0.009672448970377445, 0.06180010363459587, 0.3774964511394501, 0.0034643353428691626, 0.004877998027950525, 0.005692399572581053, 0.009629175998270512, 0.07759847491979599, 0.015772463753819466, 0.030441995710134506, 0.00683241430670023, 0.005295689683407545, 0.024724803864955902, 0.0036680102348327637, 0.005637137684971094, 0.3649826645851135, 0.03847141191363335, 0.002862372202798724, 0.004305307287722826, 0.008324882946908474, 0.003938587848097086, 0.10746748000383377, 0.004196997731924057, 0.0026662645395845175, 0.006871085613965988, 0.004115634597837925, 0.004061275627464056, 0.003694493556395173, 0.004236006177961826, 0.009029640816152096, 0.012533684261143208, 0.0002651809772942215, 0.003929805010557175, 0.004815980792045593, 0.006267537362873554, 0.005020716227591038, 0.005195624195039272, 0.009112916886806488, -1]}
